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Chapter 1 
General introduction 
Parts of this chapter were published as review article in International Journal of Pharmaceutics: 
Teresa Kraus, Gerhard Winter, Julia Engert 
Test Models for the Evaluation of Immunogenicity of Protein Aggregates 
International Journal of Pharmaceutics 559 (2019) 192-200. 
 General introduction  
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 Immunogenicity of biopharmaceuticals 
The development of therapeutic protein drugs has revolutionized the treatment of many severe 
diseases such as cancer, rheumatoid arthritis, and Crohn’s disease1. Besides their benefits including 
less side effects and highly specific treatment, a major drawback of biopharmaceuticals is their ability 
to induce immune responses in patients2. In many cases this bears without any clinical consequences 
for the patient, but in some cases with severe immune reactions such as pure red cell aplasia (PRCA)3 
or anaphylactic responses4,5. One suspects, that the immune response is caused by the development 
of antibodies to the administered drugs, so called anti-drug antibodies (ADAs)6. Generation of anti-
drug antibodies has been previously reported after treatment of patients for a considerable number 
of biologicals such as EPO3,7, Insulin8, human GM-CSF9, Factor VIII4,10, Interferon alpha11 and several 
monoclonal antibodies12. Immunogenicity can have an impact on the safety and efficacy of the drug 
and is therefore unwanted. The Food and Drug Administration (FDA) has edited a Guideline for Industry 
“Immunogenicity Assessment for Therapeutic Proteins Products” describing the background of 
immunogenicity and giving recommendations for risk mitigation of immunogenicity during the 
development of biopharmaceutical products13. In fact, the FDA published recommendations 
concerning immunogenicity and, of course, the occurrence of clinical consequences related to 
immunogenicity after administration of a drug to patients emphasizes the significance of this topic. 
Due to the risk to the patients, there is an essential need for further investigations of the potential of 
therapeutic protein drugs to elicit undesired immunogenicity. The further sections in this chapter focus 
on induction factors and clinical consequences of immunogenicity, illustrate the relation between 
immunogenicity and protein aggregates, and summarize currently used test models for the prediction 
of immunogenicity. Finally, the human artificial lymph node model, which was mainly used as test 
model for testing the immunogenicity of protein aggregates during this thesis, is presented in detail. 
 Induction factors of immunogenicity 
Factors influencing immunogenicity can be distinguished between patient-, production- or drug-
related factors14. The origin of the drug, meaning if the protein is foreign or human, plays a major 
role15. Moreover, protein folding or changes in the primary structure of the protein may influence the 
potential of the drug to induce immunogenicity13,14. Glycosylation or pegylation16 of a drug may alter 
the tendency of inducing immunogenicity by reducing protein aggregation and by shielding the protein 
from the immune system17,18. Among the production related factors, protein aggregates have been 
discussed for a long time to elicit immunogenic reactions19,20. Besides, the presence of leachables or 
extractables21,22, production related impurities23 or additives24 may contribute to immunogenicity. 
Finally, the packaging process and the interaction between the container and the protein may also 
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have an impact on immunogenicity25. Fradkin et al. found that glass microparticles with adsorbed 
protein can induce immunogenicity26. Moreover, glass and air interfaces might trigger protein 
aggregation and denaturation27 and finally, glass can delaminate which might also increase the risk of 
immunogenic reactions28. 
Besides all these product related factors, there are also factors related to the patient affecting 
immunogenicity. First, the history of allergy, the immunologic status and competence of the patient 
play a major role13. Patients receiving immunosuppressive substances during a treatment might show 
lower immune response compared to patients having an active immune system as exemplarily shown 
by Baert et al.29 for the treatment of Crohn’s disease using Infliximab. Also, the age of the patient may 
influence the development of an immune response, which is in particular true for infants, small 
children, and elderly people13,30,31.The route and frequency of administration, as well as the dosing are 
also factors affecting immunogenicity32,33. One suspects that the subcutaneous route of administration 
poses a greater risk for immunogenic reactions than intravenous applications34. A review of Hamuro 
et al.35 points out that this was true for four out of six marketed products where clinical data regarding 
the route of administration was available. However, a review comparing intravenous versus 
subcutaneous monoclonal antibodies for the treatment of asthma revealed that the described 
antibodies have a relatively low immunogenicity and, if observed, immunogenic reactions were found 
for i.v. and s.c. administrations36. Furthermore, genetic factors, especially some human leukocyte (HLA) 
haplotypes, increase the risk for some patients to the develop immunogenic reactions37. In summary, 
immunogenic reactions occur not only due to one risk factor but can be influenced by several factors 
at the same time. 
 Clinical consequences 
Describing clinical consequences of immunogenicity, one can differentiate between consequences 
regarding the efficacy or the safety of a drug. As regards the efficacy of therapeutic proteins, the 
generation of anti-drug antibodies (ADAs) is a key issue. There are two types of anti-drug antibodies 
described in literature: a) Neutralizing and b) non-neutralizing anti-drug antibodies38,39 (see Figure 1-1A 
and B). Neutralizing ADAs, as their name already suggests, bind to the active site of therapeutic 
proteins and therefore block the efficacy of the drug. In contrast, non-neutralizing ADAs do not target 
the active site of the drug but bind to a different site, so that the therapeutic protein can still bind to 
its target38. However, the pharmacokinetic parameters such as the clearance of the drug can be 
induced. If anti-drug antibodies show cross-reactivity to endogenous protein the clinical consequences 
might be severe7,13,25. 
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Immunogenicity does not necessarily result in severe clinical complications, but if so, the safety of the 
drug is affected. According to the Guidance for Industry about “Immunogenicity Assessment for 
Therapeutic Protein Products” there is a range of acute effects that may be induced by immunogenicity 
varying from indisposition to severe acute reactions such as anaphylaxis or cytokine release 
syndrome13,40,41. These acute reactions are often categorized as “infusion reactions”13. Clinical 
consequences can also occur temporarily delayed, meaning not chronologically linked to the 
administration of the drug. Non-acute reactions can be delayed hypersensitivity reactions 
accompanied by symptoms such as delayed outbreak of fever, rash or arthralgia42,43,e.g., as described 
in the FDA Guideline13. The presence of ADAs in patients after administration has been reported for 
several therapeutic proteins12,44. For example, Adalimumab, a human anti-TNFα monoclonal antibody, 
leads to the formation of anti-drug antibodies in many patients. Bender et al. showed in a trial in 
regular clinical settings, that 87% of the patients with rheumatoid arthritis participating in this study 
developed anti-drug antibodies against Adalimumab45. Although this study included a rather small 
number of 15 patients, it shows the clinical relevance of anti-drug antibody formation. Even if 
immunogenic reactions do not consequently lead to obvious clinical symptoms, it is necessary to 
diminish the risk for patients and ensure a safe and efficient therapy. A permanent loss in therapy 
efficacy would also result in an increased therapy cost. Therefore, the risk assessment of 
immunogenicity of therapeutic proteins is an essential obstacle which must be faced during 
development to ensure a safe and efficient drug therapy. 
A 
 
B 
 
Figure 1-1: Schematic drawing of neutralizing (A) and non-neutralizing anti-drug antibodies (ADAs): Neutralizing ADAs bind 
to the active site of the drug and therefore block the efficacy of the drug. Non-neutralizing ADAs bind to a different site of 
the drug, so that the drug can still bind to its target, but the pharmacokinetics of the drug can be influenced; adopted from 
Carrascosa et al.38. 
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 Immunogenicity and protein aggregates 
It has been known for a long time, that protein aggregates contribute to the immunogenicity of 
biopharmaceuticals19,20. Protein aggregation is one of the instabilities of proteins possibly occurring 
throughout the entire development and production of a protein drug46. In particular during the 
manufacturing process, biopharmaceutical proteins are exposed to various conditions such as 
fermentation, purification, pumping, filling, shipment, and storage, which may trigger aggregation 
processes47. Not all types of aggregates are equally immunogenic. Meanwhile one suspects that 
submicron particles as well as protein aggregates with strong chemical modifications show the 
strongest immunogenic effects48,49. Until now, only little is known about the exact mechanism of 
protein aggregates to elicit immune responses. In general, there are two mechanisms for the formation 
of anti-drug antibodies discussed in literature: T-cell dependent (TD) and T-cell independent (TI) 
activation of immunogenic reactions. The first describes the “classical” immune response (Figure 1-2): 
The antigen is recognized, internalized and processed by antigen presenting cells (APCs) such as 
dendritic cells (DCs)20. Stimulated DCs migrate to the lymph nodes where they present the antigen via 
MHC class II molecules to T-cells50. Finally, an interaction between the antigen primed T-cells and B-
cells via T-cell receptor (TCR), MHC II and CD40 ligand and CD40 receptor leads to the activation of B-
cells, thus to the formation of ADAs20,51,52. Another hypothesis specifies that protein aggregates can 
directly activate B-cells to produce anti-drug antibodies (Figure 1-3). Protein aggregates can either lead 
to polyclonal B-cell activation via binding to Toll-like receptors (TI mechanism type I) or by cross-linking 
BCRs due to repetitive structures of protein aggregates (TI mechanism type II)53. To date, the relevant 
mechanism is still not exactly known. The isotypes of secreted anti-drug antibodies as well as the type 
of secreted cytokines can partially indicate the type of immune response. IgG anti-drug antibodies 
usually indicate T-cell help, whereas B-cells produce IgM anti-drug antibodies without memory. 
However, isotype switching from IgM to IgG antibodies can occur, thereby making it difficult to draw 
conclusions about the underlying mechanisms51,52,54. Thus, further investigations of protein aggregates 
need to be carried out to gain a deeper understanding of the underlying mechanisms of 
immunogenicity. 
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Figure 1-2: Schematic overview of the T-cell dependent mechanism of anti-drug antibody formation. 
 
Figure 1-3: Schematic overview of the T-cell independent mechanism of anti-drug antibody formation. 
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 Test models for the evaluation of immunogenicity of protein aggregates 
Over the last years, the capacity of protein aggregates to elicit immunogenicity has been investigated 
in a variety of studies using different in vitro and in vivo models (see Table 1-1 and Table 1-2). The most 
common models used for the assessment of immunogenicity of protein aggregates are mouse models 
(see Table 1-2). Besides animal models, in vitro models have been used to evaluate the immunogenicity 
of protein aggregates (see Table 1-1). In the following section, the focus is on test models that have 
been used for the evaluation of immunogenicity of protein aggregates. Their value regarding the 
prediction of immunogenicity in humans and the mechanisms of immunogenicity are discussed. 
Furthermore, we summarize advantages and drawbacks of the test models in use and discuss gaps and 
challenges for the future. 
 2D In vitro models 
Most of the in vitro assays used for the evaluation of immunogenicity of protein aggregates are based 
on the use of peripheral blood mononuclear cells (PBMCs) from humans (Table 1-1). Using such system, 
the aim is to investigate the ability of protein aggregates to induce the maturation of immature 
monocyte-derived DCs to mature DCs. Therefore, PBMCs are isolated from human blood or buffy 
coats. Sometimes they are further differentiated into CD14+ and CD14- cells using magnetic beads to 
optimize the purity of the isolated monocytes55. Subsequently, monocytes are incubated with different 
protein aggregate formulations for a few hours until several days, and finally, upregulation of DC 
maturation markers such as CD83, CD80 and CD86 or the release of different cytokines are 
investigated55–59. Incubation times of protein aggregates with PBMCs range from several hours until 
several days to monitor the early and late phase of the cytokine release59,60. Besides PBMC assays, T-
cell proliferation assays are also a well-used tool to investigate the ability of protein aggregates to 
trigger an immune response. Therefore, PBMCs including T-cells are challenged with the desired 
formulations, and after 5-8 days, the proliferation of CD4+ T-cells can be measured using a thymidine 
incorporation assay58,59 or CFSE staining, which is easier to use61. To date, only few groups investigated 
the potential of different kind of protein aggregates using PBMC based in vitro assays (see Table 1-1). 
Results showed differences between the potential of certain protein aggregates to induce T-cell 
proliferation, DC activation and cytokine signals. Ahmadi et al.58 stimulated dendritic cells and CD4+ 
cells with small amounts of sub-visible aggregates of Rituximab and Trastuzumab. Besides cytokine 
secretion and T-cell proliferation, they also investigated the uptake of fluorescent-labelled particles of 
Rituximab into dendritic cells using confocal microscopy. The group could show that Rituximab 
particles were taken up efficiently by MoDCs, and that low amounts of aggregates (< 3% of total 
protein) were able to trigger the innate immune system. According to this study, the level of activation 
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of the immune system also depends on the intrinsic clinical immunogenicity of the investigated 
proteins. There were only small differences in DC activation and T-cell proliferation of aggregated and 
unstressed Rituximab (high clinical immunogenicity), whereas aggregated Trastuzumab (low clinical 
immunogenicity) led to T-cell proliferation. Moussa et al.56 evaluated the immunogenicity of 
aggregated intravenous immunoglobulin using PBMCs and primary monocytes in comparison to 
human monocyte cell lines (THP-I and MM6 cells). Aggregates generated by mechanical stress (stirring 
and shaking) led to an increase in cytokine release when tested in PBMCs and primary monocytes. 
Cytokine secretion in both cell lines, THP-1 and MM6 cells, was comparable to the response in primary 
monocytes, even though secreted cytokine concentrations were lower. Besides, they also tested the 
dose-response to aggregates generated by mechanical stress and observed that the relative dose-
responsiveness to increasing aggregate doses was similar between THP-1 cells and primary cells. MM6 
cells were previously used by Zaitseva et al. to develop in vitro assays to predict toxicity of adjuvants 
in vivo62. Moussa et al.56 did not report any correlation data of MM6 cells and primary monocytes due 
to inconsistency and variability of the results of dose responses of MM6 cells with primary monocytes 
responses. The THP-1 cell line as an in vitro cell model is well described by Chanput et al63. Accordingly, 
advantages of this cell line compared to PBMC derived cells are a faster growing rate, an easy and safe 
use, the possibility of stock building in liquid nitrogen, culture times up to three months without 
changes of cell activity or sensitivity and low batch to batch variability. The latter is a disadvantage of 
cell lines at the same time, since a high donor to donor variability reflects genotype effects which may 
play an important role regarding immunogenicity2,64,65. A further drawback of cell lines is that the 
cultivation conditions can influence cell sensitivity and therefore lead to different results than primary 
cells.  
In general, PBMC based in vitro assays have many advantages. First of all, large numbers of samples 
can be investigated at the same time, including a high variety of donors and HLA diversity59. They 
include the essential immune cells to simulate a potential immune response upon administration of a 
drug without intervention of other blood components. Additionally, the assays can be run for several 
days to investigate not only an early stage immune response but also a late stage immune response or 
T-cell proliferation57,59,60. Finally, the range of readout parameters regarding an innate immune 
response is broad. Multiplex assays allow the analysis of several cytokines at the same time, DC 
maturation marker and T-cell proliferation can be analyzed (see Table 1-1). However, a major 
drawback is that 2D in vitro assays only represent a small part of the human immune system66. 
Enclosing tissue or lymph nodes are not present, and the influence of biodistribution and circulation 
cannot be investigated either20. A further disadvantage of in vitro assays is that the long-term 
formation of ADAs cannot be measured, and, with a few exceptions mentioned above, incubation 
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times of PBMCs and aggregated protein samples are often short. Therefore the focus of such assays is 
on an early stage immune response56,58. 2D in vitro assays present a useful method to investigate the 
capacity of protein aggregates to elicit immunogenicity on the level of an innate response, but it is 
questionable, if 2D in vitro assays can predict immunogenicity of protein aggregates in humans. 
 In vivo models 
In contrast to in vitro models, animal models possess a fully trained immune system making them a 
popular test model used for the assessment of immunogenicity67. The most widely spread animal 
models for the evaluation of immunogenicity of protein aggregates are mice. Non-human primates 
have been used to test the immunogenicity of different biopharmaceuticals, but to the best of our 
knowledge no study exists in which higher order animals have been used to test the immunogenicity 
of protein aggregates 68–72. The FDA guidance for Industry “Immunogenicity assessment of therapeutic 
protein products” also mentions murine models only 13. Table 1-2 displays an overview of the murine 
models recently used for the evaluation of immunogenicity of protein aggregates. Among many 
different models wild-type strains and transgenic mice are the most common mouse models. The 
further sections will evaluate these different models regarding their utility for the assessment of 
immunogenicity of protein aggregates. 
 Wild-type mouse models 
Even though wild-type mice respond to human recombinant proteins as foreign substances, they are 
still used in many studies as a model to investigate the immunogenicity of protein aggregates32,73–78. 
Wild-type strains are commercially available and their breeding is considered simple67. However, it is 
questionable, if wild-type mice are a suitable model to predict immunogenicity in humans. First, the 
underlying mechanism of immunogenic reactions in humans differs from the classical immune 
response against foreign species or proteins, since human recombinant proteins are not foreign to 
humans. However, wild-type mice strains can be used for testing murine proteins and may be a 
valuable test system to evaluate the relative immunogenicity between different products or protein 
aggregates67,79. Freitag et al.73 investigated the immunogenicity of different types of aggregates of a 
murine monoclonal antibody, which is closely related to a human drug antibody, in two wild-type 
mouse strains: BALB/c and C57BL/6 mice. The latter was chosen because the murine monoclonal 
antibody they used was produced in this strain, thus the protein was not considered as foreign. 
Additionally, BALB/c mice were also included due to their known sensitivity and strong Th2 response. 
The study revealed that the results differ strongly between the two mouse strains. While the murine 
mAb1 was not immunogenic in C57BL/6 J mice, a strong immune response against mAb1 was detected 
in BALB/c mice. A high anti-drug antibody response towards the buffer control in C57BL/6 J mice made 
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it difficult to evaluate data and distinguish between the immunogenicity of the different types of 
aggregates. In contrast in BALB/c mice, all aggregated formulations showed a higher immune response 
than the native mAb1 and especially insoluble aggregates generated by light resulted in a high IgG1 
response. Differences between the two mouse strains are known and described in literature80,81. 
C57BL/6 J mice belong to Th1 responder while BALB/c mice are preferred Th2 responders. Conversely, 
Ratanji et al. used BALB/c mice to show that sub-visible scFV and OVA aggregates induce a Th1 
response75. The differences between the strains highlight the difficulty to select an appropriate mouse 
model for the assessment and prediction of immunogenicity in humans on the one hand but may also 
reflect the genetic variety among patients on the other hand. However, using a particularly sensitive 
mouse strain such as BALB/c mice bears the risk of overestimating immunogenicity. Shomali et al. used 
BALB/c and C57BL/6J mice to evaluate the immunogenicity of different dose levels of protein 
particulates generated by the adsorption of a murine monoclonal antibody (mAb1) onto glass or 
aluminum hydroxide microparticles and silicon oil droplets32. Also, in this study, the immune responses 
were different depending on the type of the mouse strains: In general, the immune response to the 
mAb1 formulations was stronger in BALB/c mice than in C57BL/6 J mice and BALB/c mice produced 
mainly IgG1 anti-mAb1 antibodies, whereas C57BL/6 J mice produced anti-mAb1 antibodies of IgG3 
and IgG2b isotypes. The authors hypothesized that the target of the anti-mAb1 response might be 
different in the two mouse strains. In BALB/c mice the immune response may be directed against the 
allogenic Fc region, whereas in C57BL/6 J mice the immune response could be directed against 
neoepitopes generated by aggregation or adsorption. The authors also performed a PK analysis and 
found that the concentration of mAb1 in all formulations declined faster in BALB/c mice than in 
C57BL/6 J mice. These results were in line with the increased ADA levels in BALB/c mice. The mentioned 
studies show, that results are partially contradictive and that it is challenging not to overestimate 
immunogenicity using only wild-type mouse strains. In many studies the formulations of interest were 
therefore tested in wild-type and transgenic mice 48,74,76–78,82–85. Moreover, wild-type strains might also 
be interesting for testing the immunogenicity of aggregates of proteins that are part of a replacement 
therapy for patients who cannot produce certain proteins such as Factor VIII, for example. In this case, 
the human recombinant protein might also be discerned as foreign67. A further possibility to 
investigate the immunogenicity of Factor VIII protein aggregates is to use Hemophilia A and von 
Willebrand Factor knockout (vWF-/-) mice86. Accordingly, these mouse models are often used to 
investigate the relative immunogenicity of Factor VIII formulations. Primarily because of their 
intolerance towards Factor VIII but also because these mice produce a qualitatively similar immune 
response to Factor VIII like humans87. 
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 Transgenic mouse models 
Transgenic mice are bread to be immune tolerant to the human recombinant protein supposed to be 
evaluated for its immunogenicity. The development and generation of such transgenic mouse models 
is complex and time-consuming88,89 and the models can only be used for one type of protein67. Van 
Beers et al.90 used a transgenic C57Bl/6 x FVB/N hybrid mice and their wild-type littermates89 to 
investigate the immunogenicity of recombinant human IFNβ and the induction of an immunological 
memory. While wild-type mice showed high IgG titer upon the re-challenge with rhIFNβ on day 63, 
transgenic mice did not show any increase of IgG titers. Thus, they did not develop an immunological 
memory. Fradkin et al.84 investigated the immunogenicity of aggregates of recombinant human growth 
hormone using naïve adult, neonatally primed and transgenic mice resulting in different anti-hGH IgG 
levels of the same formulations in each model. Whereas ADA levels in naïve adult and neonatally 
primed mice mainly differed in the concentration levels, no ADAs were detected in the transgenic 
mouse model. On the contrary, the study of Hermeling et al. showed that oxidized recombinant human 
IFNα2b was able to break the immune tolerance of transgenic mice76. According to the publication of 
Fradkin et al.84 not only the investigated proteins were different but also the used transgenic mice 
resulted from cross-breeding different mouse strains. However, differences in the immune response 
might also depend on the type of protein aggregates. Several studies have shown that not all types of 
protein aggregates are equally immunogenic73,76,82. In a recent study78, only metal-catalyzed oxidized 
recombinant human IFN2b was able to break the immune tolerance in transgenic mice while protein 
aggregates generated by oxidation using hydrogen peroxide, by cross-linking with glutaraldehyde or 
by incubation at elevated temperatures did not trigger the formation of anti-drug antibodies in a 
transgenic mouse model. Boll and colleagues used a transgenic mouse model to evaluate the 
immunogenicity of differently produced sub-visible particles48 and could show that only sub-visible 
particles with strong chemical modifications triggered an immune response. These studies indicate 
that transgenic mouse models can be useful to evaluate the relative immunogenicity between 
different types of protein aggregates as well as the breaking of immune tolerance. Besides, transgenic 
mice are also useful to predict neo-epitopes. Bessa and colleagues developed a novel transgenic mouse 
model to evaluate the immunogenicity of various antibody aggregates. They found that only protein 
aggregates bearing neo-epitopes, thus chemical modifications, created by exposure to light could 
break the immune tolerance83. Despite all the diverse studies using transgenic mice as a test model, 
there are still many drawbacks to overcome. First, transgenic mice still own a murine immune system 
making the predictability regarding immune reactions in humans questionable. Second, it is also 
uncertain if the presence of the target protein is sufficient to mimic the situation in humans, since the 
human recombinant protein is usually not biologically active after administration in mice77 and/or 
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biological effects of the proteins in mice are unforeseeable67. Moreover, expression levels of the target 
proteins might not correspond to those of humans67. 
 Conclusion and future aspects 
The currently used test models for the assessment of immunogenicity of protein aggregates have 
advantages and disadvantages. One of the essential questions is which test model simulates the 
human immune system best? At the moment, in vivo models are still seen as most suitable model since 
they have a fully trained immune system and therefore they are valuated as “closest” to humans67. 
However, evaluating the immunogenicity of protein aggregates in wild-type and transgenic mouse has 
not yet provided clearness neither about types of protein aggregates that elicit immunogenicity most 
nor about the mechanisms of immunogenicity of protein aggregates. Meanwhile one suspects, that 
especially protein aggregates with chemical modifications as well as protein aggregates in the 
submicron range are most prone to elicit immunogenicity48,49. Bi and colleagues tried to overcome the 
drawbacks of transgenic and wild-type mice developing a “Xeno-het mouse”, a crossbreed between 
the XenoMouse® and the wild-type strain C57BL/6 J, to assess the immunogenicity of different 
aggregated protein formulations91. This mouse model combined the tolerance to human IgG2 of the 
XenoMouse® with the robust immune response of the C57BL/6 J strain. However, the model still 
utilizes mouse MHC, mouse T-cells and APCs to elicit an immune response and therefore the 
predictability of immunogenicity in humans is again arguable. Compared to in vitro cell assays, in vivo 
models enable a long-term exposition of the drug with the possibility of multiple re-stimulations and 
ADAs can be analyzed. In contrast, the readout parameters of in vitro cell assays often base on the 
analysis of activation marker or cytokines, but the formation of ADAs cannot be monitored. Moreover, 
exposure times of the investigated drug are rather short. Neither of the used models represents the 
ideal one to investigate and predict the immunogenicity of protein aggregates in humans. An 
interesting approach to combine in vitro and in vivo testing might be to use the secretion of cytokines 
such as TNF alpha as in vitro markers for an increased risk of immunogenicity in vivo as shown by 
Fathallah and co-authors92. Nevertheless, to learn more about the underlying mechanisms of 
immunogenicity, a shift to models based on human cells with a human immune system is 
indispensable. Recently, a lot of effort has been put in the development of so-called micro-organoid 
systems such as a 3D in vitro skin model or human artificial lymph node models66,93. The latter is 
especially interesting, since lymph nodes belong to the secondary lymphatic organs and represent the 
interaction between the adaptive and innate immune response66. A human artificial lymph node model 
was developed by Giese et al.94 and represents a disposable, matrix-assisted 3D model of a human 
lymph node. It is operated with cells from human donors which are implanted in a 3D gel matrix where 
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follicles and micro-organoid structures are formed. The model offers a wide range of read-out 
parameters on the B- and T-cell level and enables a long-term exposure of the drug including multiple 
re-stimulations. The human artificial lymph node model has already been used successfully for testing 
the immunogenicity of vaccines95 and might be a promising development to overcome the drawbacks 
of the currently used models. 3D in vitro models such as the human artificial lymph node model might 
improve the predictability of immunogenicity of protein aggregates and make it possible to gain more 
insight into the underlying mechanisms of immunogenicity triggered by protein aggregates. Beside the 
development of 3D in vitro models the prediction of immunogenicity in silico gained interest of some 
research groups96–98. Successful correlations between in silico prediction of immunogenicity and 
corresponding experimental data has been published already98,99. However, in silico prediction of 
immunogenicity of therapeutic proteins is mainly based on the prediction and identification of T-cell 
epitopes binding to MHC molecules97. The focus is especially set on the primary structure of the 
proteins and factors such as aggregation e.g. are not considered100. Until now there are no publications 
available on in silico prediction of immunogenicity of protein aggregates. However, in silico methods 
for the prediction of immunogenicity will certainly be further developed in the upcoming years and 
could also be a complementary method to evaluate the immunogenicity of protein therapeutics and 
maybe also of protein aggregates. In summary, some studies were able to identify certain types of 
protein aggregates that triggered immunogenicity most in their study48,78, other studies using similar 
stress conditions of the proteins but different test models led to contradictory results76,84. For future 
experiments, a harmonized test model would help to evaluate and compare the immunogenicity of 
various types of protein aggregates. 
Finally, it is noteworthy to mention in-line filtration as a strategy to minimize particles in 
biopharmaceuticals prior to administration. It is without doubt that product manufacturers put a lot 
of effort in formulation development to release high quality products fulfilling the limitations set for 
particles in the Pharmacopoiea and USP101,102. However, particles and aggregates that form due to 
mishandling by the clinic staff or the patients or during transportation are not monitored and such 
particles can be administered to patients, e.g. during infusion therapy103. Ueda et al.104 recently 
published a study showing that mishandling of a Factor VIII product during reconstitution led to higher 
particle counts possibly being delivered to patients during administration of the drug. In the context 
of the immunogenicity risk of protein aggregates, in-line filtration represents a possibility to reduce 
particle numbers in products that were generated during post production mishandling and thus, to 
protect patients from particles potentially leading to immunogenic reactions. It has been shown 
already that filtration is an effective tool to remove larger particles104,105. Moreover, a very detailed 
report about in-line filtration revealed that almost 16% of all approved protein drugs listed in the Rote 
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Liste® require a filtration before administration106. Therefore in-line filtration could be a helpful tool to 
reduce the particle burden in infusion therapy, e.g., provided that the used filters are compatible with 
the protein and problems like filter shedding and protein adsorption are investigated. In parallel, test 
models used for the evaluation of immunogenicity must be further developed regarding their 
predictability of immunogenicity in humans. 
Table 1-1: Summary of studies evaluating the immunogenicity of protein aggregates using in vitro models. 
Protein Sample preparation Model Investigation of Reference 
Human 
recombinant 
mAbs 
Freeze/Thaw 
Shear 
Heat /Shaking 
PBMC 
Isolation of monocytes 
and differentiation to 
immature dendritic cells 
DC maturation 
 
Rombach-
Riegraf et 
al.55 
Intravenous 
immunoglobulin 
Heat 
Metal oxidation 
Mechanical stress (stirring/shaking) 
PBMC 
Primary monocytes 
Immortalized human 
monocyte-like cell lines: 
THP-1 and MM6 cells 
Innate immune 
response 
Cytokine release 
Complement 
activation 
Innate immune 
response 
E.M. 
Moussa et 
al.56 
mAb Stirring  
Heat (control sample) 
Fractionation of samples by 
centrifugation/sedimentation/FACS 
PBMC 
 
Early phase 
Late phase of 
immune response 
Cytokine profile 
Srivalli 
Telikepalli 
et al.60 
Human mAbs Stirring 
Shear stress 
Heat  
PBMC 
HLA-DR haplotyping 
 
Innate immune 
response 
Cytokine release 
profile 
T-cell proliferation 
Marisa K. 
Joubert et 
al.57 
Rituximab 
Trastuzumab 
Mechanical stress 
Heat  
Freeze/Thaw 
PBMC Cytokine release 
profile 
T-cell proliferation 
Uptake of 
aggregated 
antibodies by 
MoDCs 
Maryam 
Ahmadi et 
al.58 
mAbs Stirring PBMC 
HLA-DR haplotyping 
Cytokine release 
profile 
T-cell proliferation 
 
Marisa K. 
Joubert et 
al.59 
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Table 1-2: Summary of studies evaluating the immunogenicity of protein aggregates using in vivo models. 
Protein Stress condition Model Type of immune 
response 
Reference 
mAbs Heat/ Mechanical 
UV-Vis light 
Chemical stress (AAPH or H2O2) 
(in combination with heat and 
mechanical stress) 
Fractionation of samples by FACS 
hIgG1 transgenic mouse 
model 
wild-type mice (C57BL) as 
control 
ADAs Boll et al.48 
mAb Freeze/Thaw 
pH shift stress 
Heat stress 
Shake stress 
Metal-catalyzed oxidation 
Transgenic and non-
transgenic mice 
ADAs V. Filipe et 
al.82 
mAb and 
bispecific 
antibody-based 
construct 
Heat stress Swiss Webster mice, 
outbred 
ADAs Fathallah et 
al.92 
Murine mAb UV light stress 
Stirring stress 
Shaking stress 
Heat stress 
Fractionation of samples by 
AF4/centrifugation 
Female C57BL/6 J 
Female BALB/c  
ADAs Freitag et 
al.73 
Murine mAb Adsorption onto silicone oil 
microdroplets, glass 
microparticles or Alhydrogel® 
Female C57BL/6 J 
Female BALB/c 
ADAs Shomali et 
al.32 
rhIFNβ-1a Adjuvant solution Transgenic and non-
transgenic mice 
ADAs Kijanka et 
al.107 
mAbs Stirring stress 
Oxidation using H2O2 
Coating onto microspheres 
Xeno-het-mouse ADAs Bi et al.91 
rhIFNβ-1a 
rhIFNβ-1b 
Bulk 
Incubation at low pH and in 
presence of sodium chloride 
Isolation of soluble aggregates via 
a Superose 12 SEC column 
Transgenic and non-
Transgenic mice (C57B1/6 
x FVB/N hybrid mice) 
ADAs Van Beers 
et al.74 
Humanized scFv Heat stress 
Stir stress 
Female BALB/c strain 
mice 
ADAs Rantanji et 
al.75 
rhIFNβ-1a 
 
Metal-catalyzed Oxidation 
Oxidation using H2O2 
Guanidine mediated 
unfolding/refolding  
Wild-type mice 
Transgenic mice 
ADAs Van Beers 
et al.90 
mAb Low pH value 
Light stress 
Fractionation of samples by 
preparative exclusion 
chromatography 
Transgenic mice ADAs Bessa et 
al.83 
rhIFNα2b Metal-catalyzed oxidation 
Heat stress at various pH values 
Wild-type mice 
Transgenic mice 
ADAs Hermeling 
et al.76 
IFNα2a Cross-linking with glutaraldehyd Wild-type mice 
Transgenic mice 
ADAs Braun et 
al.77 
rhGH Agitation (Shaking) 
Freeze-thaw stress 
Disaggregation using high-
hydrostatic pressure 
Naïve adult mice 
Neonatally primed mice 
Transgenic mice 
ADAs Fradkin et 
al.84 
rhIFNα2b Metal-catalyzed oxidation 
Cross-linking with glutaraldehyde 
Oxidation with hydrogen peroxide 
Heat stress 
Wild-type mice 
Transgenic mice 
ADAs Hermeling 
et al.78 
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Factor VIII Incubation at 37°C and 80°C Von Willebrandt Factor 
deficient and Hemophilia 
A mice 
ADAs 
T-cell 
proliferation 
Cytokine analysis 
Pisal et al.86 
Adalimumab 
(mAb) 
Shaking stress with siliconized and 
nonsiliconized syringes 
BALB/c mice ADAs Uchino et 
al.108 
Human 
recombinant 
IFNα2b 
Agitation stress at 37°C 
Incubation at low pH 
Metal catalyzed oxidation 
Transgenic FVB/N mice 
Wild type FVB/n mice 
ADAs Human et 
al.85 
Murine 
monoclonal 
antibody 
Low pH + stirring 
Elevated temperature + stirring 
Fractionation of samples by 
centrifugation/SEC 
BALB/c mice  ADAs 
Follicular T-
helper cell 
detection 
Kijanka et 
al.49 
Murine growth 
hormone 
UV radiation BALB/c mice 
Nude BALB/c mice 
ADAs 
(IgG1, IgG3, IgM) 
Fradkin et 
al.109 
 The human artificial lymph node model 
 Lymph nodes 
Beside the spleen and mucosa associated lymphatic tissue, lymph nodes belong to the secondary 
lymphatic organs. Their function is to develop an adaptive immune response to antigens. The lymph 
node tissue can be divided into three areas: paracortex, cortex and medulla66,110. Within this area there 
are fissures and channels draining the lymph fluid and stromal cells such as MRCs (marginal reticular 
cells), FRCs (fibroblastic reticular cells) and FDCs (follicular dendritic cells) provide the lymphatic 
compartments with their structure66,111. The cortex is dominated by B-cells which are arranged as 
follicles and germinal centers, whereas the paracortex is dominated by T-cells66. The medulla contains 
transient plasma cells, macrophages and B-cells66. When an antigen presenting cell caught an antigen 
in the periphery, it will process the antigen, migrate to the lymph node and present it to T-cells in the 
paracortical zone via MHC class II molecules. Antigen-specific activated T-cells will then proliferate and 
migrate toward the boarder of the cortical zone, where they get in contact with B-cells66. After T/B-cell 
interaction, B cells will differentiate and start to produce antigen specific antibodies in the germinal 
centers66. Thus, lymph nodes are the site of action regarding the adaptive immune response. The 
application of a human artificial lymph node for the evaluation of immunogenicity of protein 
aggregates could therefore be a step into the future to improve the predictiveness of the currently 
used test models. 
 The human artificial lymph node model 
The human artificial lymph node model (HuALN) (Figure 1-4) is a micro-organoid culture system 
developed by Giese et al94. It is operated with peripheral blood mononuclear cells (PBMCs) and 
dendritic cells (DCs) from human donors in combination with allogeneic MSC-derived stromal cells 
which are embedded in hydrogel matrix sheets94,112. The housing is made of polysulfone and consists 
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of two compartments which are divided by a set of hollow fibres providing a continuous gas supply. 
The bioreactor can be challenged with the antigen via the injection port which is located at the media 
inlet port. Beside the continuous perfusion of the bioreactor with gas, the device is also perfused with 
media and cell suspension to ensure long-term cultivation under steady-state conditions. Moreover 
the cycling B-cell solutions simulates the lymph flow and ensures B-cell contact with the antigen 
primed DCs and T-cells95. The bioreactor system can be challenged multiple times during a culture time 
of 15-30 days. Sampling via a needle-free sampling port can be performed daily and a broad selection 
of read-out parameters can be analyzed95 (see 1.7.3). 
 
Figure 1-4: Schematic drawing of the HuALN bioreactor device (HIRIS™ III): Oxygenating membranes are surrounded by an 
immobilized matrix-assisted cell suspension. The gas supply perfuses horizontally and cell culture media and cell 
suspension flow vertically95. 
 Read-out parameters, advantages and applications of the human artificial lymph 
node model 
The human artificial lymph node system offers various read-out parameters on the level of cellular and 
humoral immunity. First, the secretion of cytokines as well as of antigen specific antibodies (IgG/IgM) 
can be analyzed95. Moreover, the histology of the cells after finishing the experiment can be 
investigated by flow cytometry and microscopy to gain further insight to the generation of follicle 
structures as shown by Giese et al.95 or to the kind of immune response which was induced (T-cell 
dependent or T-cell independent). This broad selection of read-out parameters represents one of 
several advantages that come along with the 3D human artificial lymph node system. The HuALN 
represents an in vitro model based on cells isolated from human donors with a fully developed immune 
system. Continuous and moderate perfusion enables the formation of antigen-dependent immune 
competent micro-organoid structures95. Besides, a long-term culture of more than four weeks is 
possible, and sampling can be performed daily. During the HuALN run, multiple re-stimulations by APCs 
and the drug can be performed simulating the real situations in patients when they get in contact with 
General introduction 
- 23 - 
 
an antigen. A further advantage of the HuALN system is its applicability in several fields. So far it has 
especially been used for testing immune modulators and small molecules, to proof the immunogenicity 
of vaccines and to exclude toxicity94,95. Due to the complexity of tissue engineering66, the development 
of a human artificial lymph node system has been a progress regarding the need for improved test 
models. However, the HuALN has not been used to evaluate the immunogenicity of protein aggregates 
yet and the following studies will show if the HuALN represents a future model for the pre-clinical 
assessment of immunogenicity. 
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 Objectives of this thesis 
The overall aim of this thesis was to evaluate the immunogenicity of protein aggregates of therapeutic 
antibodies in 2D and 3D in vitro models. The main focus was on the evaluation of a novel 3D artificial 
lymph node model, which was developed by Giese and colleagues1, for testing the immunogenicity of 
protein aggregates. The human artificial lymph node model represents a complex 3D matrix assisted 
bioreactor system differing from the currently used in vitro or in vivo systems in several aspects: The 
system is based on human cells, it enables long-term cultivation including several re-stimulations, it 
mimics the structure of a human lymph node by forming germinal centers and lymphatic follicles, and 
it has a broad range of read-out parameters on the B- and T-cell level1. The HuALN model has already 
been used to evaluate the immunogenicity of vaccines2, but it has not been used for testing the 
immunogenicity of protein aggregates yet. Even though many studies exist investigating the 
immunogenicity of protein aggregates in in vitro and in vivo, it is still unclear which types of protein 
aggregates possess the strongest immunogenicity. Recently, the focus of interest has shifted in 
particular to submicron particles and particles with strong chemical modifications3,4. However, results 
of these studies are often contradictive which is also due to the variety of different test models that 
have been used and the questionable predictiveness of immunogenicity in humans (see Chapter 1). 
The aim of the first part of this thesis was to evaluate the novel 3D in vitro human artificial lymph node 
model for testing the immunogenicity of protein aggregates. In addition, a further aim of this thesis 
was to determine the types of protein aggregates that are most immunogenic. To achieve these goals, 
protein aggregates had to be generated by exposing the monoclonal antibodies to different stress 
conditions. Chapter 4 describes the methodical approach to establish appropriate stress conditions 
and time points to generate protein aggregates of two monoclonal antibodies in a sustainable and 
reproducible amount. Moreover, a thorough analysis of the stressed protein samples is described. 
Based on the results of Chapter 4, the stress conditions and time points were selected for further 
studies. In addition, the stability of the selected stressed samples during storage at 2-8°C was 
investigated for the course of the HuALN experiment and results are described in Chapter 4. 
Chapter 5 focuses on the evaluation of the 3D human artificial lymph node model for testing the 
immunogenicity of protein aggregates. A selected panel of cytokines and DC marker was analyzed and 
compared between a 2D in vitro assay and the 3D HuALN. Moreover, the analysis of anti-drug 
antibodies of cell culture supernatants of the 3D HuALN is described. Finally, the diffusion behavior of 
particles through a dextran gel matrix was investigated to ensure that the generated protein 
aggregates diffuse into the gel matrix in the HuALN system so that the aggregates get in contact with 
immobilized leukocytes in the gel matrix. 
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The focus of the second part of this thesis was on “in-line filtration”. In-line filtration, also known as 
“bedside filtration”, can be described as a filtration step directly prior to the administration of a 
biopharmaceutical drug to the patient. Benjamin Werner showed in the scope of his thesis that in-line 
filtration is a highly effective method to reduce the particle burden in biopharmaceutical products5,6. 
He also addressed several issues that are associated with (in-line) filtration such as particle shedding 
from filters, leachables, protein adsorption, and conformational changes of the protein. However, it 
still remains to be investigated if in-line filtration has a positive effect on immunogenicity, meaning 
that in-line filtration is not only a tool to reduce particles but also in turn to reduce immunogenicity. 
Therefore, the aim of the study described in Chapter 6 was to evaluate the effect of in-line filtration 
on immunogenicity in a 3D HuALN model and a 2D in vitro dendritic cell assay which was developed 
and established for this study. Differently stressed samples of a monoclonal antibody prior to and after 
filtration were used to stimulate the HuALN or dendritic cells in a 2D assay. Dendritic cell markers and 
the presence of cytokines in the cell culture supernatants were analyzed, accordingly. 
Regarding particle numbers, biopharmaceutical products must comply with the limits of the 
Pharmacopoeias. For infusion or injection products in containers with a volume smaller than 100 mL, 
particles ≥ 10 µm are limited to 6000 particles and particles ≥ 25 µm to 600 particles per container7. It 
is without doubt, that pharmaceutical companies do their best to develop and produce biologic 
products of high quality. However, particles ≤ 10 µm are not limited by the Pharmacopoeias and might 
also pose a risk regarding immunogenicity3,8,9. Moreover, once the product has left the pharmaceutical 
manufacturer, the formation of particles can be triggered by transportation or inadequate post-
production handling by the clinic staff in hospitals or by patients, for example. Recently, some research 
groups focused on this topic and observed that incorrect product handling may lead to the formation 
of particles which are possibly administered to patients10,11. An in-line filtration step prior to the 
administration of the biological might provide the patient from particles in the product generated 
during transportation or incorrect post-production handling. To investigate particle numbers in 
marketed lyophilized and liquid biological products, several proteins/products were randomly selected 
and purchased to obtain marketed products with some shelf time. The aim of the study, described in 
Chapter 7, was to investigate if in-line filtration would be a possibility to reduce the particle burden in 
marketed products. Therefore, particle counts in marketed lyophilized and liquid biologics were 
analyzed and an in-line filtration step was performed before particle analysis was repeated. The focus 
hereby was on sub-visible and submicron particles. 
Materials and methods that were used for this thesis are described in Chapter 3. A final summary of 
this thesis is provided in Chapter 8. 
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 Materials 
 Monoclonal antibodies Adalimumab and Bevacizumab 
Two monoclonal antibodies, Adalimumab and Bevacizumab, were kindly provided by ProBioGen 
(Berlin, Germany). Adalimumab was formulated in a buffer containing 14 mM phosphate, 7 mM citrate 
and 105 mM sodium chloride at pH 5.2. The initial concentration of the used Adalimumab batches was 
45.1 mg/mL or 50.6 mg/mL. Bevacizumab was formulated in a 51 mM phosphate buffer at pH 6.2 at a 
concentration of 24.8 mg/mL or 16.6 mg/mL. Citric acid and sodium chloride were purchased from 
Bernd Kraft (Duisburg, Germany). Sodium citrate, disodium hydrogen phosphate and sodium 
dihydrogen phosphate were purchased from VWR International (Radnor, USA), AppliChem GmbH 
(Gatersleben, Germany) and Grüssing GmbH (Filsum, Germany), respectively. For the preparation of 
all buffers, highly purified water, generated by a PURELAB Plus instrument (USF Elga, Celle, Germany) 
was used. All buffers were sterile filtered using a 0.2 µm cellulose acetate filter (VWR International, 
Radnor, USA) before use. Prior to the exposure to different stress conditions, the antibody solutions 
were diluted to the desired concentration for the planned study and filled into cleaned, depyrogenized 
10R vials. Finally, the vials were sealed with rubber stoppers and crimped. 
The Bevacizumab batch used for the in-line filtration study (see Chapter 6) had an initial concentration 
of 26.1 mg/mL. For this experiment, a volume of 16 mL of the antibody solution was filled into cleaned 
and depyrogenized 20R vials, sealed with autoclaved rubber stoppers and crimped. 
 Methods used for the generation of protein aggregates 
 Light stress 
For exposition of the samples to light, a Sunset CPS radiation chamber (Heraeus Holding, Hanau, 
Germany) was used. Radiation intensity was set to 55±5 W/m². A xenon lamp was used as light source. 
The desired volume of the antibody solution was filled into 10R vials and positioned in the center of 
the radiation chamber. For the stress study (see Chapter 4), sampling was performed after 24 and 
48 hours (only Adalimumab), four and seven days. For control experiments, only buffer was exposed 
to light as well as protein solution completely shielded with aluminum foil to control the influence of 
temperature increase (30-35°C) during exposure to light. 
 Stir stress 
For stir stress, 10R glass vials were filled with the desired volume of the antibody solution. 
Polytetrafluorethylene (PTFE)–coated stir bars of a size of 10x3 mm and a Variomag multipoint stirrer 
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(Thermo Fisher Scientific, Schwerte, Germany) were used. Speed was set to 240 rpm, and the samples 
were stirred at room temperature for 4, 24 and 72 hours. For control experiments, pure buffer solution 
was treated using the same conditions. 
 Heat stress 
Heat stress of Bevacizumab was performed in 10R glass vials filled with the desired volume of antibody 
solution. The vials were incubated in a cabinet dryer (Memmert, Schwabach, Germany) at a 
temperature of 50°C for up to 7 days. For the stress study (Chapter 4), sampling was performed after 
24 hours, four, and seven days. For control experiments, pure buffer solution was exposed to heat 
using the same conditions. 
 Chemical oxidation stress using tert-butyl hydroperoxide (tBHP) 
For the chemical oxidation, a volume of 10 mL of the antibody solution was incubated with 1 % tBHP, 
(Merck, Darmstadt, Germany) for 16 hours at room temperature and protected from light. The 
reaction was stopped by dialysis of the protein solution against a volume of 3L of the pre-cooled 
formulation buffer using a Slide-A-Lyzer® gamma irradiated dialysis cassette (Thermo Fisher Scientific, 
Waltham, USA) with a 10 kDa molecular weight cut-off. Dialysis was performed for 24 hours at room 
temperature. The buffer was exchanged after four and eight hours. Finally, the sample was filled into 
cleaned and depyrogenized vials, sealed with rubber stoppers and crimped. 
 Methods used for the analysis of protein aggregates 
 Turbidity 
For turbidity measurements, a volume of 2 mL of the sample was measured by 90°C light scattering at 
λ=860 nm using a NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany). Results are reported in 
formazine nephelometric units (FNU). Samples were not diluted for turbidity measurements and 
measured in triplicates. 
 Light Obscuration 
Light obscuration was measured using a PAMAS-SVSS-C Sensor HCB-LD 25/25 (Partikelmess- und 
Analysensysteme GmbH, Rutesheim, Germany). Before each measurement, 0.3 mL of the sample were 
flushed through the system, afterwards three aliquots of 0.2 mL of each sample were analyzed. 
Between the measurements, the system was cleaned with highly purified water until less than 
30 particles per mL could be detected. Particle numbers were calculated as mean value out of three 
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measurements, referring to a volume of 1 mL. Samples were not diluted for the measurements, if 
possible. If sample measurements were not possible due to high particle numbers, samples were 
diluted in order to reach the concentration range of the PAMAS. 
 Flow imaging microscopy 
Particle numbers were also determined using a FlowCam® 8000 (Fluid Imaging Technologies, Inc., 
Scarborough, USA) with a 10x magnification. A volume of 200 µl of each sample was analyzed using a 
flow rate of 0.15 mL/min. After each measurement, the system was flushed with highly purified water 
and 2% Hellmanex® solution until the flow cell was free of particles. Particle numbers were calculated 
as mean value out of three measurements, referring to a volume of 1 mL. Data was evaluated using 
the VisualSpreadsheet® Software (Fluid Imaging Technologies, Inc., Scarborough, USA). 
 Dynamic light scattering (DLS) 
A Malvern Zetasizer Nano ZS (Malvern, Herrenberg, Germany) was used for DLS measurements. 
Temperature was set to 25°C, and non-invasive backscattering at an angle of 173° was performed at 
25°C using a Helium-neon-laser at 633 nm. The refractive index was set to 1.45 (aqueous protein 
solution). A volume of 700 µl of the antibody solution was measured in half-micro cuvettes made of 
polystyrene (Fisher Scientific, Schwerte, Germany). Some samples had to be diluted due to strong 
turbidity. All samples were measured in triplicates. Finally, the polydispersity index (PDI) and the Z-
average diameter (Zave) were calculated using the Dispersion Technology Software (Version 7.0, 
Malvern). 
 Size exclusion chromatography (SEC) 
Size exclusion chromatography measurements were conducted using a Waters system with UV 
detection (Waters GmbH, Eschborn, Germany). As solid phase a TSKgel G3000SWXL column (Tosoh 
Bioscience) or a YMC-Pack-Diol 300 (YMC Europe GmbH, Dinslaken) were used. The different columns 
provided equal resolution of the protein peaks and the change between the suppliers was justified by 
financial aspects. A PBS buffer containing 50 mM phosphate and 300 mM sodium chloride at pH 7.0 
with a flow rate of 0.5 mL/min was used as mobile phase. In order to remove insoluble aggregates, 
samples were centrifuged at 5000 rpm for 10 min before injection. The injection volume for samples 
of the stress study described in Chapter 4 was 10 µl at a concentration of 4 mg/mL. Bevacizumab 
samples used for the in-line filtration study described in Chapter 6 were diluted 1 to 20 to a final 
concentration of 1.305 mg/mL and a volume of 20 µl was injected. Each sample was measured as 
duplicate. The area under the curve (AUC) of the unstressed sample was defined as 100%. 
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 Protein A chromatography 
Protein A chromatography measurements were conducted using a Waters system with UV detection 
(Waters GmbH, Eschborn, Germany). As solid phase, a PA ID Sensor cartridge (Life Technologies, 
Carlsbad, California, USA) was used. Solvent A was a Dulbecco’s phosphate buffered saline (DPBS) 1x 
in water at pH 7.4. Solvent B contained 100 mM acetic acid and 150 mM NaCl at a pH of 2.8. After 10 
minutes of 100% solvent A, the percentage of solvent B rose to 60% within 30 minutes. Within one 
minute the percentage was increased to 100% solvent B and was held for 10 minutes before the 
percentage of solvent B dropped again to 0% within one minute. Samples were measured at a 
concentration of 26.1 mg/mL. In order to remove insoluble aggregates, samples were centrifuged at 
14 000 rpm for 10 min before injection. The injection volume was 10 µl and each sample was measured 
as triplicate. As a positive control, Bevacizumab at a concentration of 26.1 mg/mL was incubated with 
2% tert-butyl hydroperoxide (tBHP) for 56 hours to create a fully oxidized sample. The area under the 
curve (AUC) of the unstressed sample was defined as 100%. 
 Ion exchange chromatography (IEX) 
To detect the influence of heat and stir stress on the charge variants of Bevacizumab, ion exchange 
chromatography (IEX) was performed according to Farnan et al.1. IEX was performed using a Waters 
2695 Separation Module coupled to a Waters 2487 Dual λ Absorbance Detector (Waters GmbH, 
Eschborn, Germany). For separation, a 4 mm x 50 mm Dionex ProPac® WCX-10G guard column was 
connected to an analytical 4 mm x 250 mm Dionex ProPac®WCX-10 column. A volume of 50 µl of each 
sample at a concentration of 1 mg/mL was injected. Mobile phase A contained Trizma Base® (2.4 mM), 
imidazole (1.5 mM) and piperazine (11.6 mM) at a pH of 6.0. Mobile phase B contained Trizma Base® 
(2.4 mM), imidazole (1.5 mM), piperazine (11.6 mM), and 20 mM NaCl at a pH of 9.5. The flow rate 
was set to 1 mL/min. The gradient of mobile phase B is graphically illustrated in Figure 3-1. 
 
Figure 3-1 Gradient of mobile phase B for IEX measurements of Bevacizumab. 
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 Fourier transform infrared spectroscopy (FT-IR) 
Native and stressed protein samples were analyzed using a Bio ATR II unit of a Tensor 27 spectrometer 
(Bruker Optics GmbH, Ettlingen, Germany). The samples were not diluted for the measurements. 
Temperature was set to 20°C. Spectra were collected from 4000 cm-1 to 1000 cm-1 with a resolution of 
4 cm-1. Scans (120 in total) were averaged for each sample measurement. Each spectrum was 
background corrected and vector normalized by the OPUS software (Version 7.5, Bruker Optics, 
Ettlingen, Germany). Second derivatives were calculated and smoothened on 17 points. 
 Extrinsic fluorescence spectroscopy 
Extrinsic protein fluorescence measurements were conducted using a Varian Cary Eclipse fluorescence 
spectrometer (Varian, Inc., Darmstadt, Germany). Bis-ANS (4,4′-Dianilino-1,1′-binaphthyl-5,5′-
disulfonic acid) at 20 µM concentration was used as fluorescent dye. Samples were diluted to a 
concentration of 0.5 mg/mL or 1 mg/mL and measured in triplicates in black 96-well plates (Nunc, 
Denmark), using a volume of 200 µl for each well. In order to remove the insoluble aggregates, samples 
were centrifuged at 5000 rpm for 10 minutes before pipetting into the well plate (only for samples of 
the stress study (Chapter 4)). Temperature was set to 20°C. The excitation wavelength was set to 
385 nm, the excitation slit was fixed at 5 nm. Emission was recorded from 395 nm to 600 nm using a 
5 nm emission slit. Scanning rate was set to 120 nm/min or 30 nm/min and the voltage of the 
photomultiplier was set to 800V. The mean spectrum of each triplicate was calculated. 
 Intrinsic fluorescence spectroscopy  
Intrinsic protein fluorescence measurements were conducted on a Varian Cary Eclipse fluorescence 
spectrometer (Varian, Inc., Darmstadt, Germany). Temperature was set to 20°C. The samples were 
diluted to a concentration of 1 mg/mL and measured in triplicates in black 96-well plates (Nunc, 
Denmark), using a volume of 200 µl for each well. In order to remove the insoluble aggregates, samples 
were centrifuged at 5000 rpm for 10 minutes before pipetting the sample into the well plate (only for 
samples of the stress study (Chapter 4)). The excitation wavelength was set to 295 nm and the 
excitation slit was fixed at 10 nm. Emission was recorded from 300 to 500 nm using a 5 nm emission 
slit. The scanning rate was set to 30 nm/min and the voltage of the photomultiplier was set to 800 V. 
The mean spectrum of each triplicate was calculated. 
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 Endotoxins 
 Endochrome - K® Test 
The endotoxin content of the samples was tested using a Limulus Amebocyte Lysate Endosafe 
Endochrome-K® Test (Charles River, Wilmington, USA). The samples were prepared and analyzed 
according to the manufacturer’s instruction. The absorbance was measured at 405 nm and 37°C using 
a FLUOstar Omega (BMG Labtech, Ortenberg, Germany). Prior to testing in the HuALN, all samples 
were diluted to a concentration of 1 mg/mL and 0.5 mg/mL, respectively. Therefore, we accepted an 
upper limit of endotoxins of 3 EU/mL in the undiluted samples. The endotoxin levels of all samples 
were found to be below this limit. 
 Endosafe® - PTS Device 
The endotoxin levels of the Bevacizumab samples for the in-line filtration studies were detected using 
an ENDOSAFE®- PTS device (Charles River,Wilmington, USA). The test was performed according to the 
manufacturer’s instruction. The cartridges had a sensitivity range of 0.5 - 0.005 EU/mL and all samples 
had to be diluted 1:20 for the measurement. The endotoxin levels of all samples were found to be 
below the limit of 3 EU/mL. 
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 Methods used for the evaluation of immunogenicity of protein aggregates 
in a 3D human artificial lymph node model (Chapter 5) 
 Generation of protein aggregates 
For the generation of protein aggregates, the two monoclonal antibodies were exposed to light, 
mechanical and heat stress for a defined time as described in Table 3-1. A volume of 4 mL (2D in vitro 
assay) or 6 mL (HuALN) of the protein solution were filled into 10R vials (MGlas AG, Münnerstadt, 
Germany), respectively, sealed with rubber stoppers (West Pharmaceutical Services, Exton, USA) and 
crimped. Adalimumab at a concentration of 20 mg/mL (2D in vitro assay) or 45.1 mg/mL (HuALN) and 
Bevacizumab at a concentration of 10 mg/mL (2D in vitro assay) or 24.8 mg/mL (HuALN) were exposed 
to light for 48h and 24h, respectively. Light stress was performed in a Sunset CPS radiation chamber 
(Heraeus Holding, Hanau, Germany) using a xenon lamp as light source. The radiation intensity was set 
to 55 ± 5 W/m². To generate aggregates by mechanical stress, the samples were stirred using 10x3 mm 
sized polytetrafluorethylene (PTFE)–coated stir bars on a Variomag multipoint stirrer (Thermo Fisher 
Scientific, Schwerte, Germany) at 240 rpm for 24h. Bevacizumab was additionally exposed to heat for 
4 days in a cabinet dryer (Memmert, Schwabach, Germany) at 50°C. 
Table 3-1: Overview of samples tested in the human artificial lymph node model. 
Protein Sample Stress conditions Duration 
Adalimumab    
 Unstressed1 - - 
 Light stress 55 ± 5 W/m² 48h 
 Stir stress 240 rpm 24h 
 Formulation buffer2 - - 
Bevacizumab    
 Unstressed1 - - 
 Light stress 55 ± 5 W/m² 24h 
 Stir stress 240 rpm 24h 
 Heat stress 50°C 4 days 
1 “Unstressed“ = Unstressed protein solution; 2 “Formulation buffer“ = Formulation buffer only (no protein in sample). 
 Extrinsic fluorescence spectroscopy 
Extrinsic protein fluorescence measurements were conducted using a Varian Cary Eclipse fluorescence 
spectrometer (Varian, Inc., Darmstadt, Germany). Bis-ANS (4,4′-Dianilino-1,1′-binaphthyl-5,5′-
disulfonic acid) at 20 µM concentration was used as fluorescent dye. Samples were diluted to a 
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concentration of 1 mg/mL and measured in triplicates in black 96-well plates (Nunc, Denmark), using 
a volume of 200 µl for each well. For instrument settings see section 3.3.9. 
 Fourier transform infrared spectroscopy (FT-IR) 
Native and stressed protein samples were analyzed at 24.8 mg/mL (Bevacizumab) or 45.1 mg/mL 
(Adalimumab) using a Bio ATR II unit of a Tensor 27 spectrometer (Bruker Optics GmbH, Ettlingen, 
Germany). For instrument settings see section 3.3.8. 
 Size exclusion chromatography 
Size exclusion chromatography measurements were performed using a Waters system with UV 
detection at 280 nm (Waters GmbH, Eschborn, Germany). As solid phase a YMC-Pack-Diol 300 (YMC 
Europe GmbH, Dinslaken) was used. A PBS buffer containing 50 mM phosphate and 300 mM sodium 
chloride at pH 7.0 at a flow rate of 0.5 mL/min was used as mobile phase. Samples were diluted to a 
concentration of 1.24 mg/mL (Bevacizumab, 1:20 dilution) and 1.13 mg/mL (Adalimumab, 1:40 
dilution), respectively. In order to remove insoluble aggregates, samples were centrifuged before 
injection. The injection volume was 20 µl, and each sample was measured in duplicates. 
 Cell preparation 
Cells were prepared as described previously2,3. Briefly, PBMCs were isolated from leukapheresis 
material by density gradient centrifugation. The monocytes were further isolated by CD14-magnetic 
bead separation and differentiated into iDCs using rhIL-4 and rhGM-CSF (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany). After 6 days of cultivation, differently stressed samples of Bevacizumab 
and Adalimumab (`stressed antibody samples´) were added to iDC culture for 24h. Generated DCs were 
tested by a panel of DC markers (CD80, CD83, CD86, HLA-DR, HLA-ABC; Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) according to the manufacturer´s protocol. The CD14-negative fraction 
(CD14- PBMCs) was stored cryopreserved for later use. 
ATSVF cells (Adipose tissue stromal vascular fraction/Human Stromal Vascular Fraction; Pelobiotech 
GmbH, Planegg, Germany) were differentiated into Fibroblastic reticular cells (FRC)-like cells using a 
10-day protocol. ATSVF cells were stimulated with 100 ng/ml Lymphotoxin α1β2 (R&D Systems Inc., 
Minnesota, USA) and 10 ng/ml TNF-α (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany) for 10 days 
to induce Fibroblastic reticular cells (FRC)-like development as described previously4. 
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 2D cell culture experiments 
Differently stimulated DCs and CD14- PBMCs were seeded into multiwell-compartments (1:10) (n=2) 
at a total density of 2.75*106/ml, supplemented with stressed antibody samples (0.05 mg/ml, 
0.5 mg/ml, 5 mg/ml Bevacizumab and 0.1 mg/ml, 1 mg/ml, 10 mg/ml Adalimumab) and cultivated for 
48h including controls lacking one of the two cell fractions as well as negative control (w/o any 
supplement) and positive control (IL-1β, IL-6, TNFα at 10 ng/ml and PGE2 at 1 µg/ml). A co-culture 
control was stimulated with 2 mg/mL Concanavalin A (ConA) (Sigma, Taufkirchen, Germany). 
Supernatant volumes of 100 µl each were collected for cytokine analysis (see End point analysis). Cells 
were harvested with PBS + 2 mM EDTA (Fisher Scientific, Loughborough, UK) and analyzed by flow 
cytometry (DC marker: see Cell preparation; Co-culture marker: CD3, CD4, CD8, CD25, CD69 (Miltenyi 
Biotec GmbH) and EdU (EdU DetectPro Cell Proliferation Flow Cytometry Kit, Baseclick GmbH, Neuried, 
Germany, according to suppliers’ protocol). Supernatant from DC culture and co-cultures were 
collected and analyzed for cytokine levels (IL-2, IL-4, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-13, IFN-γ, TNF-
α) using V-PLEX Proinflammatory Panel 1 Human Kit (Meso Scale Diagnostics, Rockville, Maryland, USA) 
on MESO QuickPlex SQ 120 as described in the supplier´s technical note. 
 
Figure 3-2: Schematic illustration of the DC/T-cell assay used in this study. PBMCS were isolated from human blood and 
monocytes were isolated by magnetic bead separation. Immature dendritic cells were generated by cultivation with IL-4 
and GM-CSF. Finally, immature dendritic cells were stimulated with the desired antigen, incubated and CD14 depleted 
PBMCs were added to obtain a co-culture. After incubation, cells and culture supernatants were analyzed. PBMC: 
Peripheral mononuclear cells; iDC: immature dendritic cells; mDCs: mature dendritic cells. 
 Human artificial lymph node (HuALN) bioreactor experiments 
The HIRISTMIII bioreactor2 enables high-density matrix-assisted cultures of more than 
1*108 cells/bioreactor including a large T cell repertoire. The bioreactor culture was already described 
before3. Briefly, each bioreactor was inoculated with 1*107 DCs, 1.5*108 autologous CD14- PBMCs 
(1:15) and 5*105 stromal cells split in two sheets of RGD-dextran hydrogel matrix (Cellendes GmbH, 
Reutlingen, Germany) as recommended by the supplier. Medium perfused the bioreactor system at a 
rate of 1 mL/day and filled the incorporated sample reservoir. The HuALN system was initially 
stimulated with unstressed or stressed antibody samples (0.5 mg/ml Bevacizumab, 1 mg/ml 
Adalimumab) and re-stimulation on day 7, 14, and 21 included in addition freshly prepared dendritic 
cells. Bioreactor culture time was 28 days. 
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 In-process controls and end point analyses 
Cell culture supernatant was collected daily from the bioreactor reservoir, subsequently aliquoted, and 
stored at -20°C. Samples were subject to cytokine analysis (as described above). On the day of harvest, 
matrix sheets were removed from the bioreactor and digested by dextranase 1:200 in PBS (Cellendes 
GmbH, Reutlingen, Germany) for 1h at 37°C. Cell number and viability was determined (ViCell, 
Beckman Coulter) as well as CD marker expression using flow cytometry (MACS Quant, Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany). 
 Analysis of HuALN culture experiments 
Analyzed supernatant cytokine levels were displayed as time response over the entire culture time of 
28 days. The area under curve was calculated using the linear trapezoidal rule method for every single 
cytokine profile over the time (OriginLab Version 8.1 Integration). The curve was divided into pieces 
and the software calculates the sum of each trapezoid to estimate the integral by  
 
This AUC value was calculated for each run, and each cytokine profile and subsequently normalized to 
the control run, which was in this case the unstressed antibody sample. Values below 1 indicate 
downregulation of the particular cytokine compared to the control, whereas values larger than 1 imply 
an upregulation. In a next step, the sum of the normalized values (AUC*) from different cytokines 
belonging to one or more of 4 selected groups as shown in Table 3-2 which are pro-inflammatory 
immune response (Pro-inf), anti-inflammatory immune response (Anti-inf), T helper cell 1 (TH1) and 
T helper cell 2 (TH2) immune response, was calculated. Afterwards the sums were divided by the 
number of cytokines within the current group resulting in values of 1 for the control run and values 
larger or smaller than 1 for every other run. Visualizing these values in a spider grid diagram allows 
recognizing the overall effect of the drug in a simplified way. The drug either promotes or suppresses 
the immune reaction of the HuALN in a specific direction. For further explanation, see Figure 3-3. 
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Table 3-2: Cytokine groups: analyzed cytokines are classified to groups based on their immunological function for a 
simplified analysis of immune responses in HuALN bioreactors. 
Groups Assorted cytokines 
Pro-inflammatory IL-1β 
IL-6 
IFN-у 
TNF-α 
Anti-inflammatory IL-6 
IL-10 
TH1 IL-2 
IL-12p70 
IFN-у 
TNF-α 
TH2 IL-4 
IL-6 
IL-10 
IL-13 
 
IFNAUC c  
IFNAUC drug1 
AUC* c = IFNAUC c / IFNAUC c = 1 
AUC* drug1 = IFNAUC drug1 / IFNAUC c = x 
 
 
Example: 
q Th1 = (IL-1ßAUC* drug1 + IL-6AUC* drug1 + IFNyAUC* drug1 + TNFaAUC* drug1) /z TH1 
Figure 3-3: Additional formula for the explanation of the applied method for cytokine evaluation. AUCs are derived from 
cytokine profiles over time, which are normalized and then merged into groups before visualization. 
 Analysis of anti-drug antibodies (ADAs) 
Anti-drug antibodies were analyzed via a bridging ELISA assay (see Figure 3-4), which was performed 
using MSD Gold 96-well-Streptavidin Quickplex plates (MSD, Kenilworth, USA). The ADA assays for 
Adalimumab and Bevacizumab were established according to the manufacturer’s instructions (MSD, 
Kenilworth, USA) and performed at ProBioGen (Berlin, Germany). For analyzing ADAs in the cell culture 
supernatants, a volume of 50 µl of master mix (containing biotinylated drug and SULFO-TAG labeled 
drug mixture) and 25 µl of sample or standard were added to each well of a non-binding 96-well plate, 
c = control run (unstressed antibody sample) 
AUC = area under curve of the specified cytokine 
AUC*= normalized AUC 
z = number of cytokines in group 
q = extent of immune response 
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accordingly. The plate was sealed and incubated for 1-2 hours at room temperature with moderate 
shaking or incubated overnight at 4°C. During the master mix incubation, a volume of 150 µl of blocking 
solution was added to each well of the streptavidin gold plate. The plate was sealed and incubated for 
at least 30 minutes at room temperature. Subsequently, the blocking solution was removed from the 
streptavidin gold plate and the plate was washed with washing buffer. A volume of 50 µl from each 
well of the “pre-incubation” plate with the master mix was transferred to the streptavidin gold plate. 
The plate was sealed and incubated for one hour at room temperature shaking at 300-700 rpm. 
Subsequently, the plate was washed three times with at least 200 µl of wash buffer per well. A volume 
of 150 µl per well of 2x read buffer T was added and finally, the electrochemoluminescence was 
measured on a Meso Quickplex SQ120 (MSD, Kenilworth, USA). A standard curve with concentrations 
of 2500 ng/mL, 625 ng/mL, 156.25 ng/mL, 39.06 ng/mL, 9.77 ng/mL, 2.44 ng/mL and 0.61 ng/mL for 
Adalimumab and Bevacizumab was monitored, accordingly, and concentrations of anti-drug 
antibodies were calculated using DISCOVERY WORKBENCH 4.0. 
 
Figure 3-4: Schematic overview of a bridging ELISA assay. 
 Investigations on the diffusion behavior of fluorescent particles through a 3D Life 
dextran-CD hydrogel using a Franz Cell model 
 Materials and set-up 
Green fluorescence microsphere suspensions of particles at a concentration of 10 mg/mL and a size of 
26 nm and 2 µm (Distrilab Particle Technology B.V., Leusden, Netherlands) were used as model 
particles. The experiment was performed using a Franz Cell model (see Figure 3-5) with PBS Buffer 
(SIGMA Aldrich, St. Louis, Missouri, USA) as acceptor medium. The Franz Cell was tempered at 37°C 
and sampling was performed after 24, 48, 72 hours and 4 days or after 24, 48, 72 hours, 6 and 7 days. 
As controls, cellulose acetate membranes with a cut-off of 0.2 µm and 5 µm were used. An amount of 
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5 mg of particles was pipetted on top of the membrane or gel, respectively. In order to obtain a 
homogenous distribution of particles in the acceptor medium, a stir bar was added to the Franz Cell. 
The Franz Cells were placed on a magnetic stirrer (Thermo Fisher Scientific, Waltham, USA), and 
rotation speed was set to 200 rpm. 
 
Figure 3-5: Schematic drawing of a Franz Cell model used for this experiment. 
 Preparation of 3D Life Dextran–CD hydrogel SG 
The components and its concentrations of the used 3D Life Dextran-CD Hydrogel (Cellendes, GmbH, 
Reutlingen, Germany) are listed in Table 3-3. According to the manufacturer’s instructions, water, 
10xCB and the SG-polymer (SG-Dextran) were pipetted into a reaction tube and mixed well by pipetting 
up and down. The RGD-peptide (thiol-peptide) was added and mixed immediately. The sample was 
incubated for 20 minutes at room temperature. Finally, the cross-linker (CD-Link) was added and the 
mixture was pipetted up and down few times before the gel was placed in a custom-made teflon mold 
within one minute. The diameter of the dextran gel was 30 mm with a height of 2 mm. The gel was 
incubated at least for 10 minutes at room temperature to allow the gel to solidify. The solidified gel 
was subsequently used for the experiment. 
Table 3-3: Overview of components and concentrations used for the preparation of the 3D Life dextran-CD hydrogel SG. 
Component Stock concentration [mMol/L] Final concentration [mMol/L] 
Thiol-reactive polymer 30 2.5 
Crosslinker 20 2 
Thiol-peptide 20 0.5 
Thioglycerol 0 - 
 Analysis of acceptor medium by fluorimetry 
The concentration of fluorescent particles diffused to the acceptor medium was determined using 
fluorescence spectroscopy. Measurements were performed on a Varian Cary Eclipse fluorescence 
spectrometer (Varian, Inc., Darmstadt, Germany). The excitation wavelength was set to 468 nm and 
the excitation slit was fixed at 5 nm. The emission wavelength was set to 508 nm using a 2.5 nm 
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emission slit. The voltage of the photomultiplier was set to 600V. Samples were measured in triplicates. 
In order to calculate the particle concentration in the samples, calibration curves were measured for 
26 nm and 2 µm particles, respectively (Figure 3-6). Finally, the yield was calculated and displays the 
particle concentration in % relative to the applied particle amount in mg. 
A 
 
B 
 
Figure 3-6: Calibration curves for 2 µm (A) and 26 nm (B) fluorescent particles in PBS. 
 Analysis of 3D Life Dextran-CD hydrogel SG by microscopy 
On the last day of the experiments, the hydrogels were washed with PBS until the washing solution 
was clean (determined by fluorescence spectroscopy, see 3.5.11.3) and analyzed using a Keyence 
BZ8100 Fluorescence microscope (Keyence, Osaka, Japan) equipped with a Nikon SPlan Fluor 20x/0.45 
objective (Nikon, Japan). The gel was screened from the top to the bottom and photographs were 
taken. 
 Methods used for investigating the effect of in-line filtration on 
immunogenicity (Chapter 6) 
 In-line filtration process used for the evaluation of immunogenicity in a 3D human 
artificial lymph node model 
For the analysis of the filtered samples, a volume of 4 mL of the heat stressed and stir stressed samples 
was filtered using PharmAssure® syringe filters (Pall Corporation, New York, USA) with a pore size of 
0.2 µm. For evaluating the effect of in-line filtration in the human artificial lymph node model, a volume 
of about 1 mL was filtered directly prior to the stimulation of the dendritic cells or the human artificial 
lymph node model using PharmAssure® syringe filters (Pall Corporation, New York, USA) with a pore 
size of 0.2 µm. The unstressed protein solution was also filtered using a PharmAssure® filter (Pall 
Corporation, New York, USA) with a pore size of 0.2 µm. 
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 In-line filtration process used for the evaluation of immunogenicity in a 2D dendritic 
cell assay 
For the analysis of unstressed and stressed Bevacizumab and for testing the effect of in-line filtration 
in a 2D dendritic cell assay, the desired samples were filtered using an Acrodisc® syringe filter (Pall 
Corporation, New York, USA) with a pore size of 0.2 µm directly prior to cell stimulation or analysis of 
the filtered samples. 
 Hold-up volume PharmAssure® filter 
In order to determine the hold-up volume of the used PharmAssure® syringe filter (Pall Corporation, 
New York, USA), a volume of 2 mL formulation buffer was filtered by a PharmAssure® filter. The filtrate 
was weighed prior to and after filtration. To optimize the hold-up volume, 6 mL of air were filtered 
through the used filter and the mass of the filtrate was determined again after purging a volume of 
3 mL of air and after reaching the bubble point. 
 Hold-up volume Acrodisc® filter 
The hold-up volume was also determined for the Acrodisc® syringe filter (Pall Corporation, New York, 
USA). A volume of 2 mL formulation buffer was filtered by an Acrodisc® filter and the filtrate was 
weighed prior to and after filtration. To optimize the hold-up volume, a volume of 1 mL of air was 
purged through the used filter and the mass of the filtrate was determined again. 
 Filter quality PharmAssure® filter 
To ensure the quality of the PharmAssure® filters (Pall Corporation, New York, USA), a solution of a 
monoclonal antibody at a concentration of 25 mg/mL was stirred with a 10x3 mm sized PTFE–coated 
stir bar and a Variomag multipoint stirrer (Thermo Fisher Scientific, Schwerte, Germany) for 24 hours. 
The speed was set to 240 rpm. The stressed protein solution was subsequently filtered with ten 
PharmAssure® filters (Pall Corporation, New York, USA) and particle numbers were determined by light 
obscuration using a PAMAS-SVSS-C Sensor HCB-LD 25/25 (Partikelmess- und Analysensysteme GmbH, 
Rutesheim, Germany). Before each measurement, 0.3 mL of the sample were flushed through the 
system, afterwards three aliquots of 0.2 mL of each sample were analyzed. Between the 
measurements, the system was flushed with highly purified water until the system was clean. Particle 
counts were calculated as mean value out of three measurements, referring to a volume of 1 mL. 
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 Methods used for the evaluation of immunogenicity using a 2D dendritic cell assay 
 Isolation of mononuclear cells from human peripheral blood by density gradient 
centrifugation 
Human blood (approx. 7.5 mL) was transferred to a 50 mL falcon tube and diluted with 27.5 mL (total 
volume of diluted blood sample 35 mL) of pre-cooled (2-8°C) PBS buffer containing 2 mM EDTA at 
pH 7.2. The diluted cell suspension was carefully layered over 5 mL Ficoll-Paque® Reagent (GE 
Healthcare, Uppsala, Sweden) and centrifuged at 400xg for 30 minutes at 20°C in a swinging-bucket 
rotor without brake. After aspirating the upper layer, the interphase containing lymphocytes, 
monocytes and thrombocytes was transferred to a new Falcon tube (50 mL). The tube was filled with 
PBS buffer containing 2 mM EDTA to a total volume of 50 mL and centrifuged at 300xg for 10 minutes 
at 20°C. The supernatant was removed completely. For the removal of platelets, the cell pellet was 
resuspended in 50 mL of PBS buffer containing 2 mM EDTA and subsequently centrifuged at 200xg for 
10 minutes at 20°C. The washing step was repeated once, and the supernatant was removed 
completely. Finally, the cell pellet was resuspended in 20 mL of MACS buffer (PBS incl. 2 mM EDTA and 
0.5% BSA at pH 7.2) for the isolation of CD14 positive cells from PBMCs. 
 Isolation of CD14 positive cells from PBMCs and differentiation of Mo-DCs 
After determining the cell number, the cell suspension was centrifuged at 300xg for 10 minutes and 
the supernatant was removed completely. The cell pellet was resuspended in 80 µl of buffer containing 
2 mM EDTA and 0.5% BSA at pH 7.2 per 107 total cells. A volume of 20 µl of CD14 Microbeads (Miltenyi 
Biotech, Bergisch-Gladbach, Germany) per 107 total cells was added, mixed well and incubated for 
15 minutes at 2-8°C. Finally, cells were washed by adding 1 mL of MACS buffer per 107 cells and 
centrifuged at 300xg for 10 minutes. The supernatant was removed completely and up to 108 cells 
were resuspended in 500 µl of buffer. The magnetic separation was performed using LS columns 
(Miltenyi Biotech, Bergisch-Gladbach, Germany). The column was placed in the magnetic field and 
washed with 3 mL MACS buffer. Subsequently, the cell suspension was added to the column. To collect 
the unlabeled fraction, 3x3 mL MACS buffer were passed through the column. Finally, the column was 
removed from the magnetic field and placed on a 15 mL falcon tube. A volume of 5 mL of MACS buffer 
was pipetted onto the column and immediately flushed out by pushing the plunger into the column. 
The cell number was determined, and cells were seeded at a density of 107 cells per 10 mL Mo-DC 
differentiation medium (Miltenyi Biotech, Bergisch-Gladbach, Germany) in T-75 flasks (10 mL cell 
suspension per T-75 flask). Cells were incubated for two days at 37°C and 5% CO2. After two days, a 
volume of 10 mL of Mo-DC Differentiation medium (Miltenyi Biotech, Bergisch-Gladbach, Germany) 
was added to each flask and mixed well. Cells were incubated for further four days at 37°C and 5% CO2. 
On day 6, cells were used for cell experiments. 
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 Activation of iDCs for analysis of cytokines and DC Marker 
Immature Mo-DCs were harvested on day 6. The cell suspension of the flasks was transferred into a 
50 mL Falcon tube. In order to remove adherent cells, a volume of 20 mL of PBS buffer containing 
2 mM EDTA was added to the flask and incubated for 15 minutes at 37°C. Cells were centrifuged at 
300xg for 5 minutes. The supernatant was removed, and cell pellets were resuspended in cell culture 
medium (RPMI 1640 medium containing 10 % Human AB serum). The cell number was determined. 
200 000 cells per well were seeded in a 96-well plate (200 µl of a 106 cells/mL suspension). Cells were 
stimulated with different formulations at a concentration of 0.5 mg/mL. LPS at concentration of 
3 µg/mL was used as a positive control and cell culture medium only was used as negative control. The 
well plate was incubated at 37°C and 5% CO2 for 22 hours. 
 Analysis of DC Marker  
After 22 hours of incubation, cell supernatants were transferred into 1.5 mL tubes and centrifuged at 
300xg for 10 minutes. In order to remove adherent cells 200 µl/well of PBS buffer containing 2 mM 
EDTA were added to the flask and incubated for 15 minutes at 37°C. The supernatants of the 
centrifuged samples were transferred into new 1.5 mL tubes and subsequently stored at -80°C for 
cytokine analysis. The cell pellets were washed with a PBS buffer containing 2 mM EDTA and 
centrifuged at 300xg for 10 minutes. Supernatants were carefully discarded, and cell pellets were 
resuspended in 100 µl of a PBS buffer containing 0.5% BSA and 2 mM EDTA. Finally, the antibodies 
CD 80, CD 83, CD 86 and HLA –DR were added in amounts recommend by the manufacturer (Miltenyi 
Biotech, Bergisch-Gladbach, Germany). All samples were mixed well and incubated in the dark a 2-8°C 
for 10 minutes. After incubation a volume of 1 mL of buffer was added to each tube and centrifuged 
at 300xg for 10 minutes. The supernatant was aspirated completely, and the cell pellets were 
resuspended in 500 µl of buffer and stored at 2-8°C until measurement (samples were measured on 
the same day). 
 Analysis of cytokines using MACSPlex Cytokine Basic Kit 
Cytokines were analyzed using a MACSPlex Cytokine Basis Kit (Miltenyi Biotech, Bergisch Gladbach, 
Germany). First, the MPx Cytokine 12 Standard was prepared. The stock solution had a concentration 
of 10 000 pg/mL and was diluted with MACSPlex buffer, respectively, to obtain different 
concentrations: 2 000 pg/mL, 400 pg/mL, 80 pg/mL, 16 pg/mL, 3.2 pg/mL. MACSPlex buffer was kept 
as blank control (0 pg/mL). Cell culture supernatants were centrifuged at 10 000xg for 10 minutes at 
4°C and transferred into a new tube. A volume of 50 µl of each standard and sample was pipetted into 
the corresponding 1.5 mL tubes. MPx Capture Beads (Miltenyi Biotech, Bergisch Gladbach, Germany) 
of IL-10, IL-6, TNF-α and IFN-γ were mixed and diluted according to the manufacturer’s instructions 
and a volume of 20 µl of diluted MPx Capture Beads (Miltenyi Biotech, Bergisch Gladbach, Germany) 
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was added to each tube. The samples were incubated for two hours protected from light on an orbital 
shaker (450 rpm). After washing twice with 500 µl MACSPlex buffer, 80 µl of diluted MACSPlex 
detection reagent were added to each tube (mixed and diluted according to manufacturer’s 
instructions). The samples were incubated for one hour protected from light on an orbital shaker 
(450 rpm). The washing steps were repeated and a volume of 400 µl of MACSPlex buffer was added to 
each tube. Samples were analyzed by flow cytometry (Attune NxT flow cytometer, Thermo Fisher 
Scientific, Waktham, USA). Data was evaluated using Flowlogic™ and Beadlogic™ Softwares (Miltenyi 
Biotech, Bergisch Gladbach, Germany). 
 Methods used to investigate the particle burden in biologics (Chapter 7) 
 Materials 
 Monoclonal antibody IgG1 
A lyophilized monoclonal antibody IgG1 was used as model protein. The antibody was formulated in a 
buffer containing 0.02 mol/L histidine, 0.21 mol/L trehalose, 0.01 mol/L methionine and 0.04% 
polysorbate. A volume of 1.25 mL of the stock solution (equal to 150 mg antibody) of the monoclonal 
antibody was lyophilized on a Christ Epsilon 2-6D freeze dryer (Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode am Harz, Germany) using a conventional lyophilization cycle (see Figure 3-7). The 
lyophilized antibody was reconstituted by adding 7.2 mL water for injections and waiting for five 
minutes. Subsequently, the turbidity and the number of particles in the reconstituted solution was 
measured. Finally, the reconstituted antibody was filtered using a 0.2 µm Acrodisc® filter (Pall 
Corporation, New York, USA) and turbidity and particles numbers were analyzed again. In addition, the 
lyophilized monoclonal antibody was stored at 2-8°C for six months and particle numbers directly after 
reconstitution and after an additional in-line filtration step were analyzed again. 
 
Figure 3-7 Lyophilization cycle applied to the solution of the model monoclonal antibody IgG1. 
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 Marketed lyophilized products 
3.7.1.2.1 Actilyse® 
Actilyse® (Boehringer Ingelheim, Ingelheim am Rhein, Germany) contains an amount of 10 mg of 
lyophilized Alteplase. The product was reconstituted in a volume of 10 mL of water for injection 
according to the manufacturer’s technical information. The final concentration of the reconstituted 
Alteplase solution was 1 mg/mL. After analyzing the turbidity and the number of subvisible and 
submicron particles of the reconstituted protein, the solution was filtered using an Acrodisc® syringe 
filter with a diameter of 13 mm and a pore size of 0.2 µm (Pall Corporation, New York, USA), and 
turbidity and particles numbers were analyzed again. 
3.7.1.2.2 Gammagard® 
Gammagard® (Shire Pharmaceuticals, Lexington, Massachusetts, USA) contains an amount of 5 g of 
human immunoglobulin per vial. The protein was reconstituted according to the technical information. 
A volume of 96 mL water for injection was added to achieve a final protein concentration of 50 mg/mL. 
After analyzing the turbidity and the number of subvisible and submicron particles of the reconstituted 
protein, the solution was filtered using an Acrodisc® syringe filter with a diameter of 13 mm and a pore 
size of 0.2 µm (Pall Corporation, New York, USA) and turbidity and particles numbers were analyzed 
again. 
3.7.1.2.3 Flixabi® 
Flixabi® (Samsung Bioepis NL B.V., Delft, Netherlands) contains an amount of 100 mg of the 
monoclonal antibody Infliximab. The protein was reconstituted according to the technical information 
by adding a volume of 10 mL water for injection and waiting for five minutes. After analyzing the 
turbidity and the number of subvisible and submicron particles of the reconstituted protein, the 
solution was filtered using an Acrodisc® syringe filter with a diameter of 13 mm and a pore size of 
0.2 µm (Pall Corporation, New York, USA) and turbidity and particles numbers were analyzed again. 
 Marketed liquid products 
The products Pulmozyme®, containing Dornase alfa at a concentration of 1 mg/mL (Genentech, South 
San Francisco, California, USA), Beriglobin®, containing human immune globulin at a concentration of 
160 mg/mL (CSL Behring, Pennsylvania, USA), and Truxima®, containing the monoclonal antibody 
Rituximab at a concentration of 10 mg/mL (Mundipharma, Frankfurt am Main, Germany) were used 
to determine the particle numbers in liquid products. The turbidity and the number of subvisible and 
submicron particles was analyzed prior to and after an in-line filtration step using an Acrodisc® syringe 
filter with a diameter of 13 mm and a pore size of 0.2 µm (Pall Corporation, New York, USA). 
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 Methods to determine the number of subvisible and submicron particles in biologics 
Methods used for turbidity, light obscuration and flow imaging measurements are described in 
sections 3.3.1, 3.3.2 and 3.3.3, respectively. 
 Tunable resistive pulse sensing (TRPS) 
The number of submicron particles was measured by tunable resistive pulse sensing (TRPS) on a qNano 
Gold instrument (IZON, Oxford, UK). The samples prior to and after filtration were prepared as 
described in Table 3-4. Prior to the measurements, a nanopore NP300 with a size range of 150-900 nm 
was fitted into the qNano Gold and a stretch of 47 mm was applied. A volume of 70 µl and of 35 µl of 
filtered (0.22 µm) coating solution was loaded to the lower and upper fluid level. Subsequently, a 
pressure of +20 mbar was applied for 30 minutes, followed by applying a pressure of -20 mbar for 
15 minutes. The coating solution was removed from the upper and lower fluid level which were both 
rinsed with highly purified water and the upper fluid level was additionally dried with pressurized air. 
A volume of 70 µl of electrolyte (60 mM NaCl + 0.05% polysorbate 80) was added to the lower fluid 
level. The electrolyte was identical to the sample, if applicable. If the exact composition was not known, 
the ionic strength was matched as close as possible by adjusting the concentration of NaCl in the 
electrolyte using a 1 M NaCl stock solution. Calibration beads (CPC400) were diluted twice 1 to 100 in 
filtered electrolyte for a final dilution of 1/10000 in electrolyte. For the measurements, a volume of 
35 µl of electrolyte was added to the upper fluid level and a pressure of +10 mbar was applied to check 
the cleanliness of the system (less than 10 particles/10 minutes were required). After cleaning the 
upper fluid level, a volume of 35 µl of the sample (calibration beads or protein sample) was added to 
the upper fluid level and a pressure of 10 mbar was applied. Finally, the measurement was started. A 
particle read of > 500 particles or a maximum recording time of 10 minutes were chosen as limits. For 
calibration beads measurements, the limit was set to a particle rate of 250-400 particles/min for a 
1/10000 dilution. The recording was paused if blockages occurred and the nanopore was unblocked 
according to the manufacturer’s advice. 
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Table 3-4: Sample preparation of tested products for the analysis of submicron particles using a qNano Gold TRPS. Measurements were performed by Andreas Stelzl. 
 
Product Sample preparation Reason for sample preparation Pipetted volumes Calibration 
beads 
Ly
o
-P
ro
d
u
ct
s 
Gammagard® diluted 1/10 in 60 mM electrolyte1 high viscosity in undiluted samples 
caused instable baseline 
100 µl Gammagard®  
+ 900 µl 60 mM NaCl 
CPC400 in  
60 mM NaCl 
Actilyse® no dilution, no spiking electrolyte concentration sufficient 
for analysis 
200 µl Actilyse® CPC400 in  
60 mM NaCl 
Flixabi® 50 mM electrolyte spiked in from 1M NaCl stock 
solution1 
increase electrolyte concentration 
without large dilution 
190 µl Flixabi®  
+ 10 µl 1M NaCl 
CPC400 in  
60 mM NaCl 
IgG1 50 mM electrolyte spiked in from 1M NaCl stock 
solution1 
increase electrolyte concentration 
without large dilution 
190 µl IgG1 
 + 10 µl 1M NaCl 
CPC400 in  
60 mM NaCl 
Li
q
u
id
-P
ro
d
u
ct
s 
Beriglobin® diluted 1/10 in 60 mM electrolyte1 high viscosity in undiluted samples 
caused instable baseline 
100 µl Beriglobin®  
+ 900 µl 60 mM NaCl 
CPC400 in  
60 mM NaCl 
 after dilution: 5 µm filtration step applied 
(Acrodisc® 32 mm syringe filter with 5 mm Supor® 
membrane, Pall Corporation) 
high number of blockages through 
larger particles, if 5 µm filtration was 
not applied 
 
Pulmozyme® no dilution, no spiking electrolyte concentration sufficient 
for analysis 
200 µl Pulmozyme® CPC400 in  
120 mM NaCl 
Truxima® no dilution, no spiking electrolyte concentration sufficient 
for analysis 
100 µl Truxima® 
+ 900 µl 60 mM NaCl 
CPC400 in  
60 mM NaCl 
1The electrolyte solution was filtered using an inorganic membrane filter Anotop®25 Whatman® with a pore size of 0.02 µm. 
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 Introduction 
The introduction was published as part of the review article “Test Models for the Evaluation of 
Immunogenicity of Protein Aggregates” in International Journal of Pharmaceutics 559 (2019) 192-200. 
Protein aggregation is a well-known instability of protein drugs and poses a major challenge to the 
development and manufacturing of biopharmaceuticals1. Protein aggregation can occur during 
development, manufacturing, shipment, and storage of the protein drug product2,3. It leads not only 
to a compromised product quality, but it may also increase the risk of immunogenic side events when 
administered to patients4. Protein aggregates can be formed by different pathways and can therefore 
result in a variety of different types of protein aggregates. Mahler et al.3 suggested a classification of 
protein aggregates by (a) the type of bond: non-covalent vs. covalent protein aggregates; (b) 
reversibility: reversible vs. irreversible protein aggregates; (c) size: small soluble vs. larger insoluble 
aggregates and (d) protein conformation: protein aggregates with native structure vs. protein 
aggregates with a non-native structure. Irreversible aggregates often involve covalent cross-linking. 
According to Narhi et al.5 there are two types of reducible disulfide crosslinking which are 
intermolecular and intramolecular crosslinking of the proteins. Also, non-reducible crosslinks such as 
thioether and dityrosine covalent bonds can be present in protein aggregates. Protein aggregates can 
also be classified due to their reversibility3,5. Irreversible protein aggregates are mostly higher 
molecular weight species and the aggregation process cannot be reversed without the addition of a 
denaturant or reducing agent5. On the contrary, reversible aggregates can dissociate into their “native” 
form again. According to Narhi et al.5 reversible aggregates “exist in equilibrium with the native 
monomeric form”. A common way to classify protein aggregates is according to their size3,5,6. 
Aggregates in the nanometer range < 100 nm are usually referred to as soluble aggregates or 
oligomers, whereas aggregates in the range of 100 – 1000 nm are usually referred to as submicron 
particles. Aggregates in the range of 1 – 100 µm can be classified as subvisible particles and aggregates 
larger than 100 µm are referred to as visible particles5,7. Finally, protein aggregates can be classified 
according to the conformation of the protein in aggregates. A protein can be present in its native 
structure, it can be partially unfolded, misfolded, unfolded or amyloid, for example5. 
Aggregation mechanisms can be differentiated into physical and chemical aggregation. According to 
the Lumry-Eyring model (Figure 4-1), changes in the conformation of a protein lead to an intermediate 
state of the protein, which is then prone to aggregate and subsequently, irreversible (or reversible) 
protein aggregates are formed8. This model suggests that aggregation is based on conformational 
changes. However, aggregation can also be induced by chemical instabilities such as crosslinking of 
protein chains or changes of the hydrophilicity of the protein9. Chemical modifications are usually 
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based on modifications of amino acid residues. The most commonly described chemical reactions are 
oxidation, reduction, deamidation, hydrolysis, arginine conversion, β-elimination, and racemization10. 
 
Figure 4-1: The Lumry-Eyring model of protein aggregation. A protein in a native state can form an intermediate, which 
can either reversibly unfold or lead to irreversible or reversible protein aggregates (adopted from Wang et al.9). 
Besides the “natural occurrence”, protein aggregation can also be intentionally triggered by the 
exposure to various stress conditions such as elevated temperature11,12, freezing and thawing11,13, 
agitation stress, such as stirring and shaking12,14, high protein concentration15, solvent and surface 
effects like changes in the pH or ionic strength and chemical modifications3,9,16,17. Different stress 
conditions may lead to different kinds of protein aggregates. To distinguish between different protein 
aggregates a variety of analytical methods is available3,9. In fact, there is no analytical method available 
covering the complete size range of protein aggregates, making the analysis of protein aggregates 
rather complex6,14. Chromatographic methods such as size exclusion or reversed phase 
chromatography, for example, are used to analyze soluble aggregates in the nanometer range. Further 
commonly used methods for the analysis of subvisible aggregates are light obscuration, coulter 
counter or flow imaging and other microscopy techniques. Spectroscopic methods such as 
fluorescence spectroscopy, (FT-)IR spectroscopy, Raman spectroscopy or circular dichroism are used 
to analyze the structure and conformation of proteins and protein aggregates3,7. Due to the different 
information gained by such methods, it is recommended to apply several methods. At that point it is 
particularly favorable and recommended by the authorities to use orthogonal methods, hence 
methods with different underlying mechanisms, to reduce artefacts and misinterpretations as far as 
possible7. 
The aim of the study described in this chapter was to generate different types of protein aggregates 
by exposing two monoclonal antibodies, Adalimumab and Bevacizumab, to various stress conditions. 
Moreover, we aimed at finding appropriate time points and stress conditions for the two investigated 
monoclonal antibodies with the further aim of evaluating the immunogenicity of the generated protein 
aggregates in a human artificial lymph node model. Therefore, samples of Bevacizumab and 
Adalimumab were exposed to light, stir and heat stress (Bevacizumab only) for different periods of 
time and the samples were subsequently analyzed by light obscuration, turbidity, dynamic light 
scattering, size exclusion chromatography, Fourier-transform infrared spectroscopy and intrinsic and 
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extrinsic fluorescence spectroscopy. Based on the results of this chapter, stress conditions and time 
points for following experiments were selected. Once the selection was made, we investigated the 
stability of the desired samples during storage at 2-8°C to ensure the stability and a consistent 
composition of the aggregated samples over the run time of the human artificial lymph node model. 
Additionally, we also tested the stability of the samples stored at 2-8°C for six weeks after storage at 
- 80°C prior to the experiment. 
 Results 
 Turbidity 
Turbidity measurements can be a helpful tool to assess protein aggregation. Even though the method 
cannot provide quantitative information about aggregate size or particle counts, it can be a helpful 
qualitative method to estimate if aggregation occured18. The results of turbidity measurements of 
Adalimumab and Bevacizumab after exposition to different stress conditions are displayed in Figure 
4-2. In general, stir stress of both monoclonal antibodies led to the strongest increase and highest 
turbidity values. Compared to the unstressed proteins and the buffer controls, turbidity increased 
already after 4 hours of stirring. This trend continued until the detection limit of 1300 FNU was reached 
after 24 hours stirring of Adalimumab and 72 hours stirring of Bevacizumab. Exposing Adalimumab to 
light stress also resulted in an increase of turbidity starting after 48 hours of light exposition. After 7 
days of light exposure, the turbidity increased to > 1000 FNU. The same is true for Bevacizumab where 
no major increase in turbidity was detectable after 24 hours of light stress but after 4 days of light 
exposition turbidity rose to approximately 140 FNU. Remarkably, a decreased turbidity value was 
determined after 7 days of light stress. This is probably due to the fact, that the protein was completely 
aggregated and precipitated after 7 days of exposure to light while the supernatant was relatively 
clear. The exposure of Bevacizumab to elevated temperature also resulted in increased turbidity 
values. However, values were in general much lower than after stir stress for example. After 7 days of 
incubation at 50 °C, a turbidity of 14 FNU was measured. In summary, it can be found that turbidity 
increased with increasing exposure times to the distinct stress conditions. 
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Figure 4-2: Results of turbidity measurements displayed in FNU of Adalimumab after light stress (A) and after stir stress (B) 
and Bevacizumab after light stress (C), after stir stress (D) and after heat stress (E). Note the different y-axes in (C) and (E). 
 Light obscuration  
Subvisible particles were detected using light obscuration. The European Pharmacopoeia limits the 
number of particles larger than 10 µm to 6000 and of particles larger than 25 µm to 600 particles per 
container for infusion and injection products filled in a container with a volume of ≤ 100 mL19. The 
cumulative particle counts of particles ≥ 1 µm, ≥ 10 µm and ≥ 25 µm of Bevacizumab and Adalimumab 
after exposure to the different stress conditions are displayed in Figure 4-3. The results show that stir 
stress strongly triggered the formation of particles of Adalimumab and Bevacizumab. After 4 hours of 
stirring there was already a strong increase in particles ≥ 1 µm and ≥ 10 µm compared to the particle 
burden of the unstressed antibodies. The number of particles of those ≥ 25 µm, increased with longer 
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exposure times. In contrast, light stress led to lower particle counts. In the case of Adalimumab, the 
total particle count was only slightly increased after 24 hours and 4 days, but after 7 days there was a 
sudden increase in particle numbers of particles ≥ 1 µm, ≥ 10 µm and ≥ 25 µm. Bevacizumab appeared 
to be more sensitive to light stress regarding the particle increase. A strong increase in particle counts 
of particles ≥ 1 µm, ≥ 10 µm and ≥ 25 µm was already detected after 4 days of exposure to light. The 
lower particle counts for the Bevacizumab sample that was exposed to light for 7 days is again 
explainable with a total precipitation of the protein after 7 days of light exposure as mentioned before. 
The exposure of Bevacizumab to elevated temperature for 24 hours resulted in an increase in particles 
in the range of 1 – 10 µm. The number of particles ≥ 10 µm was slightly elevated compared to the 
unstressed protein. After 4 days of incubation at 50°C, particle numbers ≥ 1 µm and ≥ 10 µm increased 
strongly and particles ≥ 25 µm were formed. As reported for 7 days of light stress, the exposure to heat 
for 7 days also resulted in a decrease of particles ≥ 1 µm and ≥ 10 µm and in this case, a slight increase 
in particles ≥ 25 µm. Due to the precipitation of the protein after 7 days of heat stress, the smaller 
particles might have agglutinated, and no more smaller particles could be detected. 
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Figure 4-3: Cumulative particle counts per mL of Adalimumab after exposure to light (A) and stir stress (B) and of 
Bevacizumab after exposure to light (C), stir stress (D) and to elevated temperature (E). 
 Dynamic light scattering (DLS) 
Dynamic light scattering is used to determine the hydrodynamic size of proteins and protein 
aggregates within a size range from 1 nm – 10 µm, whereby DLS is especially suitable for the analysis 
of smaller aggregates in the nanometer range7. The hydrodynamic diameter is reported as Z-average 
(Zave) diameter and represents the mean diameter. Results of DLS measurements of Adalimumab and 
Bevacizumab after exposure to different stress conditions are shown in Figure 4-4 and Table 4-1 and 
Table 4-2. The intensity peaks of Adalimumab and Bevacizumab after light stress shifted towards larger 
particle sizes after exposure to light. Longer exposure times resulted in larger Zave diameter values and 
the polydispersity indexes also increased (Table 4-1 and Table 4-2). After 7 days of light stress of 
Adalimumab, the Zave diameter increased to 1163 ± 113 nm and the PDI to 0.92 ± 0.06. This is also true 
for Bevacizumab. The intensity graph of Bevacizumab after light stress (Figure 4-4C) shows a clear shift 
of the monomer peak towards larger particle sizes over the exposure time. Stir stress triggered the 
formation of rather large particles. After 4 hours of stirring of Adalimumab, parts of the monomer peak 
were still detectable. In contrast, 24 hours of stirring already led to a complete shift of the monomer 
peak towards particle sizes larger than 1000 nm. The PDI values, representing the homogeneity of the 
particle sizes, of the stirred samples increased to values larger than 0.3 in the case of Bevacizumab and 
larger than 0.8 for Adalimumab. The exposure of Bevacizumab to heat triggered the formation of 
submicron particles as displayed in Figure 4-4E. The Zave diameter increased from 11.62 ± 0.09 nm of 
the unstressed antibody to 61.53 ± 9.73 nm after 24 hours of heat stress, to 74.87 ± 11.09 nm after 4 
days of heat stress and to 393 ± 94 nm after 7 days of heat stress and PDI values rose again to values 
larger than 0.3. 
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Figure 4-4: Results of DLS measurements of Adalimumab after exposure to light (A) and stir stress (B) and of Bevacizumab 
after exposure to light (C), stir stress (D) and elevated temperature (E). 
Table 4-1: Values for Zave diameter and PDI of Adalimumab after light and stir stress. 
 Unstressed Light 24h Light 48h Light 4d Light 7d 
Zave [nm] 11.40 ± 0.09 12.37 ± 0.08 18.72 ± 0.2 35.72 ± 0.13 1163 ± 113 
PDI 0.04 ± 0.02 0.07 ± 0.01 0.2 ± 0.01 0.18 ± 0.01 0.92 ± 0.06 
  Stir 4h Stir 24h Stir 72h  
Zave [nm]  296 ± 77 2334 ± 597 1898 ± 326  
PDI  0.92 ± 0.07 0.83 ± 0.29 1 ± 0  
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Table 4-2: Values for Zave diameter and PDI of Bevacizumab after light, stir and heat stress. 
 Unstressed Light 24h Light 4d Light 7d 
Zave [nm] 11.62 ± 0.09 15.78 ± 0.12 874 ± 224 111 ± 1 
PDI 0.03 ± 0.01 0.19 ± 0.01 0.87 ± 0.06 0.28 ± 0.03 
  Stir 4h Stir 24h Stir 72h 
Zave [nm]  1236 ± 442 2660 ± 243 2141 ± 919 
PDI  0.58 ± 0.28 0.36 ± 0.04 0.91 ± 0.16 
  Heat 24h Heat 4d Heat 7d 
Zave [nm]  61.53 ± 9.73 74.87 ± 11.09 393 ± 94 
PDI  0.34 ± 0.06 0.56 ± 0.32 0.42 ± 0.05 
 Size exclusion chromatography (SEC) 
To analyze soluble aggregates, size exclusion chromatography was performed. The distribution of 
protein species of Adalimumab and Bevacizumab and the protein recovery is displayed in Figure 4-5. 
In the case of both monoclonal antibodies, light stress strongly triggered the formation of soluble 
aggregates of different sizes as displayed in Figure 4-5A and E. The longer the proteins were exposed 
to light, the larger the amount of high and low molecular weight species was in the samples. This 
increase in high and low molecular weight species correlated with a strong decrease in total protein 
and monomer recovery (Figure 4-5B and F). Exposure to light for 7 days resulted in a monomer 
recovery of less than 10%. On the contrary to light stress, stir stress did not lead to the formation of 
soluble aggregates of Adalimumab after 4 and 24 hours of stirring. In the case of Bevacizumab, the 
amount of high molecular weight species increased slightly during stirring compared to the unstressed 
monoclonal antibody. It is notable, that after 72 hours of stirring the number of fragments suddenly 
increased to more than 15% for both antibodies. Moreover, there is a decrease in total protein and 
monomer recovery over time (Figure 4-5D and H). The exposure of Bevacizumab to elevated 
temperature resulted in the formation of soluble aggregates and fragments at the same time (Figure 
4-5I) and longer exposure times led to larger amounts of the high and low molecular weight species. 
After 7 days of heat stress the number of fragments (LMW1 and LMW2) increased to more than 15%. 
The total protein and monomer recovery decreased slightly over time. 
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Figure 4-5: Distribution of protein species of Adalimumab after light stress (A) and after stir stress (C) and of Bevacizumab 
after light stress (E), stir stress (G) and heat stress (I). Corresponding recovery data is displayed in graphs (B), (D), (F), (H) 
and (J). The black line represents the total recovery and the red line displays the monomer recovery. HMW 2 > HMW 1; 
LMW 1 > LMW 2. 
 Extrinsic fluorescence 
Fluorescence spectroscopy techniques were used to analyze possible changes in the tertiary structure 
of Bevacizumab and Adalimumab after exposure to different stress conditions. In Figure 4-6, the results 
of extrinsic fluorescence measurements using Bis-ANS as noncovalent dye are displayed. Noncovalent 
fluorescence dyes are usually non-fluorescent in aqueous medium, but become highly fluorescent in a 
hydrophobic environment20,21. Additionally, the spectra showed a blue shift, meaning that the 
fluorescence spectra shifted to smaller wavelengths. The emission maxima of the fluorescence spectra 
of Adalimumab and Bevacizumab after exposure to different stress conditions are presented in Table 
4-3 and Table 4-4. The fluorescence intensity of the Adalimumab samples exposed to light for 24 hours 
or 4 days increased with longer exposure times indicating a more hydrophobic environment compared 
to the unstressed antibody. This was also confirmed by a blue shift of the spectra that increased after 
4 days of light exposure. However, after 7 days of light stress, fluorescence intensity was smaller than 
after 4 days and, there was no further blue shift compared to the sample that was exposed to light for 
4 days. This could be due to the precipitation of the protein after 7 days of light exposure and therefore, 
the aggregated protein was not in solution anymore. The spectra of Bevacizumab after light stress 
(Figure 4-6C) show increasing fluorescence intensity with increasing exposure times to light and the 
blue shifts of the spectra also increased corresponding to the exposure times. This indicates an 
increasing hydrophobic environment upon light stress. No remarkable increase in fluorescence 
intensity and only a blue shift after 72 hours of stirring could be detected after stir stress of 
Bevacizumab. In contrast, after stirring of Adalimumab a decrease in fluorescence intensity was seen. 
However, one must keep in mind, that the stirred stressed samples had high counts of particles that 
possibly interfered with the measurement. Therefore, one must be cautious with interpreting the data 
after stir stress. For Bevacizumab after heat stress, there was a small increase in fluorescence intensity 
compared to the unstressed protein, but also here increasing particle counts make it difficult to 
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determine a trend. In summary, light stress had the largest influence on the extrinsic fluorescence. 
However, it should be mentioned that the data of the latest time points of both proteins was difficult 
to interpret, because of the presence of large amounts of particles or the precipitation/denaturation 
of the antibodies after 7 days of light stress, for example. 
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Figure 4-6: Extrinsic fluorescence emission spectra of Adalimumab at a concentration of 1 mg/mL after exposure to light 
(A) and stir stress (B) and of Bevacizumab after exposure to light (C), stir stress (D) and elevated temperature (E). The black 
line represents the formulation buffer, the red line represents the unstressed protein, the blue line represents 
Adalimumab/Bevacizumab after 4h of stir stress or 24h of light stress or 24h of heat stress; the pink line represents 
Adalimumab/Bevacizumab after 24h of stir stress or 4d of light stress or 4d of heat stress and the green line represents 
Adalimumab/Bevacizumab after 72h of stir stress or 7d of light stress or 7d of heat stress, respectively. 
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Table 4-3: Peak positions of Bis-ANS fluorescence emission spectra of Adalimumab after light and stir stress. 
Light stress Unstressed 24h 4 days 7 days 
Peak position [nm] 507.01 505.97 495.97 498.05 
Stir stress Unstressed 4h 24h 72h 
Peak position [nm] 507.01 508.05 500 505.97 
 
Table 4-4: Peak positions of Bis-ANS fluorescence emission spectra of Bevacizumab after light, stir and heat stress. 
Light stress Unstressed 24h 4 days 7 days 
Peak position [nm] 508.95 501.04 498.95 492.98 
Stir stress Unstressed 4h 24h 72h 
Peak position [nm] 508.95 508.95 508.95 501.94 
Heat stress Unstressed 24h 4 days 7 days 
Peak position [nm] 508.95 504.02 502.98 504.02 
 
 Intrinsic fluorescence 
The results of intrinsic fluorescence spectroscopy are displayed in Figure 4-7. The most substantial 
alterations in fluorescence intensity were detected after light stress. One can state that with increasing 
exposure times to light, the fluorescence intensity decreased, except for Adalimumab after 24 hours 
of light stress where no decrease was detectable. This reduced fluorescence intensity may be due to 
quenching of fluorescence intensity of tryptophan by intrinsic quenchers such as amine, carboxylic 
acids, disulfide or histidine groups21 and implies conformational changes such as unfolding. The same 
is true for Bevacizumab after exposure to elevated temperature. The fluorescence intensity decreased 
slightly after 4 and 24 hours of exposure to 50°C and decreased even stronger after 7 days of heat 
stress. Also stirring had an impact on the fluorescence intensity. In case of Bevacizumab, the intensity 
decreased again with longer stirring times. It is remarkable, that 72 hours of stirring led to a very strong 
decrease of fluorescence intensity, comparable with the level of intensity after 7 days of light stress. 
In contrast, the intensity of Adalimumab after 72 hours of stirring dropped to a lesser extent, after 
24 hours of stirring the intensity was not changed compared to the unstressed protein and after 
4 hours of stirring, fluorescence intensity even increases slightly compared to unstressed Adalimumab. 
However, as mentioned before, the stir stressed samples contained high numbers of particles which 
could possibly have interfered with the fluorescence measurements. 
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Figure 4-7: Intrinsic fluorescence emission spectra of 1 mg/mL of Adalimumab after exposure to light (A) and stir stress (B) 
and of Bevacizumab after exposure to light (C), stir stress (D) and elevated temperature (E). The black line represents the 
formulation buffer, the red line represents the unstressed protein, the blue line represents Adalimumab/Bevacizumab 
after 4h of stir stress or 24h of light stress or 24h of heat stress; the pink line represents Adalimumab/Bevacizumab after 
24h of stir stress or 4d of light stress or 4d of heat stress and the green line represents Adalimumab/Bevacizumab after 
72h of stir stress or 7 of light stress or 7d of heat stress, respectively. 
 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR measurements have been widely used to investigate alterations in the secondary structure of 
protein samples22,23,24. Usually, amide band I with its spectral region is between 1700 and 1600 cm-1 is 
used to detect conformational changes. The 2nd derivative spectra of the unstressed and stressed 
antibody samples are displayed in Figure 4-8A-E. In the case of Adalimumab alterations of amide band I 
were detected after light stress. Slight decreases of the main valley around 1638 cm-1 were already 
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seen after 24 and 48 hours. The changes increased after 4 days and after 7 days of exposure to light, 
the valley significantly decreased and shifted towards 1630 cm-1. Moreover, a second valley between 
1640 and 1650 started to form. The same is true for Bevacizumab after light stress. Stirring for 4 to 24 
hours only led to minor decreases of the amide band I of Bevacizumab and Adalimumab, but 72 hours 
of stirring resulted in clear decreases of the valley and a shift towards 1630 cm-1. In the case of 
Bevacizumab after heat stress, again increasing exposure times to heat led to increasing alterations in 
the shape of the spectra, whereas after 24 hours and 4 days of heat stress the alterations of the spectra 
were based on a decreasing main valley. 
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Figure 4-8: 2nd derivative FT-IR spectra of Adalimumab after exposure to light (A) and stir stress (B) and of Bevacizumab 
after exposure to light (C), stir stress (D) and elevated temperature (E). 
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 Stability of aggregated samples of Adalimumab and Bevacizumab after storage at 
2 - 8°C over a period of 6 weeks 
As the immunogenicity of the aggregated samples of Adalimumab and Bevacizumab was investigated 
in a human artificial lymph node model over a period of 4 weeks, it was essential to show that the 
samples were stable after storage at 2-8°C. The composition of the aggregated samples was 
investigated by size exclusion chromatography and samples were analyzed weekly. We chose a period 
of 6 weeks to show the stability during the experiment running for 28 days but also some additional 
days for transportation or in case the start of the experiment had to be delayed, for example. The 
results for aggregated Adalimumab and Bevacizumab samples are shown in Figure 4-9 and Figure 4-10, 
respectively. The distribution of protein species of Adalimumab and Bevacizumab did not change 
dramatically during storage. Moreover, no additional or new protein species such as aggregates or 
fragments of different sizes were formed upon storage. On day 42, slight changes in the distribution 
of the protein species of Bevacizumab could be detected. There was a small increase in HMW 1 species 
after heat stress and alterations in the aggregate content after light stress. However, alterations were 
rather small. Therefore, it can be stated, that all samples were stable during storage at 2-8°C over a 
period of 6 weeks. 
 Stability of aggregated samples of Adalimumab and Bevacizumab after storage at 
− 80°C for 6 months and further storage at 2-8°C for 6 weeks after thawing 
The stability of the aggregated samples of Adalimumab and Bevacizumab was also investigated after 
storage at -80°C for 6 months. After thawing, the samples were further stored at 2-8°C for 6 weeks and 
analyzed weekly by size exclusion chromatography. The distribution of the protein species of 
Adalimumab and Bevacizumab after thawing and storage at 2-8°C is displayed in Figure 4-11 and Figure 
4-12. The composition of the Bevacizumab samples did not change dramatically during 6 weeks of 
storage at 2-8°C after thawing. In contrast, there were changes in the composition of the aggregated 
Adalimumab samples after light stress starting at day 14. Figure 4-11C displays the distribution of 
protein species of Adalimumab after light and stir stress after thawing and storage at 2-8°C for 14 days. 
The percentage of HMW 2 aggregates and the total recovery decreased compared to day 9 (Figure 
4-11B). This trend continued until day 42 and might indicate increasing particle formation during 
storage at 2-8°C after thawing. 
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Figure 4-9: Distribution of protein species of Adalimumab after 48 hours of light and 24 hours of stir stress directly after 
production (A) and after storage at 2-8°C for 7 days (B), 14 days (C), 21 days (D), 28 days (E), 35 days (F) and 42 days (G). 
The black squares represent the total recovery of the protein, the red dots represent the monomer recovery; HMW 2 > 
HMW 1; LMW 1 > LMW 2. 
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Figure 4-10: Distribution of protein species of Bevacizumab after 24 hours of light, 24 hours of stir and 4 days of heat stress 
directly after production (A) and after storage at 2-8°C for 7 days (B), 14 days (C), 21 days (D), 28 days (E), 35 days (F) and 
42 days (G). The black squares represent the total recovery of the protein, the red dots represent the monomer recovery; 
HMW 2 > HMW 1 > LMW. 
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Figure 4-11: Distribution of protein species of Adalimumab after 48 hours of light and 24 hours of stir stress after storage 
at – 80°C for 6 months directly after thawing (A) and after further storage at 2-8°C for 9 days (B), 14 days (C), 21 days (D), 
28 days (E) and 42 days (F). The black squares represent the total recovery of the protein, the red dots represent the 
monomer recovery; HMW 2 > HMW 1; LMW 1 > LMW 2. 
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Figure 4-12: Distribution of protein species of Bevacizumab after 24 hours of light, 24 hours of stir stress and 4 days of heat 
stress after storage at – 80°C for 6 months directly after thawing (A) and after further storage at 2-8°C for 9 days (B), 14 
days (C), 21 days (D), 28 days (E) and 42 days (F). The black squares represent the total recovery of the protein, the red 
dots represent the monomer recovery; HMW 2 > HMW 1 > LMW. 
 Discussion 
In this study, we evaluated different stress conditions and time points with the aim to generate 
different types of protein aggregates in a reasonable amount for further experiments. Therefore, we 
used common stress conditions such as elevated temperature, light and mechanical stress that can 
possibly occur during the entire development, production, storage and handling of therapeutic 
proteins. It has been shown in many studies that different stress conditions lead to different protein 
aggregates3,25,26. Stirring, for example, is known as a rather harsh stress condition to trigger protein 
aggregation14,27,28. Also, in our study, stir stress strongly triggered the formation of subvisible particles 
as indicated by very high particle counts measured by light obscuration. According to the literature, 
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the mechanism of particle formation upon stirring is based on a mixture of shear and interfacial effects, 
cavitation, local thermal effects during stirring and accelerated transportation of aggregates or 
adsorbed protein species into the solution possibly leading to further aggregation14,27. In the case of 
Adalimumab and Bevacizumab stirring especially led to the formation of particles larger than 1, 10 and 
25 µm and less to the formation of soluble aggregates as indicated by size exclusion chromatography. 
It is remarkable, that stirring for more than 24 hours led to fragmentation of Bevacizumab and 
Adalimumab, since the percentage of fragments after 72 hours of stirring was increased for both 
proteins. This might be explained by the increasing exposure time to mechanical stress. 
Light stress is known to trigger the formation of soluble aggregates and oxidation17,29–33. Amino acid 
residues such as of methionine, cysteine, histidine, tryptophan and tyrosine are prone to undergo 
photooxidation30, which may lead to protein aggregation. In our study, light exposure of the 
monoclonal antibodies was the most effective way to generate soluble aggregates as shown by size 
exclusion chromatography. The exposure to elevated temperature is also a well-known method to 
trigger protein aggregation11,34. Higher temperatures promote chemical modifications such as 
oxidation and deamidation leading to increasing protein aggregation34,35. In this study, we only 
exposed Bevacizumab to heat; since we knew from preliminary studies (data not shown) that heat 
stress of Adalimumab did not lead to a sustainable amount of protein aggregates within an acceptable 
period of time (7 days). The exposure of Bevacizumab to heat led to the formation of soluble 
aggregates and fragments on the one side, but also to the formation of insoluble protein aggregates, 
thus particles. Compared to light stressed Bevacizumab less soluble aggregates were formed upon heat 
stress. However, the heat stressed samples contained a moderate number of particles, soluble 
aggregates and fragments at the same time. 
Dynamic light scattering was used to determine the hydrodynamic radius of the generated protein 
aggregates in the range of 1 nm – 10 µm. The data show that in case of both monoclonal antibodies, 
stir stress triggered protein aggregates with hydrodynamic diameters > 1000 nm. In contrast protein 
aggregates generated by the exposure to light and elevated temperature revealed to have 
hydrodynamic diameters smaller than 1000 nm. Since protein aggregates have various shapes and are 
usually not of perfect spherical form, data obtained from DLS measurements of protein aggregates 
should be interpreted with care. This is especially true for samples with a high polydispersity index. 
Moreover, DLS measurements are intensity-based measurements. Regarding the fact that the 
scattering intensity depends on the diameter of the protein aggregates to the power of six according 
to the Rayleigh approximation, the resulting intensity-based size distribution can be biased to larger 
aggregates.7 Despite these disadvantages, dynamic light scattering is a helpful complementary method 
to characterize aggregated protein samples. 
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Conformational changes of the proteins were investigated by intrinsic fluorescence, extrinsic 
fluorescent dyes and FT-IR spectroscopy. The latter was used to detect alterations in the secondary 
structure of the proteins which are characterized by changes in the amide band I of the spectra22. The 
most pronounced alterations in the 2nd derivative spectra of Adalimumab and Bevacizumab were 
detected after 7 days of light exposure. The main peak shifted towards 1630 cm-1 and a second valley 
arose around 1648 cm-1. The latter is, according to Yang et al.22 a characteristic band for random coil 
structures whereas bands between 1624 and 1642 cm-1 are assigned to β-sheet structures24,36. 
Alterations in the spectra for the other light stress time points were rather small with exception of 
Adalimumab after 4 days of light stress where alterations were already more pronounced. Stir stress 
affected the secondary structure only after 72 hours of stirring, since similar trends as for the light 
stressed samples in alterations of the 2nd derivative spectra could be detected, to a lower extent 
though. Less hours of stirring (4 and 24 hours) did not lead to remarkable changes in the spectra. The 
same can be stated for heat stressed Bevacizumab. After incubating the antibody at 50°C for 7 days 
similar changes in the spectra as after 7 days of light stress could be detected. In summary, it can be 
said that the secondary structure was affected only under rather harsh and long exposure times to the 
respective stress conditions. Thus, the extent of the changes in secondary structure increased with 
longer exposure times. Among the different stress methods, light stress triggered alterations in the 
secondary structure most, followed by heat and stir stress. 
Alterations in the tertiary structure of proteins can lead to protein aggregation as described by the 
Lumry-Eyring theory8. Changes in the tertiary structure were investigated by fluorescence 
spectroscopy (intrinsic and extrinsic). Intrinsic fluorescence measurements of proteins are based on 
the fluorescent amino acid residues of tryptophan, phenylalanine and tyrosine. Among these amino 
acids, the fluorescence spectrum of tryptophan is decisively dependent on its environment and the 
spectrum can be blue shifted to shorter wavelengths when the environment gains hydrophobicity or 
when residues are buried in hydrophobic cores due to protein aggregation21. Furthermore, quenching 
of the tryptophan fluorescence can be induced by the interaction with intrinsic quenchers such as 
amine, carboxyl acid, disulfide or histidine groups or by addition of various other substances such as 
iodide, hydrogen peroxide, acrylamide21,37. A drawback of measuring the intrinsic fluorescence is the 
relatively small quantum yield in comparison to the usage of extrinsic dyes21. Therefore, the extrinsic 
fluorescence using Bis-ANS as non-covalent fluorescence dye of the monoclonal antibodies was also 
determined. The principle of measuring extrinsic fluorescence is because non-covalent extrinsic 
fluorescence dyes such as ANS and Bis-ANS are non-fluorescent in a polar environment, but get 
strongly fluorescent in an apolar, hydrophobic surrounding. The spectra often show a blueshift and 
fluorescence intensity is clearly increased20,21. In summary, changes in the fluorescence intensity 
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indicate alterations in the surrounding environment of the protein, thus indicating unfolding 
processes. Among all applied stress methods light stress led to the strongest alterations in fluorescence 
intensity. With longer exposure times to light, the intrinsic fluorescence decreased strongly indicating 
tryptophan quenching. Extrinsic fluorescent measurements confirmed these assumptions. The 
fluorescence intensity of Bis-ANS increased with longer exposure times to light (except for 
Adalimumab after 7 days of exposure to light) and spectra were blue shifted indicating an increasing 
presence of hydrophobic regions which may be caused by protein aggregation or unfolding processes. 
Due to high particle counts the interpretation of the intrinsic fluorescence measurements after stir 
stress was difficult. However, after 72 hours of stirring a remarkable decrease in fluorescence intensity 
for Bevacizumab and a smaller decrease for Adalimumab could be shown. As mentioned above, 
mechanical stress such as stirring is mixture of shear, interfacial effects between the protein and the 
stir bar e.g., cavitation and local thermal effects14. These effects might also lead to conformational 
changes such as unfolding and it is known from literature that heat stress can lead to conformational 
changes3,11,34. The exposure of Bevacizumab to elevated temperature also resulted in a decrease of 
intrinsic fluorescence intensity indicating unfolding processes. The extent of the decrease elevated 
with longer exposure times. The extrinsic fluorescence measurements of the heat stressed 
Bevacizumab revealed no remarkable changes in fluorescence intensity compared to the unstressed 
protein. A blueshift of the spectra after 24 hours and 4 days of heat exposure could be shown. 
However, the particle burden in the sample was elevated which might have interfered with the 
extrinsic fluorescent dye. 
The current study had two principal aims: First, we determined suitable stress conditions for 
Adalimumab and Bevacizumab to generate different types of protein aggregates; and second, to find 
respective time points to generate samples with a sustainable amount of protein aggregates but still 
contain enough monomer, thus are not fully denatured. Table 4-5 and Table 4-6 represent an overview 
of the selected stress methods and time points for following experiments using the human artificial 
lymph node model for the evaluation of immunogenicity of protein aggregates. For Adalimumab we 
selected light stress for 48 hours and stir stress for 24 hours. The latter represents a sample containing 
primarily insoluble aggregates, thus particles. Due to the high particle burden the monomer recovery 
was decreased slightly to 88.94 %. Contrarily, the light stressed sample especially contained various 
high and low molecular species coinciding with a decreased monomer recovery of 55.93%. The number 
of particles was also increased but to a lower extent than after stirring. The same is true for 
Bevacizumab after stir and light stress with the difference that 24 hours of light exposure were enough 
to generate protein aggregates of different sizes. For the heat stressed sample we chose 4 days as an 
appropriate time point, since this sample contained soluble aggregates, fragments and particles at the 
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same time and a monomer recovery of 87.44% was acceptable. The secondary structure of the stir 
stressed antibodies was preserved, for the light and heat stressed sample(s) we detected small 
modifications. The tertiary structure of the Bevacizumab was especially influenced by light stress. Since 
the time point after 48 hours was analyzed later, no fluorescence data was available for the current 
study. In the following studies we applied fluorescence spectroscopy to all stressed samples. 
Moreover, we investigated the stability of the aggregated samples of Adalimumab and Bevacizumab 
after storage at 2-8°C and after storage at -80°C for 6 months and subsequent storage at 2-8°C for 6 
weeks after thawing. The aim of this stability study was to ensure the quality of the generated samples 
during the reactor run time over 4 weeks. The results revealed that the composition of the aggregated 
samples of Bevacizumab and Adalimumab did not change dramatically when stored at 2-8°C directly 
after production. When the samples were frozen at -80°C for 6 months before they were thawed and 
again stored at 2-8°C for 6 weeks, a trend towards the generation of larger molecular weight species 
in Adalimumab samples after light stress was detectable. In combination with a decrease in total 
recovery, this might indicate particle formation. Thus, it can be assumed that, aggregated Adalimumab 
samples are less stable once they were stored at -80°C prior to the experiment. In contrast, aggregated 
Bevacizumab samples did not show any changes in the composition after thawing and storage at 2-
8°C. Therefore, aggregated Bevacizumab samples can be stored at -80°C prior to the start of the reactor 
run, while it is recommended for aggregated Adalimumab samples to be used within 6 weeks after 
production and storage at 2-8°C. However, it is possible to store all aggregated samples of Adalimumab 
and Bevacizumab at 2-8°C for a period of 6 weeks. Thus, the quality of the samples remains consistent 
during the reactor run time. 
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Table 4-5: Overview of selected stress methods and time points for Adalimumab. HMW= High molecular weight species, 
LMW= Low molecular weight species; HMW 2 > HMW 2/1 > HMW 1; LMW 1 > LMW 2; - no significant changes; + moderate 
changes; ++ strong changes. 
Adalimumab Turbidity Increased 
number 
of 
particles 
Formation 
of soluble 
aggregates 
Formation 
of 
fragments 
Monomer 
recovery 
(SEC) 
Altered 
secondary 
structure 
(FT-IR) 
Altered 
tertiary 
structure 
(Fluorescence) 
Unstressed 1.54 FNU - - - 100% - - 
Light stress 48h 3.21 FNU + ++ 
7.53% 
HMW2 
6.12% 
HMW2/1 
15.83% 
HMW1 
+ 
6.97% 
LMW1 
4.65% 
LMW2 
55.93% + n.d. 
Stir stress 24h  >1300 
FNU 
++ - - 88.94% - n.d. 
 
Table 4-6: Overview of selected stress methods and time points for Bevacizumab. HMW= High molecular weight species, 
LMW= Low molecular weight species; HMW 2 > HMW 1; LMW 1 > LMW 2; - no significant changes; + moderate changes; 
++ strong changes. 
Bevacizumab Turbidity Increased 
number 
of 
particles 
Formation 
of soluble 
aggregates 
Formation 
of 
fragments 
Monomer 
recovery 
(SEC) 
Altered 
secondary 
structure 
(FT-IR) 
Altered 
tertiary 
structure 
(Fluorescence) 
Unstressed 1.82 FNU - + - 99.64% - - 
Light stress 24h 4.04 FNU + ++ 
6.55% 
HMW2 
14.54% 
HMW1 
+ 
2.61% 
LMW2 
 
77.16% + ++ 
Stir stress 24h  587.0 FNU ++ + 
1.14% 
HMW1 
- 91.19% - n.d. 
Heat stress 4d  13.27 FNU ++ + 
1.99% 
HMW2 
4.39% 
HMW1 
+ 
2.32% 
LMW2 
87.44% + n.d. 
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 Introduction 
Biopharmaceuticals are a steadily growing group of drugs to treat severe diseases such as cancer, 
multiple sclerosis, Crohn’s disease and rheumatoid arthritis1. However, it is known, that 
biopharmaceuticals bear the risk to elicit immunogenicity in patients e.g. resulting in the formation of 
anti-drug antibodies (ADAs). Clinical consequences can be severe allergic reactions such as anaphylaxis 
or the loss of efficacy of the drug23. Besides patient-related factors like the immunological status, the 
history of allergy of patients, the route and frequency of administration and the dosing that are likely 
to modulate immunogenicity, product related factors may also contribute to immunogenicity 
substantially. These include the product origin, the primary structure of the protein, containers, 
additives, impurities from the manufacturing process and in particular protein aggregates3–6. The effect 
of protein aggregates on the immune system has been discussed and investigated for a long time7. In 
various studies, protein aggregates were generated by exposure of the protein to various stress 
conditions such as light, mechanical, thermal and chemical stress, and the immunogenicity was 
evaluated using either in vitro or in vivo models8–13. Some groups tested a mix of different sized protein 
aggregates9,10, while others used fractionation methods such as asymmetrical flow field flow 
fractionation (AF4) or fluorescence–activated cell sorting (FACS) to evaluate the immunogenicity of a 
distinct group of protein aggregates12,14,15. Despite all these studies it remains uncertain, which types 
of protein aggregates pose the greatest risk to elicit immunogenicity. Recently, research focused 
especially on subvisible particles in the size range of 0.1-10 µm and protein aggregates with 
considerable chemical modifications14,16–18. It is a challenge to establish an appropriate test system to 
evaluate and predict immunogenicity in humans. For the evaluation of immunogenicity of protein 
aggregates, in vitro and in vivo models are used19. In vitro models are often based on the interaction 
of protein aggregates with antigen presenting cells and T-cells isolated from human peripheral blood 
mononuclear cells (PBMCs). Several DC markers, cytokine profiles and T-cell proliferation can be 
analyzed1,20. However, it needs to be considered that only specific immune cells are investigated, and 
that cell assays represent only a small part of the human immune system1. In contrast, in vivo models 
enable to evaluate immunogenicity in an organism with a fully trained immune system and to 
investigate the formation of anti-drug antibodies21. The most common in vivo models used for the 
assessment of immunogenicity of protein aggregates are mouse models12,14,22–25. Yet, the choice of an 
appropriate mouse strain is complex and may influence immunogenic answers21. Furthermore, the 
assessment of immunogenicity in mouse models is not necessarily predictive of immune responses in 
humans1,26. Recently, the development of various 3D models of human organs to mimic human 
immunity attracted great interest. Generally, these models can be divided into non-lymphoid organs 
imitating innate immunity and lymphoid human organs mimicking adaptive immunity20. Among 
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lymphoid organs, the development of lymph node models is a key aspect, since lymph nodes play a 
major role in an immune response20. Giese and colleagues developed and optimized a 3D human 
artificial lymph node (3D HuALN) model to mimic the interface between the innate and adaptive 
immune response in vitro20,27,31. The HuALN is a miniaturized, disposable 3D in vitro culture model 
based on cells from human donors. Continuous perfusion of the bioreactor device ensures long-term 
cultivation under steady-state conditions and allows repeated drug exposition as well as a broad range 
of read-out parameters on T- and B-cell levels. The system was already successfully used for testing 
albumins and vaccines28, but has not yet been utilized for evaluating the immunogenicity of protein 
aggregates. 
In this chapter, a HuALN model was used to evaluate the immunogenicity of preparations of two 
monoclonal antibodies. Protein aggregates were formed by exposing two monoclonal antibodies to 
different stress conditions. The protein aggregates were thoroughly analyzed regarding their size and 
structure, tested in a 2D co-culture assay format (DC/T cell assay) and finally the HuALN was stimulated 
with the generated samples. Cell culture supernatants were harvested daily and analyzed for the 
presence of various cytokines. Moreover, some additional data regarding the presence of anti-drug 
antibodies (ADAs) in the cell culture supernatants of the HuALN culture and the diffusion behavior of 
particles through a dextran gel matrix was collected. 
 Evaluation of a 3D human artificial lymph node model as test model for 
the assessment of immunogenicity of protein aggregates 
 Results and Discussion 
 Analysis of prepared protein aggregates after stir, light and heat stress 
Adalimumab and Bevacizumab were exposed to different stress conditions (see Materials and 
Methods, Chapter 3) and analyzed using turbidity, light obscuration, size exclusion chromatography, 
FT-IR, and extrinsic fluorescence spectroscopy to characterize the aggregated samples. The turbidity 
of Adalimumab and Bevacizumab increased after exposure to different stress conditions (Table 5-1) 
indicating changes in the aggregation status of the proteins. The strongest increase was detected for 
the samples after stir stress, when turbidity reached values of 313 FNU for Adalimumab and 848 FNU 
for Bevacizumab. After the exposure of the antibodies to light stress, turbidity values of 66.37 FNU 
(Adalimumab) and 25.87 FNU (Bevacizumab) were detected. Heat stressed Bevacizumab led only to a 
small increase in turbidity (12.19 FNU) compared to unstressed Bevacizumab (8.76 FNU). To detect 
subvisible particles larger than 1 µm, light obscuration measurements were performed. The 
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cumulative particle counts per mL of Adalimumab and Bevacizumab after exposure to different stress 
conditions are summarized in Table 5-1. High particle numbers were observed for Adalimumab and 
Bevacizumab after stir stress which strongly triggered the formation of particles between 1 µm and 
25 µm. After light stress a moderate increase in particles sized between 1-10 µm was observed for 
both proteins. Particles larger than 10 µm also increased, but standard deviations were high making a 
statement difficult. Heat stress of Bevacizumab predominantly triggered the formation of subvisible 
particles in the range of 1-10 µm. The presence of soluble aggregates was investigated by size exclusion 
chromatography. The distribution of protein species of Adalimumab and Bevacizumab is displayed in 
Table 5-2. It is apparent that light stress strongly induced the formation of soluble aggregates and 
fragments of different sizes (HMW 2 > HMW 1; LMW 1 > LMW 2). As a result, the monomer content 
was reduced significantly to 37.13 ± 0.25% for Adalimumab and 59.91 ± 0.02% for Bevacizumab. In 
contrast, stir stress did not lead to an increase in the content of soluble aggregates or to the formation 
of fragments compared to the unstressed antibody solutions. Heat stress of Bevacizumab moderately 
triggered the formation of soluble aggregates (4.54 ± 0.04%) and fragments (0.72 ± 0.03%). FT-IR 
measurements were performed to detect alterations in the secondary structure. Second derivative FT-
IR spectra of unstressed Adalimumab and Bevacizumab and after light, stir and heat stress are shown 
in Figure 5-1. Light, stir and heat stress did not lead to significant changes of the amide I band. 
However, already minimal changes in the intensities of the second derivatives indicate that the 
contents of the secondary structure components may have changed, although the local secondary 
structural geometry may not have changed. 
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Table 5-1: Summary of turbidity measurements and cumulative particle counts per mL of Adalimumab and Bevacizumab samples tested in the current study. Values are reported as the mean 
of three aliquots ± standard deviation. 
Adalimumab Sample Turbidity [FNU] 
Particle counts  
≥ 1 µm 
Particle counts  
≥ 10 µm 
Particle counts 
 ≥ 25 µm 
 Unstressed 15.81 ± 0.98  14673 ± 4676 225 ± 224 8 ± 12 
 Light stress 48h 66.37 ± 2.61 344683 ± 230493 27617 ± 24702 292 ± 271 
 Stir stress 24h 313.00 ± 3.46 6429000 ± 205533 22334 ± 1179 250 ± 354 
 Formulation buffer 0.45 ± 0.03 78 ± 29 2 ± 2 0 ± 0 
Bevacizumab Sample Turbidity [FNU] 
Particle counts  
≥ 1 µm 
Particle counts  
≥ 10 µm 
Particle counts 
 ≥ 25 µm 
 Unstressed 8.76 ± 1.0 34742 ± 1214 1008 ± 907 8 ± 12 
 Light stress 24h 25.87 ± 3.82 173242 ± 47412 11300 ± 10583 117 ± 94 
 Stir stress 24h 848.33 ± 21.01 15732667 ± 181491 74250 ± 12138 2500 ± 236 
  Heat stress 4d  12.19 ± 1.43 840000 ± 61943 2200 ± 141 50 ± 71 
 
Table 5-2: Summary SEC results: Distribution of protein species of Adalimumab and Bevacizumab after exposure to different stress conditions (n=2). 1 The total protein recovery represents the 
total eluted protein normalized to the injected protein amount. 
Adalimumab Sample HMW 2 [%] HMW 1 [%] Monomer [%] LMW 1 [%] LMW 2 [%] 
Total protein 
recovery [%]1 
 Unstressed - 0.71 ± 0.24 99.29 ± 0.24 - - 98.82 ± 1.33 
 Light stress 48h 39.44 ± 1.40 17.59 ± 0.43 37.13 ± 0.25 3.13 ± 0.83 2.71 ± 0.11 84.98 ± 0.76 
 Stir stress 24h - 0.88 ± 0.05 99.12 ± 0.05 - - 96.46 ± 0.43 
Bevacizumab   HMW 2 [%] HMW 1 [%] Monomer [%] LMW [%]  
 Unstressed - 1.44 ± 0.11 98.56 ± 0.11 - 95.76 ± 0.78 
 Light stress 24h 18.50 ± 0.06 20.21 ± 0.04 59.91 ± 0.02 1.38 ± 0.04 91.54 ± 2.40 
 Stir stress 24h - 1.77 ± 0.19 98.23 ± 0.19 - 93.77 ± 1.35 
 Heat stress 4 days - 4.54 ± 0.04 94.74 ± 0.07 0.72 ± 0.03 89.59 ± 0.35 
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Figure 5-1: Second derivative FT-IR spectra of A) Adalimumab and B) Bevacizumab: The black line represents the spectrum 
of unstressed Adalimumab/Bevacizumab, the dotted line represents the spectrum of stir stressed 
Adalimumab/Bevacizumab, the dashed line represents the spectrum of Adalimumab/Bevacizumab after light stress and 
the dashed/dotted line represents the spectrum of heat stressed Bevacizumab. 
The extrinsic fluorescence emission spectra of Adalimumab and Bevacizumab using 20 µM Bis-ANS as 
fluorescence dye are displayed in Figure 5-2. The fluorescence intensity of Adalimumab increased 
clearly after light exposition indicating a more hydrophobic environment and therefore unfolding 
processes29. Moreover, the emission maxima after light stress clearly shifted to a smaller wavelength 
(495.97 nm) compared to the unstressed sample (503.43 nm). After exposure of Adalimumab to stir 
stress, fluorescence intensity also increased slightly, but to a lower extent than after light stress. The 
emission maxima after stir stress shifted to a wavelength of 502.98 nm. Thus, only a minimal blue shift 
was observed. A strong increase in fluorescence intensity and a blue shift of the emission spectra was 
also observed for Bevacizumab after light stress as shown in Figure 5-2 and Table 5-3. No shift of the 
emission maxima of Bevacizumab after stir stress was detected, but an increase in fluorescence 
intensity was observed (see Figure 5-2). No increase in fluorescence intensity could be detected for 
Bevacizumab after heat stress. Conversely, there was a blue shift of the spectra to a wavelength of 
499.55 nm, as displayed in Figure 5-2 and Table 5-3. It can be assumed that particularly light stress 
altered the tertiary structure of Adalimumab and Bevacizumab. Changes were also detectable after 
stir stress, to a lesser extent though. 
Table 5-3: Maxima of extrinsic fluorescence emission spectra of Adalimumab and Bevacizumab after exposure to different 
stress conditions. 
Adalimumab Unstressed Light stress 48h Stir stress 24h - 
Peak position [nm] 503.43 495.97 502.98 - 
Bevacizumab Unstressed Light stress 24h Stir stress 24h Heat stress 4d 
Peak position [nm] 501.94 498.05 498.05 499.55 
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Figure 5-2: Extrinsic fluorescence emission spectra of A) Adalimumab and B) Bevacizumab at 1 mg/mL using 20 µM Bis-ANS 
excited at 385 nm: The black line represents the spectrum of unstressed Adalimumab/Bevacizumab, the dotted line 
represents the spectrum of stir stressed Adalimumab/Bevacizumab, the dashed line represents the spectrum of 
Adalimumab/Bevacizumab after light stress and the dashed/dotted line represents the spectrum of heat stressed 
Bevacizumab. 
The aim was to generate aggregated protein samples by exposure of the monoclonal antibodies to 
different stress conditions that biopharmaceutics possibly face during production, handling and 
transportation30. The stress conditions were carefully selected during a pre-study to obtain 
reproducible amounts and types of protein aggregates (data not shown). In our study, light stress 
primarily led to the formation of soluble aggregates whereas stir stress strongly triggered the 
formation of particles but not of soluble aggregates. Bevacizumab was additionally exposed to 
elevated temperatures which resulted in a sample containing moderate amounts of soluble and 
insoluble aggregates and fragments at the same time. According to light obscuration data heat stress 
primarily triggered the formation of particles in the size range between 1 - 10 µm which are in 
particular of interest due to their immunogenic risk16,31. It has been shown before that subvisible 
aggregates can promote a TH1-type immune response in vivo32. Heat stress was not applied to 
Adalimumab in our study, since the reasonable conditions applied in pre-studies did not lead to a 
considerable amount of protein aggregates. The scope of our work focused particularly on the “proof 
of concept” of using a 3D HuALN model for testing the immunological risk of protein aggregates; 
therefore, no further analytics were applied. Moreover, it should be considered that the levels of 
generated protein aggregates in the stressed sample do not represent levels of protein aggregates in 
marketed drug products. 
 Analysis of 2D Cell Culture Experiments and HuALN Culture Experiments 
The aim of testing the stressed samples in a 2D in vitro assay was first the comparison of results with 
a 3D in vitro model and, second to find an appropriate test concentration of the samples for the 
evaluation of immunogenicity in the human artificial lymph node model. Stressed samples of 
Bevacizumab and Adalimumab were tested at concentrations of 0.05, 0.5 and 5 mg/mL and 0.1, 1 and 
10 mg/mL, respectively. Selected data of cytokine analysis is exemplarily shown in Figure 5-3.
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Figure 5-3: Cytokine secretion in 2D co-cultures treated with three different doses of variously stressed antibody samples in duplicates. ConcavalinA (ConA, vertically striped black line) was used 
as positive control, then grey and the light grey bar display negative controls. Where bars are out of display, concentration is displayed in boxes [pg/mL]. A) Results for Adalimumab: unstressed 
Adalimumab (solid bars), Adalimumab after light stress (dotted bars) and after stir stress (striped bars). Buffer is displayed in dark grey bars. B) Results for Bevacizumab: unstressed Bevacizumab 
(soild bars), Bevacizumab after light stress (dotted bars), stir stress (striped bars) and after heat stress (chessboard bars). Buffer is displayed in vertically striped bars. This data was provided by 
ProBioGen AG, Berlin. 
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Five cytokines (IFN-y, TNF-α, IL-2, IL-13, IL-6) were selected out of the panel of ten cytokines since 
these cytokines showed levels above 5 pg/mL, dose-dependency, and differences between stress 
conditions. Cytokine analysis of supernatants revealed enhancement of IFN-у induction by light-, 
heat- , and stir-stressed Bevacizumab (0.5 mg/ml). The secretion of TNF-α was elevated by stressed 
Bevacizumab and light-stressed Adalimumab samples, to a lower extent though. In contrast, stir-
stressed Adalimumab samples reduced TNF-α secretion. This reduced TNF-α secretion can be 
explained by the mechanism of action of Adalimumab as a member of the group of TNF-α – blockers 
binding to TNF-α to prevent its effect33. According to the cytokine data stressed Adalimumab was still 
able to bind its target. However, it remains unclear, whether the TNF-α binding refers to protein 
aggregates of Adalimumab or to the remaining non-denatured molecules present in the stressed 
antibody sample. Only Adalimumab after light stress showed a small increase in TNF-α secretion 
compared to the unstressed protein. Slight, but dose-dependent increase of IL-13 and IL-6 secretion 
for both light-stressed antibody samples was observed. Levels of CD86, CD83, CD80 and other DC 
markers were not increased by exposure with stressed antibody samples, even high doses of stir-and 
heat-stressed samples strongly decreased all markers (see Figure 5-5). Only high dose of stir-stressed 
samples reduced the expression of CD3, CD4 and CD8 on T cells (data not shown). Proliferation of T-
cells (CD3+/Edu+) in co-cultures treated with stressed samples compared to control was not enhanced 
(data not shown). Due to a down-regulation of DC markers with the highest concentration and no 
response of cells with the lowest concentration, 0.5 and 1 mg/mL were selected as test concentrations 
for Bevacizumab and Adalimumab for the HuALN experiment, respectively. The results of cytokine 
analysis after stimulation of the HuALN with the generated samples of Bevacizumab and Adalimumab 
are displayed in Figure 5-4. Stimulating the HuALN with Adalimumab after stir and light stress resulted 
in a cytokine profile comparable to unstressed Adalimumab. Thus, no differences in cytokine secretion 
profiles were seen between unstressed and stressed samples. In contrast, Bevacizumab after exposure 
to heat enhanced a pro-inflammatory (Pro-inf), T-helper 1 (TH1) as well as a slight T-helper 2 (TH2) 
immune response. The same trends were seen for light- and stir-stressed Bevacizumab, even though 
to a lower extent. 
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Figure 5-4: Spider grid diagrams for tested antibody samples: spider grid diagram of Adalimumab samples (left); spider grid 
diagram of Bevacizumab samples (right)). The mean of three independent HuALN runs each is displayed: Left: Adalimumab: 
unstressed (dashed grey line), light stress (grey line), stir stress (black line) and right: Bevacizumab: unstressed (dashed 
grey line), light stress (grey line), stir stress (black line) and heat stress (dashed black line). In brief: AUC values displaying 
the overall amount of each cytokine secreted during the entire bioreactor run are normalized to the control run, combined 
with respect to cytokine groups (TH1, TH2, Pro-inf, Anti-inf), and displayed in spider grids. Values larger/smaller than 1 
display up-/downregulation in direct comparison to control run. This data was provided by ProBioGen AG, Berlin. 
The 2D DC assay as well as the 3D HuALN model represents an in vitro model based on cells from 
human donors. Whereas the 2D in vitro assay is performed in a standard well-plate format, the human 
artificial lymph node model is a complex 3D matrix assisted model operated with PBMCs and DCs in 
combination with allogeneic MSC-derived stromal cells. By combination of functional and structural 
cells lymphatic follicles and germinal centers form and mimic the 3D structure of human lymph 
nodes28,34. Continuous perfusion of the bioreactor device ensures cultivation under steady-state 
conditions enabling a long-term exposition of the drug including multiple re-stimulations. In the 
present study, the HuALN experiment was performed for 28 days including an initial stimulation with 
the stressed samples on day 0 followed by three re-stimulations on day 7, 14 and 21. The possibility of 
a long-term exposure up to four weeks including the mentioned re-stimulations of the stressed protein 
samples represents a major advantage of the HuALN system compared to conventional 2D in vitro 
experiments. Exposure times during 2D in vitro experiments are rather short varying from several 
hours until up to a few days18,35. By re-stimulating the model weekly, delayed immune reactions can 
be monitored as well which is an important aspect for therapies with weekly applications, for 
example36. Due to its continuous perfusion the lymph node model also mimics the dilution of protein 
aggregates that occurs in vivo following an application more closely than 2D in vitro assays. Comparing 
the results from the 2D in vitro assay and the HuALN experiment, it is noticeable that primarily light – 
and heat stressed Bevacizumab triggered the secretion of IFN-у and TNF-α whereby light stress had a 
stronger effect than heat stress in 2D experiments. According to the HuALN data, heat stress led to a 
TH1 and pro-inflammatory answer which is also characterized by the secretion of IFN-у and TNF-α (see 
Table 5-4). 
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Table 5-4: Cytokine groups: analyzed cytokines are classified to groups based on their immunological function for a 
simplified analysis of immune responses in HuALN bioreactors. 
Groups Assorted cytokines 
Pro-inflammatory IL-1β 
IL-6 
IFN-у 
TNF-α 
Anti-inflammatory IL-6 
IL-10 
TH1 IL-2 
IL-12p70 
IFN-у 
TNF-α 
TH2 IL-4 
IL-6 
IL-10 
IL-13 
 
For better understanding the results of cytokine analysis of the 2D in vitro assay were also displayed 
as spider grid diagrams (see Figure 5-6). In comparison to the spider grid diagrams of the HuALN 
experiment, there was a slight trend towards a pro - inflammatory and TH2 immune response of light 
stressed Adalimumab, whereas no differences between the differently stressed Adalimumab samples 
were observed according to the cytokine analysis of the HuALN experiment. Differences between the 
induced cytokine responses were also found for Bevacizumab. The spider grid of the 2D in vitro assay 
revealed that light stressed Bevacizumab resulted in a larger effect than heat stress, both triggering a 
pro-inflammatory and TH1 immune response. However, evaluating the cytokine data over a period of 
four weeks, heat stress resulted in having the stronger effect on the cytokine secretion. For a more 
detailed analogy observation between the 2D assay and the 3D HuALN experiment, the cytokine 
secretion of similar time points of the 3D assay was analyzed. Comparison of the cytokine levels in 
bioreactor samples of day three (Figure 5-7) with the results from the 2D DC assay (see Figure 5-3 and 
Figure 5-8) revealed similar absolute levels of IL-13, IL-2, and IFN-y. Irrespective of minimal differences 
which should not be overrated, these levels were independent from stress conditions of the applied 
antibodies in the 3D HuALN experiment, at this early stage. In the 2D assay, slight increases in cytokine 
levels could be observed for Adalimumab (especially light-stressed) and Bevacizumab (all stress 
conditions). No significant differences between the stressed samples were observed on day three of 
the 3D bioreactor culture. However, TNF-α, IFN-y and IL-6 levels were increased in 3D compared to 2D 
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experiments (except from TNF-α for Adalimumab). Common for both methods was that Bevacizumab 
induced higher secretion of TNF-α and slightly of IFN-y than Adalimumab. 
A 
 
B 
 
Figure 5-5: Diagram displaying the marker expression (CD86, CD83, CD80) of DCs exposed to different concentrations of 
stressed antibodies Adalimumab (A) and Bevacizumab (B). For the highest concentration of stressed samples, a drop-down 
of marker expression was observed (to a lower extent for light-stressed material and to higher extent for stir- and heat-
stressed material). The mid dose shows comparable expression or higher levels than the low dose, this is why the mid dose 
was selected for use in the HuALN study. This data was provided by ProBioGen AG, Berlin. 
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Figure 5-6: Diagram showing spider grids for the 2D assay (for 3D assay see Fig. 4) of Adalimumab (left) and Bevacizumab 
(right). The cytokine values were directly normalized to control run (unstressed), combined with respect to cytokine groups 
(TH1, TH2, Pro-inf, Anti-inf), and displayed in spider grids. Values larger/smaller than 1 are displaying up-/downregulation 
in direct comparison to control run. This data was provided by ProBioGen AG, Berlin. 
Even though the applied methods (static DC/T cell assay (2D) and perfused HuALN (3D)) are different 
systems, also regarding cell numbers and culture volume, absolute levels of IL-13 and IL-2 were similar 
and, differences between the two antibodies were replicable. Neither the cytokine release of the 3D 
HuALN experiment on day three nor the spider grid evaluation could confirm the slight increase 
induced by light stressed Adalimumab compared to unstressed Adalimumab in the 2D assay. For 
Bevacizumab the immunogenic potential of heat-stressed material could be confirmed, whereas light- 
and stir-stressed Bevacizumab revealed no immunogenic potential in bioreactor experiments. This 
leads to the assumption that the 2D assay may be more sensitive than the 3D HuALN model, but not 
relevant regarding long-term immune responses. In addition, these results indicate that it is important 
not to monitor short-term immune reactions only, but also to investigate the long-term exposition of 
the drug, since the type of immune responses might change or develop over time. This could be 
primarily important for biopharmaceuticals which are applied several times during drug therapy. Even 
though numerous groups investigated the immunogenicity of protein aggregates using in vitro and in 
vivo test models10,12,13,18, still little is known about the underlying mechanisms. Often the predictability 
of immunogenicity in humans by the used test models is questionable. Thus, there is a need to improve 
the currently used test models regarding the simulation of the human immune system. Lymph nodes 
belong to the secondary lymphatic tissues and play a major role in human immunity. Antigen 
presenting cells such as dendritic cells take up antigens in the periphery of the human body and 
transport them to lymph nodes where they present the antigen to lymphocytes. Thus, the stimulation 
of the primary immune responses occurs in lymph nodes37,38. 
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Figure 5-7: Diagram showing the cytokine values (mean of day 3 of all three bioreactor runs) for the 5 selected cytokines, 
which are also displayed for the 2D assay (see Figure 5-3). This is supplied for comparison of 2D and 3D data at a single 
data point for Adalimumab (A) and Bevacizumab (B). This data was provided by ProBioGen AG, Berlin. 
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Figure 5-8: Extract of Figure 5-3. Cytokine data from DC/T cell assay (48h time point) displayed in Figure 5-3 reduced to the 
selected concentration (1 mg/mL Adalimumab (A) and 0.5 mg/mL Bevacizumab (B)), which was used for 3D HuALN 
experiments. This is supplied for comparison of additional 3D data (Figure 5-7) with 2D data for the selected concentration. 
This data was provided by ProBioGen AG, Berlin. 
The approach to use a human artificial lymph node model as an immunologically relevant organ to test 
the immunogenicity of protein aggregates is therefore a first step in the theoretically relevant 
direction. While 2D in vitro assays enable us to investigate the first contact of antigens with dendritic 
cells; the HuALN model is capable to monitor the next step, the interaction of dendritic cells with B- 
and T-cells in a secondary lymphatic organ. The fact that the HuALN model is not only stimulated by 
the antigen itself but also with antigen matured dendritic cells makes it possible to mimic the in vivo 
situation in patients. The HuALN model has already been used to show immunogenicity of vaccines28, 
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but was not yet applied for testing the immunogenicity of protein aggregates. Although our study is 
only the beginning of qualifying this model for its new application, we could show that the human 
artificial lymph node model is able to differentiate the immunogenicity of different types of protein 
aggregates and proteins. 
 Additional Data 
Besides section 5.2, which was published as research article “Evaluation of a 3D human artificial lymph 
node model as test model for the assessment for immunogenicity of protein aggregates” in the Journal 
of Pharmaceutical Sciences39, additional data was collected. First, the cell culture supernatants of the 
3D HuALN culture were analyzed for the presence of anti-drug antibodies against Adalimumab and 
Bevacizumab, respectively. The results are represented in section 5.3.1. In addition, stressed 
Bevacizumab samples were analyzed for the presence of submicron particles, since the focus was 
recently on submicron particles as potential trigger for immunogenicity40. The number of submicron 
particles in stressed Bevacizumab samples was analyzed after exposure to light, stir and heat stress 
using the Tunable Resistive Pulse Sensing (TRPS) technique. Since the stimulation of the HuALN with 
stressed Bevacizumab samples resulted in a more pronounced immune response than stressing with 
Adalimumab samples, only Bevacizumab after exposure to light, stir and heat stress was analyzed and 
results are displayed in section 5.3.2. 
 The analysis of anti-drug antibodies (ADAs) 
 Results 
The cell culture supernatants of the HuALN culture after stimulation with differently stressed samples 
of Adalimumab and Bevacizumab were analyzed for the presence of anti-drug antibodies (ADAs) via a 
bridging ELISA assay. In addition, the total IgM levels were analyzed. The results of analysis of anti-drug 
antibodies for all donors of Adalimumab and Bevacizumab are displayed in Figure 5-9A-F, accordingly. 
The pink and green line represent the signal for the negative control which was media only. The graphs 
show that the signal of all samples was nearly on the same level as the negative control. Thus, no anti-
drug antibodies could be found in any of the HuALN cell culture supernatants after stimulation with 
differently stressed Adalimumab or Bevacizumab samples. The analysis of ADAs in culture 
supernatants of the bioreactor with cells of donor 1 revealed a strong signal for stir stressed 
Adalimumab on day 19. However, this signal could only be observed for one donor and can therefore 
be defined as outlier. The investigation of further donors would be necessary to future evaluations. 
Besides ADAs, the titer of IgM antibodies was investigated, and results are displayed in Figure 5-10 and 
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Figure 5-11. The graphs showed reasonable and unspecific IgM release profiles and did not indicate 
major differences between the unstressed antibodies and the stressed protein samples, accordingly. 
 
A 
 
D 
 
B 
 
E 
 
C 
 
F 
 
Figure 5-9: Results of anti-drug antibody analysis after stimulation of the human artificial lymph node model with 
unstressed and stressed samples of Adalimumab and Bevacizumab. Graphs A-C: Results for Adalimumab, donor 1-3; 
Graphs D-F: Results for Bevacizumab, Donor 1-3. This data was provided by ProBioGen AG, Berlin. 
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A 
 
B 
 
C 
 
Figure 5-10: Secretion of IgM over a HuALN run period of 28 days of donor 1 (A), donor 2 (B) and donor 3 (C). Blue line: 
Unstressed Adalimumab, red line: Adalimumab after 48h light stress, yellow line: Adalimumab after 24h stir stress, black 
line: Formulation Buffer. This data was provided by ProBioGen AG, Berlin. 
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Figure 5-11: Secretion of IgM over a HuALN run period of 28 days of donor 1 (A), donor 2 (B) and donor 3 (C). Blue line: 
Unstressed Bevacizumab, purple line: Bevacizumab after 24h light stress, rose line: Bevacizumab after 24h stir stress, light 
green line: Bevacizumab after 4d heat stress. This data was provided by ProBioGen AG, Berlin. 
 Discussion 
The analysis of anti-drug antibodies is complex41. Often the presence of free drug in the samples 
falsifies results due to the generation of so-called anti-drug antibody-drug complexes preventing ADAs 
to be detected in ELISA assays. In order to exclude false negative results, an acid dissociation step was 
performed for single samples. Several groups used this technique to detect anti-drug antibodies in the 
presence of free drug12,42,43. However, also after an acid dissociation step, no ADAs could be detected 
(data not shown). Therefore, it can be assumed that Adalimumab and Bevacizumab after light, stir and 
heat stress (only Bevacizumab) did not lead to the formation of anti-drug antibodies in the HuALN 
model. There are different types and subclasses of anti-drug antibodies. Involvement of T-cells usually 
requires higher affinity ADAs of the IgG isotype, whereas IgM ADAs have a lower affinity and are 
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temporary44. However, the formation of immune complexes between the drug and the anti-drug 
antibody may lead to a loss of efficacy of the drug, changes in the pharmacokinetic profile or to severe 
clinical complications41,44. In our study, no Ig-type ADAs could be detected, and total IgM levels were 
unspecific. It is described that the drug therapy of up to 40% of patients with rheumatoid arthritis 
treated with anti-TNF-α drugs shows reduced efficacy, thus disease symptoms are not mitigated 
efficiently45. The reason therefore might be the generation of anti-drug antibodies45. It also has been 
shown that for example Adalimumab triggered the formation of anti-drug antibodies in patients with 
rheumatoid arthritis33,46–48. However, in the current study, cells from healthy donors not suffering from 
any auto-immune disease were used for the HuALN model. The health status of the patient might play 
an important role regarding immunogenicity3. For Bevacizumab, there is barely any data focusing on 
immunogenicity and the formation of ADAs for Bevacizumab has not been described in literature49. A 
critical point concerning the analysis of ADAs in this study is, that there was no positive control that 
confirmed the ability of the HuALN to be able to produce ADAs. According to ProBioGen who 
developed the HuALN system, it has been demonstrated during development that the HuALN model 
is able to secrete anti-drug antibodies. However, for further studies, it is indispensable to include such 
control runs into the experiment. In conclusion, no anti-drug antibodies were detected for 
Adalimumab or Bevacizumab in this study. Further investigations are needed to improve the analysis 
of anti-drug antibodies using the HuALN system as model for testing the immunogenicity of different 
protein aggregates. 
  
Chapter 5  
- 108 - 
 
 The analysis of submicron particles in stressed Bevacizumab samples using Tunable 
Resistive Pulse Sensing (TRPS) 
The analysis of submicron particles has always been a challenge in the development of biotech drugs50. 
For the analysis of subvisible particles ≥ 1 µm, methods such as light obscuration and flow imaging are 
available and limits for particles ≥ 10 and 25 µm are set by the Pharmacopoeia51. Recently, the 
regulatory agencies laid their focus on particles ≤ 10 µm, and even more recently submicron particles 
smaller than 1 µm are regarded as relevant. There are several techniques available to analyze 
submicron particles in protein solutions such as nanoparticle tracking analysis (NTA)52, dynamic light 
scattering (DLS)52 or resonant mass measurement (RMM)53,54. A relatively new technique for the 
analysis of submicron particles is tunable resistive pulse sensing (TRPS). This technique is based on the 
principle of the coulter counter with the difference that TRPS uses a tunable pore. There are two 
chambers filled with electrolyte solution and an ionic current is passed. The sample is added at the top 
chamber and passes through the pore. If particles pass the pore, they cause a decrease in current 
which is registered as blocking event. The dimension of the blockage determines the size of the 
particles and the frequency of blockage events is used to determine the particle concentration52,55. In 
this study, TRPS was used to determine the number of submicron particles of unstressed Bevacizumab 
and Bevacizumab after exposure to stir, light and heat stress. Figure 5-12 and Figure 5-13 display the 
results of TRPS measurements of unstressed Bevacizumab and Bevacizumab after heat, stir and light 
stress. When the samples were filtered using a syringe filter with a pore size of 5 µm (Figure 5-12), the 
heat stressed sample showed the highest number of submicron particles followed by the stir stressed 
sample. After light stress, the number of submicron particles was also increased compared to the 
unstressed protein. When the samples were filtered using a syringe filter with a pore size of 1.2 µm, 
the heat stressed sample still contained the highest amount of submicron particles. However, the 
concentration of the measured submicron particles was lower. The same was true for the stir stressed 
sample. This might be due to the different filtration processes. After the pre-filtration using a 5 µm 
cut-off, the samples still contained many particles in the range of 1-5 µm (compare also light 
obscuration data), which resulted in high particle counts and at times also in a blockage of the 
nanopore. When a 1.2 µm cut-off was used, many particles larger than 1.2 µm were removed and 
therefore, total particle numbers were smaller. However, heat stress seemed to trigger the formation 
of submicron particles most. This in an interesting fact, since Bevacizumab after heat stress resulted in 
a pro-inflammatory/TH1 helper immune answer when injected into the human artificial lymph node 
model. However, further investigations are needed to evaluate the immunogenic effect of submicron 
particles in the HuALN model. 
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Figure 5-12: Total count of submicron particles/mL determined by TRPS of unstressed Bevacizumab and Bevacizumab after 
heat, light and stir stress using a syringe filter made of PES with a 5 µm cut-off. 
 
Figure 5-13: Total count of submicron particles/mL determined by TRPS of unstressed Bevacizumab and Bevacizumab after 
heat, light and stir stress after filtration using a syringe filter made of cellulose acetate with a 1.2 µm cut-off. 
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 Investigations on the diffusion behavior of fluorescent particles through a 
3D life dextran-CD hydrogel using a Franz Cell model 
 Abstract 
Recently, a lot of effort has been put in the development of 3D in vitro models to improve the 
simulation of human organs20. Besides in vitro skin models56, also in vitro gut57, lung58 and bone marrow 
models59 have been developed. The development of human artificial lymph nodes offers great 
opportunities to test the wanted or unwanted immunogenicity of vaccines or biopharmaceuticals, for 
example. However, the development of 3D in vitro models is complex and challenging. Several 
parameters such as biomaterials, culture systems, stromal cells to simulate the functional network of 
an organ must be taken into consideration60. Also, the development of the human artificial lymph node 
model HIRIS III, developed by Giese et al.27, had to undergo various development stages until the 
development of the currently used model HIRIS III was established. According to Giese et al.27, the key 
aspects of the development were a) the qualification and source of human cells; b) the design and 
prototyping of the bioreactor; c) the qualification of in-process and end-point analyses and d) the 
evaluation of different materials for the matrix-assisted cell culture. The gel matrix is necessary for the 
stromal cells to build a network and cell clusters in combination with the immune cells. The matrix-
based system enables the cells to form follicles and germinal centers, which are indispensable for the 
functionality of the lymph node model. During development of the HuALN model, a variety of different 
materials for the matrix was tested. Criteria such as cell attachment, macroporosity, stability, cell 
growth, sterilization and handling of the material were taken into account27. At present, a hydrogel 
based on dextran including several factors that are important for cell culturing is used as hydrogel 
matrix (see Materials and Methods, Chapter 3). 
In order to investigate the immunogenicity of substances, in this case of protein aggregates, it is 
necessary that the investigated antigen gets in contact with the embedded immune cells. Thus, it is 
essential to show that the protein aggregates diffuse into the hydrogel matrix to interact with the 
cultured immune cells. In this study, the immunogenicity of protein aggregates varying in size from 
several nanometers to several micrometers was tested. The aim of this study was to investigate the 
diffusion behavior of particles of different sizes through a 3D Life dextran-CD hydrogel matrix. 
Therefore, we used green fluorescent polystyrene model particles at a size of 2 µm and 26 nm to mimic 
protein aggregates of different size ranges. A Franz Cell was used as model and the acceptor medium 
as well as the gel itself was analyzed for the presence of fluorescent particles by fluorescence 
spectroscopy or microscopy methods. For a detailed description of the used methods see Chapter 3 
(Materials and Methods). 
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 Results 
 Diffusion of 2 µm fluorescent particles 
The results of the quantification of fluorescent particles present in the acceptor medium by fluorimetry 
are displayed in Figure 5-14. Graphs A and C revealed that no fluorescent particles at a size of 2 µm 
could be found in the acceptor medium. Graphs B and D display enlargements of Graphs A and C and 
show that the fluorescence intensity of the acceptor medium of the Franz Cell with the dextran 
hydrogel as membrane was on the same level as the negative control, a cellulose acetate membrane 
with a cut-off of 0.2 µm. It is noticeable that the intensity of the acceptor medium of the positive 
control, a cellulose acetate membrane with a cut-off of 5 µm, did also not show any increase. This was 
probably due to aggregation of the model particles in PBS. The cut-off of 5 µm for particles with a 
diameter of 2 µm was very low, but no other membranes at the desired size were available. However, 
the membranes should serve as a “proof of concept” model to develop the analytical method and it 
worked fine using highly purified water as acceptor medium or using smaller particles. However, no 
increase in fluorescence intensity could be detected in the acceptor medium of the Franz Cell with the 
dextran hydrogel and therefore it can be assumed, that the particles did not diffuse through the gel 
within the investigated time of four days. At the end of the experiment after four days, the hydrogel 
was washed thoroughly with PBS buffer and analyzed by microscopy to investigate if particles diffused 
into the hydrogel and how the particles were distributed within the hydrogel matrix. The photographs 
are displayed in Figure 5-15, showing that many of the particles diffused into the upper layer of the 
gel, but only few particles diffused to the bottom of the gel. 
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Figure 5-14: Concentration of particles in the acceptor medium reported as fluorescence intensity (A and B) and as yield (C 
and D). Graphs B and D represent enlargements of graphs A and C, respectively. 
A 
 
B 
 
C 
 
D 
 
Figure 5-15: Images taken from the 3D Life Dextran – CD hydrogel at the end of the experiment; 20x magnification; A-B: 
Pictures display the upper layer of the gel. C-D: Pictures display the bottom layer of the gel. 
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 Diffusion of 26 nm fluorescent particles 
Figure 5-16 displays the results of the analysis of the acceptor medium using 26 nm fluorescent 
particles. In contrast to the particles with a size of 2 µm, there was a slight increase in fluorescence 
intensity in the acceptor medium using 26 nm particles. The yield on day 7 is about 0.25%, which was 
still very small, but a continuous increase in particle concentration in the acceptor medium during 7 
days of investigation could be shown. A cellulose acetate membrane with a cut-off of 5 µm was again 
used as positive control and the 26 nm particles could diffuse to the acceptor medium. A yield of about 
40 % was reached after 24 hours already and no further increase was detectable. After day 7 there was 
even a small decrease in intensity and yield which might be due to a slight loss of fluorescence intensity 
of the particles. The fluorescent particles at a size of 26 nm were too small to be detected in the 
microscope. However, it was clearly visible that the gel was coloured with the green fluorescence 
(Figure 5-17). There was a strong green fluorescence distributed all over the hydrogel, most intense at 
the top of the gel, slightly decreased in the centre of the hydrogel and smaller at the bottom of the 
hydrogel (Figure 5-17A-C). However, these results suggest that the particles diffused into the hydrogel 
matrix and were equally distributed within the hydrogel. 
A 
 
B 
 
C 
 
D 
 
Figure 5-16: Concentration of particles in the acceptor medium reported as fluorescence intensity (A and B) and as yield (C 
and D). Graphs B and D represent enlargements of graphs A and C, respectively. 
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Figure 5-17: Images taken from the 3D Life Dextran –CD hydrogel at the end of the experiment; 20x magnification; A-C: 
Photographs from the top (A), center (B) and bottom of the gel (C). 
 Discussion 
The results showed clear differences between the diffusion behavior of particles at a size of 2 µm or 
26 nm. While 26 nm particles are distributed equally within the hydrogel, most of the 2 µm particles 
diffused only into the upper layer of the hydrogel and only few particles diffused to the bottom of the 
gel (Figure 5-18). This leads to the assumption that larger particles cannot diffuse through the dextran 
hydrogel matrix and therefore cannot get in contact with immune cells that are embedded in the 
dextran gel matrix in the human artificial lymph node model. Thus, the human artificial lymph node 
model might be “self-selecting” by filtering larger particles. However, further investigations of the 
diffusion behavior of differently sized particles (26 nm, 500 nm and 2 µm) using the human artificial 
lymph node model are necessary to confirm this assumption, since conditions in the human artificial 
lymph node differ in several issues such as media and gas flow from the used Franz Cell model. 
A 
 
B 
 
Figure 5-18: Schematic drawing of diffusion behavior of fluorescent particles at a size of 2 µm (A) and 26 nm (B). 
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 Conclusion 
The aim of this study was to use a complex human artificial lymph node model to test the immunogenic 
risk of protein aggregates of two monoclonal antibodies. In contrast to the currently used in vitro test 
models, the human artificial lymph node represents a complex 3D matrix assisted culture model 
mimicking the key structures of a human lymph node such as lymphatic follicles and germinal centers. 
The immunogenicity of differently produced protein aggregates of two monoclonal antibodies was 
evaluated. Even if the 2D assay indicates the immunogenic potential of stressed antibodies, the 3D 
model revealed that Bevacizumab after exposure to heat triggered a TH1 and pro-inflammatory 
immune response. The analysis of anti-drug antibodies (ADAs) revealed that no ADAs could be found 
against Adalimumab or Bevacizumab. Investigating the diffusion behavior of model particles through 
the dextran gel matrix used in the HuALN model indicated that the HuALN might be “self-selecting” by 
filtering larger particles so that larger particles cannot get in contact with embedded immune cells in 
the gel matrix. In summary, the human artificial lymph node model represents a new model to test the 
immunogenicity of protein aggregates. However, further development of the HuALN is needed to 
improve the predictive power of the system regarding immunogenicity in humans. 
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6.1 Introduction 
Particulate matter in biopharmaceutical products is one of the complex challenges for pharmaceutical 
manufacturers. According to the European Pharmacopoeia injectable protein drugs must be 
“essentially free of visible particles”1,2 and the number of subvisible particles in a container having a 
volume of less than 100 mL is limited to 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm3,4 per 
container. In the past years, many research groups focused on investigating the potential of 
proteinaceous or non-proteinaceous particles to elicit immunogenicity5–9. For several years now, 
subvisible particles in the size range of 1-10 µm are suspected to be most prone to trigger 
immunogenicity8,10. The number of particles larger than 10 µm and 25 µm is limited by the European 
Pharmacopoeia and the USP3,4, as described above, however, the number of particles smaller than 
10 µm is not routinely monitored or limited11. Recently, a research group published an article reporting 
that submicron, thus particles smaller than 1  µm, are more immunogenic than particles in the 
subvisible range6. Until it is not fully clarified, which type of particles elicit immunogenicity most, it is 
necessary to minimize particle burden in order to ensure a safe and efficient drug therapy. A possibility 
to reduce particle burden in infusions or injections is in-line filtration. In-line filtration, also known as 
bedside filtration, is defined as a filtration of the applied (protein) drug solution immediately prior to 
administration. It has been shown that in-line filtration is a highly effective tool to reduce particle 
numbers in biopharmaceutical products12. In a study by Werner et al. the effectiveness of filters to 
reduce particles was investigated, but also critical aspects such as particle shedding from filters, 
protein adsorption, protein denaturation, leachables or the ejection force were assessed12. Moreover, 
a comprehensive review by Werner et al. revealed that for nearly 16 % of all approved 
biopharmaceuticals in the German Rote Liste® a filter recommendation is provided by the 
pharmaceutical manufacturer already13. A recently published study by Villa et al. showed that in-line 
filtration reduced postoperative peripheral phlebitis associated with cannulation14. Moreover, studies 
of Perez et al. showed the effectiveness and need for in-line filtration for infusion therapy in 
pediatrics15,16. Even though particles during infusion therapy do not necessarily originate from the drug 
itself but also from glass containers, plastic containers, infusion sets or incompatibilities arising from 
simultaneous administration of several drugs17, in-line filtration is an effective tool to reduce the 
particle burden and clinical complications associated with the administration of particulate matter. 
The listed examples show that in-line filtration is a relevant topic in practice, however, it is still not 
routinely used during administration of biopharmaceutical products. This is also due to the lack of 
studies evaluating in-line filtration as a common tool to reduce particle numbers and the link to 
reduced immunogenicity. 
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The aim of this study was to show the impact of in-line filtration on immunogenicity using a 3D human 
artificial lymph node model and a 2D dendritic cell (DC) assay. Bevacizumab, a monoclonal antibody, 
was exposed to stir and heat stress for the HuALN study and additionally to light stress and tert-
butylhydroperoxide for the 2D DC assay to form protein aggregates. The samples were analyzed 
thoroughly prior to and after applying an in-line filtration step and finally, the human artificial lymph 
node model and dendritic cells were stimulated, accordingly, with unstressed and differently stressed 
Bevacizumab samples with or w/o in-line filtration step prior to stimulation. Finally, cell culture 
supernatants were tested for the presence of cytokines and IgM anti-drug antibodies (HuALN study 
only) and specific dendritic cell marker were analyzed. 
6.2 Evaluation of the effect of in-line filtration using a 3D in vitro human 
artificial lymph node model 
6.2.1 Results of protein analysis 
6.2.1.1 Visual inspection 
Figure 6-1 shows photographs of unstressed Bevacizumab and Bevacizumab after heat and stir stress 
prior to and after filtration. Due to a protein concentration of 26.1 mg/mL, unstressed Bevacizumab 
was slightly turbid compared to the unstressed formulation buffer. Bevacizumab after heat and stir 
stress showed an increased turbidity compared to the unstressed protein, whereby the stir stressed 
sample was the most turbid sample of all. After filtration, the solutions showed a comparable turbidity 
to the unstressed protein, indicating that filtration removed particles which resulted from heat or stir 
stress. 
A 
 
B 
 
C 
 
Figure 6-1: Photographs of unstressed and stressed Bevacizumab samples prior to and after filtration: A: Unstressed 
Bevacizumab at a concentration of 26.1 mg/mL (left) vs. unstressed formulation buffer (right). B: Bevacizumab at a 
concentration of 26.1 mg/mL after heat stress for 4 days prior to (left) and after filtration (right). C: Bevacizumab at a 
concentration of 26.1 mg/mL after stir stress for 24h prior to (left) and after filtration (right). 
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6.2.1.2 Turbidity 
Results of turbidity measurements are depicted in Figure 6-2. A slight increase to a turbidity of 
12.82 FNU was detected after heat stress compared to the unstressed protein (6.55 FNU). Filtration of 
the heat stressed sample resulted in a decrease of turbidity to 8.54 FNU which corresponded 
approximately to the level of turbidity of unstressed Bevacizumab (6.55 FNU). However, the difference 
in turbidity of 4.28 FNU prior to and after filtration of the heat stressed sample was rather small. In 
contrast, turbidity strongly increased to a value of 141.57 FNU after stir stress and decreased to 
6.10 FNU after filtration. In both cases, filtration led to a decrease in turbidity, whereby the effect was 
more pronounced for Bevacizumab after stir stress than after heat stress. 
 
Figure 6-2: Results of turbidity measurements of unstressed Bevacizumab and after heat and stir stress prior to and after 
filtration. Turbidity is displayed in formazine nephelometric units (FNU). 
6.2.1.3 Light obscuration 
To detect particles larger than 1 µm, light obscuration measurements were performed. The results are 
displayed in Table 6-1. Heat stress as well as stir stress strongly triggered the formation of particles 
larger than 1 and 10 µm. The cumulative particle count after heat stress increased from 
4350 particles/mL in the unstressed protein solution to 698583 particles/mL. Stir stress resulted in an 
even larger increase to a particle burden of 4623667 particles/mL. Filtration of the stressed 
Bevacizumab solutions resulted in a strong decrease in particle numbers. For the stir stressed samples, 
a particle burden of less than 2000 particles/mL could be found. The number of particles in the range 
of 1-10 µm after filtration of the heat stressed decreased in comparison to the particle burden prior to 
filtration. The number of particles in the range of 1-10 µm could be reduced to 28857 particles/mL, 
thus by factor 24, approximately. In contrast, the filtration factor (particle number prior to 
filtration/particle number after filtration) for the stir stressed sample was larger than 3000. 
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Table 6-1: Cumulative particle counts per mL of Bevacizumab after heat and stir stress prior to and after filtration 
determined by light obscuration. 
Particle size Unstressed  Formulation 
Buffer 
Heat stress 4d  Heat stress 4d-Filtration  
≥ 1 µm 4350 ± 229 17 ± 8 698583 ± 16557 28857 ± 1269 
≥ 10 µm 192 ± 31 0 ± 0 3417 ± 1181 148 ± 18 
≥ 25 µm 0 ± 0 0 ± 0 83 ± 144 0 ± 0 
Particle size Unstressed Formulation 
Buffer 
Stir stress 24h Stir stress 24h-Filtration 
≥ 1 µm 4350 ± 229 17 ± 8 4623667 ± 121715 1483 ± 1170 
≥ 10 µm 192 ± 31 0 ± 0 39167 ± 2005 143 ± 24 
≥ 25 µm 0 ± 0 0 ± 0 250 ± 250 12 ± 8 
 
6.2.1.4 Flow Imaging 
As an orthogonal method to light obscuration, particle numbers were also determined by Flow Imaging 
microscopy. Table 6-2 represents the particle numbers ≥ 1, 10 and 25 µm of unstressed Bevacizumab 
and Bevacizumab after heat and stir stress prior to and after filtration. According to this data, heat as 
well as stir stress strongly triggered the formation of particles ≥ 1, 10 and 25 µm. After filtration, 
particle numbers dropped to the level of particles of unstressed Bevacizumab implying a successful 
filtration regarding the particle burden. 
In comparison to the results obtained from light obscuration measurements, the same trends were 
observed. Particle numbers increased upon exposure to stir and heat stress and filtration reduced 
particle numbers drastically. It is noticeable that, compared to the light obscuration data, a higher 
number of particles ≥ 10 and 25 µm after heat and stir stress could be detected using Flow Imaging 
microscopy. Moreover, using Flow Imaging microscopy, it was possible to analyze the morphology of 
the particles. Figure 6-3 displays photographs of some of the particles ≥ 25 µm after heat and stir stress, 
respectively. It is noticeable that particles ≥ 25 µm after heat stress had a filament-like structure and 
were transparent, while particles ≥ 25 µm after stir stress seemed to be more compact and had a 
denser structure. However, this was not evaluated statistically, but the differences in the morphology 
of the particles still represent a noteworthy difference between Bevacizumab after heat and stir stress. 
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Table 6-2: Cumulative particle counts per mL of Bevacizumab after heat and stir stress prior to and after filtration 
determined by Flow Imaging. 
Particle size Unstressed  Formulation 
Buffer 
Heat stress 4d  Heat stress 4d Filtration 
≥ 1 µm 7514 ± 1964 137 ± 59 1471800 ± 366921 2844 ± 2012 
≥ 10 µm 954 ± 702 11 ± 11 187717 ± 20739 319 ± 247 
≥ 25 µm 210 ± 128 0 ± 0 38567 ± 2691 33 ± 12 
Particle size Unstressed Formulation 
Buffer 
Stir stress 24h Stir stress 24h Filtration 
≥ 1 µm 7514 ± 1964 137 ± 59 28983400 ± 7151008 3116 ± 483 
≥ 10 µm 954 ± 702 11 ± 11 748317 ± 233091 308 ± 113 
≥ 25 µm 210 ± 128 0 ± 0 37500 ± 36680 50 ± 20 
 
A 
    
B 
  
 
 
Figure 6-3: Representative photographs of particles ≥ 25 µm of Bevacizumab after heat stress for 4 days (A) and after stir 
stress for 24 hours (B) detected by Flow Imaging microscopy. 
6.2.1.5 Dynamic light scattering (DLS) 
To detect protein aggregates in the size range 1 nm – 10 µm the samples were investigated by dynamic 
light scattering. Results are shown in Figure 6-4 and Table 6-3. After stir stress the Zave diameter 
increased to 492.87 nm and the intensity graph showed additional peaks at a larger particle size 
indicating the presence of larger aggregates. Moreover, the poly dispersity index (PDI) increased to 
0.851 compared to a PDI value of 0.019 of the unstressed protein confirming an increased 
polydispersity of the samples after stirring. After filtration the additional peak in the intensity graph 
disappeared and only the monomer peak was present. The Zave diameter and PDI decreased again to 
the level of unstressed Bevacizumab (Table 6-3). In contrast, only small changes were seen for 
Bevacizumab after heat stress prior to and after filtration. After heat stress of Bevacizumab, the Zave 
diameter and the PDI value increased slightly to 13.28 nm and 0.177, respectively. However, after 
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filtration there was no significant decrease in the Zave diameter and the PDI was even slightly increased 
(0.183). 
Table 6-3: Zave and PDI values of unstressed Bevacizumab and after heat and stir stress prior to and after filtration. 
 
Unstressed  Heat stress 4d  Heat stress 4d-Filtration 
Zave [nm] 11.47 ± 0.07 13.28 ± 0.04  13.13 ± 0.15 
PDI 0.019 ± 0.015   0.177 ± 0.002 0.183 ± 0.016  
Unstressed  Stir stress 24h  Stir stress 24h-Filtration 
Zave [nm] 11.47 ± 0.07 492.87 ± 42.75 11.48 ± 0.11 
PDI 0.019 ± 0.015   0.851 ± 0.098 0.029 ± 0.022 
 
A 
 
B 
 
Figure 6-4: DLS graphs of unstressed Bevacizumab after heat stress (A) and after stir stress (B) prior to and after filtration. 
6.2.1.6 Size exclusion chromatography (SEC) 
For the analysis of soluble aggregates smaller than 100 nm, size exclusion chromatography was 
performed. The distribution of protein species and the total and monomer recovery of unstressed 
Bevacizumab, after heat and stir stress prior to and after filtration is displayed in Figure 6-5. It is 
apparent that heat stress triggered the formation of high molecular weight species (HMW). The heat 
stressed sample contained approximately 3.5% HMWs compared to 1% HMWs in the unstressed 
sample. Moreover, heat stress also triggered the formation of fragments (LMWs). In contrast, no 
soluble aggregates were formed during stir stress. The level of HMWs in the stir stressed sample did 
not change compared to unstressed Bevacizumab. The filtration process did not influence the level of 
soluble aggregates and no substantial differences between the percentages of HMWs and LMWs could 
be observed. Interestingly, the total recovery (Figure 6-5) increased slightly after filtration. However, 
the increase was only very small and within the standard deviations, so that no clear trend was visible. 
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Figure 6-5: Distribution of protein species (A) and total and monomer recovery in % (B) of unstressed Bevacizumab and 
after heat and stir stress prior to and after filtration. 
6.2.1.7 Protein A chromatography 
Protein A Chromatography is a well-known method to analyze methionine oxidation in the Fc-part of 
antibodies18,19. Figure 6-6 displays the chromatograms of unstressed Bevacizumab after heat and stir 
stress prior to and after filtration. Bevacizumab after incubation with 2% tert-butyl hydroperoxide 
(tBHP) for 56 hours was used as positive control. The peak of the positive control was eluted faster 
compared to unstressed Bevacizumab indicating methionine oxidation. The chromatogram of 
Bevacizumab after stir stress prior to and after filtration did not show any differences compared to 
unstressed Bevacizumab. Thus, it can be assumed that stir stress did not lead to methionine oxidation 
in the Fc-part of the antibody. The chromatogram of the heat stressed Bevacizumab showed a second 
peak eluting later than the main peak (indicated by the red arrow in Figure 6-6A). If methionine 
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residues in the Fc-part of the antibody are oxidized, the species elute earlier than the main peak, since 
methionine oxidation weakens the Protein A affinity18. Thus, species eluting later than the main peak 
bind even more strongly to Protein A. However, the results of the heat stressed protein revealed no 
oxidation of the methionine residues in the Fc part of the antibody, but the appearance of an additional 
peak indicated chemical modifications. No changes in the chromatogram were detected after filtration 
of heat stressed Bevacizumab compared to the chromatogram prior to filtration. Moreover, it is 
noteworthy that there was a small overlap of the main peak of the Bevacizumab samples and the 
positive control indicating that all samples including unstressed Bevacizumab possibly contained small 
amounts of oxidized species. 
A 
 
B 
 
Figure 6-6: Protein A chromatograms of unstressed Bevacizumab and after exposure to heat (A) and stir stress (B) prior to 
and after filtration. 
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6.2.1.8 Ion exchange chromatography (IEX) 
In addition to Protein A chromatography, ion exchange chromatography (IEX) was performed to detect 
charge variants of Bevacizumab which were formed by exposure to stir or heat stress. The 
chromatograms of unstressed Bevacizumab and Bevacizumab after heat and stir stress prior to and 
after filtration and an exemplary chromatogram with the charge variants are shown in Figure 6-7 and 
Figure 6-8. It is clearly visible that Bevacizumab after exposure to heat for four days contained a larger 
amount of acidic and basic variants compared to unstressed Bevacizumab. Acidic variants can be 
formed due to deamidation, C-terminal lysine cleavage or glycation for instance. Conversely, basic 
variants can be formed due to the presence of C-terminal lysine or glycine amidation, succinimide 
formation or amino acid oxidation20. Thus, heat stress triggered at least some of these chemical 
modifications since the content of acidic and basic variants increased during heat stress. No changes 
were detectable after filtration indicating that the filtration process itself did not have an influence on 
the level of charge variants in the sample. After stir stress no changes in the IEX chromatogram 
compared to unstressed Bevacizumab were visible. Accordingly, stir stress did not have any influence 
on the level of charge variants. Again, no alterations were observed after filtration of the stir stressed 
sample. 
 
Figure 6-7: Representative IEX chromatogram of Bevacizumab after exposure to 50°C for four days. 
main peak 
acidic variants 
basic variants 
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Figure 6-8 IEX chromatograms of unstressed Bevacizumab (bottom) and Bevacizumab after heat stress (A) and after stir 
stress (B) prior to (center) and after filtration (top). 
6.2.1.9 Intrinsic fluorescence spectroscopy 
Intrinsic fluorescence measurements were performed to investigate conformational changes after 
exposure to stir and heat stress and filtration of the stressed samples. The fluorescence of tryptophan 
is dependent on its environmental conditions. Thus, alterations in the environment of the protein can 
lead to an increase or decrease in fluorescence intensity21. For example, when tryptophan residues are 
embedded in the hydrophobic core of the protein, fluorescence intensity decreases21. In contrast, 
quenching amino acids surrounding tryptophan residues can also be removed due to unfolding of the 
protein, resulting in an increase in fluorescence intensity22. The emission spectra of Bevacizumab after 
exposure to heat and stir stress prior to and after filtration are displayed in Figure 6-9. After heat stress 
an increase in fluorescence intensity was detectable indicating alterations in the environment of 
tryptophan. Fluorescence intensity of the unstressed and filtered sample was almost on the same level 
and no shifts of the emission maxima were detectable. The fluorescence intensity of stir stressed 
Bevacizumab also increased slightly compared to unstressed Bevacizumab, displayed in Figure 6-9B. 
The fluorescence intensity of the filtered sample decreased slightly compared to unstressed 
Bevacizumab. However, also after stir stress no shifts of the emission maxima were detectable. The 
changes between the samples prior to and after filtration may depend on the presence or absence of 
particles. After filtration, fluorescence intensities of the samples were almost on the same level as of 
unstressed Bevacizumab. 
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Figure 6-9: Intrinsic fluorescence of Bevacizumab after heat stress (A) and after stir stress prior to and after filtration at a 
concentration of 1 mg/mL and excitation at 295 nm. 
6.2.1.10 Extrinsic fluorescence spectroscopy 
In addition to intrinsic fluorescence, extrinsic fluorescence of unstressed Bevacizumab and the stressed 
samples using Bis-ANS as fluorescent dye was monitored. Figure 6-10 shows the extrinsic fluorescence 
emission spectra of Bevacizumab after heat and stir stress prior to and after filtration. The fluorescence 
intensity of Bevacizumab after heat and stir stress increased compared to unstressed protein. Despite 
a rather small increase from 2.5 a.u. to 10 a.u., the data still indicate changes in the local environment 
of the protein23. After filtration of the heat and stir stressed sample, respectively, the fluorescence 
intensity increased even less, indicating only minor changes in the environment. In addition to an 
increase in fluorescence intensity the spectra are often blueshifted21. Comparing the emission maxima 
of Bevacizumab after heat and stir stress prior to and after filtration (Table 6-2) it can be observed that 
the spectra after filtration were approximately 2 nm blue-shifted, which represents only a minor shift. 
Compared to the maximum of unstressed Bevacizumab, the spectra of the heat and stir stressed 
sample were red-shifted, meaning that the spectra were shifted to larger wavelengths. However, the 
results indicate that stir and heat stress might have triggered some unfolding processes. The filtered 
samples resulted in a lower fluorescence intensity than the non-filtered samples indicating that the 
presence of particles might be the reason for this slight increase in fluorescence intensity. 
Table 6-4: Peak positions of Bis-ANS fluorescence emission spectra of unstressed Bevacizumab and Bevacizumab after heat 
and stir stress prior to and after filtration. 
 Unstressed Heat stress 4d Heat stress 4d 
Filtration 
Stir stress 24h Stir stress 24h 
Filtration 
Peak position 486.56 nm 495.07 nm 492.98 nm 494.47 nm 492.98 nm 
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Figure 6-10: Extrinsic fluorescence emission spectra of 1 mg/mL Bevacizumab and 20 µM Bis-ANS after heat stress and stir 
stress prior to and after filtration. 
6.2.1.11 Fourier-transform infrared spectroscopy (FT-IR) 
Alterations in the secondary structure of Bevacizumab after heat and stir stress were analyzed using 
FT-IR spectroscopy. The 2nd derivative FT-IR spectra of unstressed Bevacizumab and after heat and stir 
stress prior to and after filtration are shown in Figure 6-11. The amide band I, which appears between 
1700-1600 cm-1, is characteristic for an intact secondary structure24. The 2nd derivative spectra of 
amide I band of Bevacizumab after heat and stir stress did not show any considerable alterations and 
the bands were not shifted significantly to different wavenumbers. Therefore, it can be assumed that 
the secondary structure of the protein was not or only little affected by heat or stir stress. Moreover, 
no alterations of the amide bands I of the heat and stir stressed Bevacizumab after filtration could be 
detected. Thus, the filtration process itself did not influence the secondary structure. 
A 
 
B 
 
Figure 6-11: 2nd derivative FT-IR spectra of amide I band of unstressed Bevacizumab, after heat stress (A) and after stir 
stress (B) prior to and after filtration. 
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6.2.1.12 Hold-up volume PharmAssure® filter 
Regarding material loss, the hold-up volume of filters is an important parameter. Therefore, the hold-
up volume of the used PharmAssure® filters was determined with the formulation buffer of the 
Bevacizumab solution and results are shown in Figure 6-12. Without implementing an air purge, the 
hold-up volume was quite large with almost 700 µl. Purging the filter with approximately 3 mL air 
reduced the hold-up volume to 300 µl. Purging the filter with air until the bubble point was reached 
resulted in a hold-up volume of 150 µl. Based on these results a filtration instruction was prepared to 
optimize the filtrate yield. 
 
Figure 6-12: Hold up volume of PharmAssure® filter, ø25 mm, with a pore size of 0.2 µm w/o air purge, 3 mL air purge and 
air purge until the bubble point is reached. 
6.2.1.13 Filter quality of PharmAssure® filter 
To exclude filter defects, the quality of ten PharmAssure® filters was tested by filtering a model protein 
solution at a concentration of 25 mg/mL (approximately same concentration as Bevacizumab samples). 
The monoclonal antibody solution was exposed to stir stress for 24 hours and a volume of 3 mL was 
filtrated using PharmAssure® filters, respectively. The particle numbers of the filtered samples, the 
unstressed and stir stressed protein solution were determined by light obscuration and are displayed 
in Figure 6-13. Particles numbers ≥ 1, 2, 5 and 10 µm clearly increased after stir stress, represented by 
the red bar in the graph. After filtration of the samples, particle numbers decreased strongly and were 
comparable to the unstressed protein. For the scope of our experiment it was positive to see that 
filtering a stressed protein solution using ten different filters resulted in particle numbers comparable 
to the unstressed protein solution and that no outlier could be detected. Thus, it can be assumed that 
the filter quality was given. 
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Figure 6-13: Cumulative particle counts per mL of a monoclonal antibody (IgG1) at a concentration of 25 mg/mL prior to 
and after filtration using PharmAssure® filters, ø25 mm, with a pore size of 0.2 µm. 
6.2.2 Results of 3D in vitro human artificial lymph node experiments 
The experimental procedure of the 3D in vitro human artificial lymph node experiments is described 
in Chapter 3 and corresponded to the procedures of the HuALN study described in Chapter 5 (except 
for the filtration step). 
6.2.2.1 Cytokine analysis 
During the bioreactor run time of 28 days, sampling was performed daily, and the cell culture 
supernatants were analyzed for the presence of various cytokines (IL-2, IL-4, IL-1β, IL-8, IL-10, IL-12p70, 
IL-13, IFN-y and TNF-α). The area under the curve of each cytokine secretion profile was calculated and 
normalized to the control run. Finally, the cytokines were assigned to different immune responses and 
results were illustrated in spider grid diagrams (see Materials and Methods, Chapter 3). Figure 6-14 
displays the results of cytokine analysis after stimulation of the human artificial lymph node model 
with Bevacizumab after heat and stir stress prior to and after filtration. The spider grid diagrams 
showed, that the responses of the three donors varied significantly. It should be mentioned that a 
different cell culture medium had to be used for the experiment with donor 1 due to supply problems 
with the standard cell culture medium. Nevertheless, the bioreactor run with donor 1 revealed a slight 
tendency towards a pro-inflammatory and TH1 immune answer for the heat stressed samples 
compared to the other samples. This was also true for donor 3. The results indicated a slight tendency 
towards a pro-inflammatory and TH1 immune response. However, since the normalization to the 
unstressed control resulted in a value of 1, one cannot speak of a strong upregulation. In contrast to 
the results of donor 1 and donor 3, cytokine analysis of donor 2 resulted in a strong TH1 and pro-
inflammatory immune response for Bevacizumab after stir stress and the formulation buffer. These 
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conflicting results indicate the importance of donor to donor variability. Regarding the difference in 
immune response of filtered and non-filtered samples, no clear trend or difference in cytokine 
response between the filtered and the non-filtered samples could be observed in the case of all three 
donors. In summary, the results revealed no clear trend towards a certain immune response and no 
effect of in-line filtration on the secretion of cytokines could be detected. However, difficulties such as 
a change in cell culture medium and contradictory results (donor 2) made the interpretation of the 
data difficult. 
 
Figure 6-14: Cytokine secretion displayed in spider grid diagrams for tested Bevacizumab samples of Donor 1-3. AUC values 
of each cytokine secretion profile of the HuALN run time of 28 days are normalized to a control run (unstressed protein), 
allocated to cytokine groups (TH1, TH2, pro-inflammatory, anti-inflammatory) and displayed as spider grids. Values 
larger/smaller than 1 indicate up-/downregulation compared to the control run. A detailed description of the data 
evaluation is provided in Chapter 3. This data was provided by ProBioGen AG, Berlin. 
6.2.2.2 Total IgM secretion 
Besides the analysis of cytokine secretion, the cell culture supernatants were also tested for the 
presence of IgM antibodies. Figure 6-15 and Figure 6-16 display the results of IgM secretion over a 
HuALN run time of 28 days and after stimulation with Bevacizumab after heat and stir stress prior to 
and after filtration. It is true for all donors that there was an initial increase in the IgM concentration 
after the first stimulation which reached its maximum of about 40 ng/mL on day 3 or 4 and decreased 
again to 10 ng/mL and lower until day 7. Re-simulations of the HuALN on day 7, 14 and 21 did not lead 
to a renewed increase. The cumulative representation of the data (Figure 6-16) did not reveal any 
significant changes between the differently stressed samples, the buffer control or the samples prior 
to and after filtration. 
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Figure 6-15: Secretion of IgM over a HuALN run period of 28 days of Donor 1 (A), Donor 2 (B) and Donor 3 (C). Blue line: 
Unstressed Bevacizumab, light pink line: Bevacizumab after 4d heat stress, red line: Bevacizumab after 4d heat stress and 
filtration, light green line: Bevacizumab after 24h stir stress, dark green line: Bevacizumab after 24h stir stress and filtration, 
black line: formulation buffer. This data was provided by ProBioGen AG, Berlin. 
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Figure 6-16: Overall IgM secretion (cumulative) of Donor 1 (A), Donor 2 (B) and Donor 3 (C). Blue bar: Unstressed 
Bevacizumab, light pink bar: Bevacizumab after 4d heat stress, red bar: Bevacizumab after 4d heat stress and filtration, 
light green bar: Bevacizumab after 24h stir stress, dark green bar: Bevacizumab after 24h stir stress and filtration, black 
bar: formulation buffer. This data was provided by ProBioGen AG, Berlin. 
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6.3 Evaluation of the effect of in-line filtration using a 2D in vitro dendritic cell 
assay 
The biological effect of in-line filtration was also tested in a 2D in vitro dendritic cell assay. Besides heat 
and stir stressed Bevacizumab, Bevacizumab was also exposed to light and incubated with 1% tert-
butyl hydroperoxide (tBHP) and the immunological effect was investigated prior to and after filtration. 
The analysis of Bevacizumab after light stress and chemically treated Bevacizumab is described in the 
following sections. The analysis of the heat and stir stressed samples was described in 6.2. 
6.3.1 Results of protein analysis 
6.3.1.1 Visual inspection 
Unstressed and stressed Bevacizumab samples were visually inspected after the exposure to light and 
tBHP prior to and after filtration. The results are presented in Table 6-5. No particles were visible after 
the exposure of Bevacizumab to tBHP prior to and after filtration. In contrast, visible particles were 
detected after light stress prior to filtration. Moreover, the sample had a slight yellow color. After 
filtration, no particles were visible anymore, but the yellow color was still present. 
Table 6-5: Results of visual inspection of Bevacizumab after exposure to light and incubation with 1% tBHP for 16 hours 
prior to and after filtration. A clear solution and no visible particles are marked by “-“; a visible increase in turbidity and 
the presence of visible particles are marked by “+”. 
Sample Prior to filtration After filtration 
Unstressed - - 
1% tBHP 16h - - 
Light stress 24h + 
Slight yellow color 
- 
Slight yellow color 
 
6.3.1.2 Turbidity 
Results of turbidity measurements are shown in Figure 6-17. The turbidity of Bevacizumab after 
exposure to 1% tBHP was increased only slightly to 7.18 FNU compared to the unstressed protein 
(6.47 FNU). Consequently, the difference between the turbidity prior to and after filtration was 
negligible. In contrast, the turbidity of Bevacizumab after light stress for 24h increased strongly to 
220.33 FNU compared to the unstressed protein and a significant decrease in turbidity of 204.8 FNU 
was detected after filtration. 
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Figure 6-17: Results of turbidity measurements of unstressed Bevacizumab and Bevacizumab after 24h light stress and 
incubation with 1% tBHP for 16h. Results are shown in formazine nephelometric units (FNU). 
6.3.1.3 Flow Imaging 
In order to determine particle numbers ≥ 1 µm, all samples were investigated using Flow Imaging. The 
results are represented in Table 6-6. In comparison to unstressed Bevacizumab, particle numbers after 
light and chemical oxidation stress increased in all size ranges. The total particle number increased to 
161951 ± 8680 particles/mL after incubation with tBHP and to 75975 ± 25178 particles/mL after 
exposure to light. Filtration resulted in a strong decrease of particles ≥ 1, 10 and 25 µm in the case of 
Bevacizumab after exposure to 1% tBHP. The reduction of particles ≥ 1 µm by filtration after light stress 
was not as effective as for the sample treated with tBHP, since the total particle count of particles 
≥ 1 µm could only be reduced to 24697 ± 5804 particles. However, the number of particles ≥ 10 and 
25 µm could be reduced strongly. 
Table 6-6 Total particle counts ≥ 1, 10 and 25 µm of unstressed Bevacizumab and Bevacizumab after 24h of light stress and 
incubation with 1%tBHP for 16h prior and after filtration determined by Flow Imaging. 
Particle size Unstressed  Formulation 
Buffer 
1% tBHP  1% tBHP Filtration 
≥ 1 µm 4449 ± 1527 223 ± 47 161951 ± 8680 5582 ± 2282 
≥ 10 µm 573 ± 382 13 ± 8 12373 ± 240 213 ± 153 
≥ 25 µm 115 ± 42 3 ± 5 944 ± 123 15 ± 7 
Particle size Unstressed Formulation 
Buffer 
Light stress 24h Light stress 24h 
Filtration 
≥ 1 µm 4449 ± 1527 223 ± 47 75975 ± 25178 24697 ± 5804 
≥ 10 µm 573 ± 382 13 ± 8 8875 ± 1127 818 ± 162 
≥ 25 µm 115 ± 42 3 ± 5 1268 ± 278 54 ± 21 
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6.3.1.4 Size exclusion chromatography (SEC) 
In order to detect soluble aggregates, all samples were investigated by size exclusion chromatography. 
The distribution of protein species of unstressed Bevacizumab and Bevacizumab after 24h of light 
stress and incubation with 1% tBHP for 16 hours prior to and after filtration is displayed in Figure 6-18. 
The percentage of high molecular weight species after exposure of Bevacizumab to 1% tBHP increased 
to approximately 2.5%, while the monomer recovery decreased slightly (Figure 6-18B). The exposure 
of Bevacizumab to light for 24h resulted in a strong increase of high molecular weight species, so that 
the sample contained approx. 35% high molecular weight species (Figure 6-18A). Moreover, the 
formation of fragments was triggered (Figure 6-18A). The strong increase in aggregates is associated 
with a decrease in monomer recovery as shown in Figure 6-18B. The filtration process did not influence 
the level of soluble aggregates or fragments. 
A 
 
B 
 
Figure 6-18: Distribution of protein species (A) and total and monomer recovery in % (B) of unstressed Bevacizumab and 
after light stress for 24h and incubation with 1% tBHP for 16h prior to and after filtration; HMW 2 > HMW 1 > LMW. 
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6.3.1.5 Protein A chromatography 
Protein A Chromatography is a well-known method to analyze methionine oxidation in the Fc-part of 
antibodies18,25. Figure 6-19 displays the chromatograms of unstressed Bevacizumab and Bevacizumab 
after light and chemical oxidation stress prior to and after filtration. Accordingly, both stress methods 
strongly triggered methionine oxidation of the Fc-part of Bevacizumab, since the peaks were clearly 
shifted to the left compared to the unstressed protein. Shifts to earlier elution times indicate less 
affinity to Protein A and therefore, it can be assumed that Bevacizumab after light stress for 24h and 
incubation with 1% tBHP for 16h contained substantial oxidative changes. However, the filtration 
process did not influence the peak position of the stressed samples. Thus, filtration did not trigger 
further oxidation according to this data. 
A 
 
B 
 
Figure 6-19: Protein A chromatograms of unstressed Bevacizumab and after exposure to tBHP (A) and light (B) prior and 
after filtration. 
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6.3.1.6 Ion exchange chromatography (IEX) 
Ion exchange chromatography was performed to detect alterations in charge variants of Bevacizumab 
formed during exposure to light or tBHP. The chromatograms of unstressed Bevacizumab and 
Bevacizumab after light and chemical oxidation stress prior to and after filtration are shown in Figure 
6-20. Compared to unstressed Bevacizumab, the area under the curve of the monoclonal antibody 
after incubation with 1% tBHP decreased clearly and after light stress for 24h, no peaks were 
detectable by IEX chromatography. This indicates, that both stress methods modified the protein 
significantly regarding chemical modifications. To further investigate changes in charge variants after 
light stress of Bevacizumab, the antibody was exposed to light for different period of times and 
analyzed by ion exchange chromatography. The results are shown in Figure 6-21. Already after two 
hours of exposure to light stress at 55 ± 5 W/m² the area under the curve decreased strongly compared 
to unstressed Bevacizumab. This trend continued until there was no peak detectable anymore after 
24h of light stress. These results indicate that light stress had a significant influence on the level of 
charge variants and exposure times of a few hours only suffice to trigger chemical modifications of 
Bevacizumab. 
A 
 
B 
 
Figure 6-20: IEX chromatograms of unstressed Bevacizumab (bottom) and Bevacizumab after incubation with 1% tBHP for 
16h (A) and after 24h of light stress (B) prior to (center) and after filtration (top). 
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Figure 6-21: IEX chromatograms of unstressed Bevacizumab and Bevacizumab after different exposure times to light. 
6.3.1.7 Hold-up volume Acrodisc® filter 
Due to a relatively large hold-up volume for the PharmAssure® filter with a diameter of 25 mm, an 
Acrodisc® filter with a diameter of 13 mm was used for filtrating the samples for the 2D in vitro 
dendritic cell assay. As already described for the PharmAssure® filter above, the hold-up volume of the 
Acrodisc® filter was also determined and the results are displayed in Figure 6-22. The volume 
remaining in the filter after filtration was approximately 140 µl. After applying an air purge with a 
volume of 1 mL, the hold-up volume could be reduced to a volume of approximately 80 µl. 
 
Figure 6-22: Hold up volume of Acrodisc® filter, ø13 mm, with a pore size of 0.2 µm w/o air purge and 1 mL air purge. 
6.3.2 Results of 2D in vitro dendritic cell assay experiments 
The experimental procedure of the 2D in vitro experiments is described in Chapter 3. 
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6.3.2.1 Analysis of dendritic cell surface marker 
After incubation of immature dendritic cells with differently stressed samples of Bevacizumab prior to 
and after filtration, cells were harvested, and the expression of various DC markers was analyzed. The 
results are shown in Figure 6-23 - Figure 6-26. CD 80, 83 and 86 are important activation markers of 
dendritic cells26,27. Therefore, their expression on immature DCs is low whereas on mature DCs, 
expression levels are high. Human leukocyte antigen-DR (HLA-DR) is highly expressed on mature 
dendritic cells but to a lower degree on immature dendritic cells. Thus, activated dendritic cells are 
supposed to show a higher expression of HLA-DR. The results showed that LPS could stimulate 
dendritic cells of both donors to express the examined activation markers. In contrast, none of the 
stressed Bevacizumab samples showed significant changes in the expression levels of CD 80, 83, 86 or 
HLA-DR. Moreover, there were no differences in expression levels between the unstressed and 
stressed samples prior to and after filtration. Donor 1 seemed to be more responsive, since some of 
the results indicated slight trends. For example, the expression of CD 80, 83, 86 and HLA-DR after 
stimulation with filtered, heat stressed Bevacizumab was higher than after stimulation with the non-
filtered sample. However, taking the standard deviation into consideration, the expression level of all 
markers after filtration was still on a comparable level with the unstressed and the non-filtered sample. 
Donor 2 showed a small trend for samples treated with tBHP: The expressions of CD 83, 86 and HLA-
DR were slightly elevated after stimulation with Bevacizumab treated with 1% tBHP. For the filtered 
tBHP sample, the expression levels were comparable to the unstressed protein. However, differences 
were rather small and within the standard deviation. In summary, no clear differences could be 
observed between the expression levels of CD 80, 83, 86 and HLA-DR among the differently stressed 
samples or prior to and after filtration. 
6.3.2.2 Analysis of cytokines 
A reduced panel of cytokines relevant for inflammatory (TNF-α, IFN-γ, IL-6) or anti-inflammatory (IL-6, 
IL-10) immune answers was investigated to assess a potential activation of dendritic cells upon 
stimulation with the stressed antibody samples. The results of cytokine analysis of cell culture 
supernatants for two donors are displayed in Figure 6-27 - Figure 6-30. LPS was used as a positive 
control and triggered the secretion of TNF-α, IL-6 and IL-10, but it could not trigger the secretion of 
IFN- γ. Overall, no significant changes in the secretion of any of the investigated cytokines could be 
observed between the negative controls and the stressed antibody samples prior to or after filtration. 
However, some samples indicated a positive effect of filtration: According to the results of donor 2, 
the concentration of IFN-γ and TNF-α was slightly lower for light stressed Bevacizumab after filtration 
compared to the non-filtered sample. However, it should be noted, that the concentration of the 
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cytokines for the light stressed samples prior to filtration was on the same level as the negative 
controls. Therefore, it is difficult to evaluate the effect of in-line filtration. 
A 
 
B 
 
Figure 6-23: Expression of CD 80 on dendritic cells of donor 1 (A) and donor 2 (B). Dendritic cells were incubated with 
unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation with tBHP. The green bars display 
negative controls (media only, buffer only and unstressed Bevacizumab), the red bars represent the positive control (LPS). 
MFI = Mean Fluorescence Intensity. Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are marked by the 
striped pattern. 
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A 
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Figure 6-24: Expression of CD 83 on dendritic cells of donor 1 (A) and donor 2 (B). Dendritic cells were incubated with 
unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation with tBHP. The green bars display 
negative controls (media only, buffer only and unstressed Bevacizumab), the red bars represent the positive control (LPS). 
MFI = Mean Fluorescence Intensity. Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are marked by the 
striped pattern. 
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A 
 
B 
 
Figure 6-25: Expression of CD 86 on dendritic cells of donor 1 (A) and donor 2 (B). Dendritic cells were incubated with 
unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation with tBHP. The green bars display 
negative controls (media only, buffer only and unstressed Bevacizumab), the red bars represent the positive control (LPS). 
MFI = Mean Fluorescence Intensity. Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are marked by the 
striped pattern. 
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A 
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Figure 6-26: Expression of HLA-DR on dendritic cells of donor 1 (A) and donor 2 (B). Dendritic cells were incubated with 
unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation with tBHP. The green bars display 
negative controls (media only, buffer only and unstressed Bevacizumab), the red bars represent the positive control (LPS). 
MFI = Mean Fluorescence Intensity. Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are marked by the 
striped pattern. 
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A 
 
B 
 
Figure 6-27: Concentration of IFN-у in the supernatant of a culture of dendritic cells of donor 1 (A) and donor 2 (B). Dendritic 
cells were incubated with unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation with tBHP 
for 22 hours. The green bars display negative controls (media only, buffer only and unstressed Bevacizumab), the red bars 
represent the positive control (LPS). Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are marked by 
the striped pattern. 
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Figure 6-28: Concentration of TNF-α in the supernatant of a culture of dendritic cells of donor 1 (A) and donor 2 (B). 
Dendritic cells were incubated with unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation 
with tBHP for 22 hours. The green bars display negative controls (media only, buffer only and unstressed Bevacizumab), 
the red bars represent the positive control (LPS). Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are 
marked by the striped pattern. 
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Figure 6-29: Concentration of IL-10 in the supernatant of a culture of dendritic cells of donor 1 (A) and donor 2 (B). Dendritic 
cells were incubated with unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation with tBHP 
for 22 hours. The green bars display negative controls (media only, buffer only and unstressed Bevacizumab), the red bars 
represent the positive control (LPS). Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are marked by 
the striped pattern. 
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Figure 6-30: Concentration of IL-6 in the supernatant of a culture of dendritic cells of donor 1 (A) and donor 2 (B). Dendritic 
cells were incubated with unstressed Bevacizumab and Bevacizumab after heat, stir, light stress and incubation with tBHP 
for 22 hours. The green bars display negative controls (media only, buffer only and unstressed Bevacizumab), the red bars 
represent the positive control (LPS). Non-filtered (NF) are marked by the grey bars, filtered (FIL) samples are marked by 
the striped pattern. 
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6.4 Discussion 
The aim of this study was to investigate the effect of in-line filtration on the immunogenicity of stressed 
samples of Bevacizumab. Besides a 3D human artificial lymph node model, a 2D in vitro dendritic cell 
assay was used to test the immunogenicity of stressed Bevacizumab samples prior to and after 
filtration. For testing the effect of in-line filtration on immunogenicity in a human artificial lymph node 
model, protein aggregates were generated by exposing the monoclonal antibody to elevated 
temperature and mechanical stress. Regarding filtration, the analysis of insoluble aggregates, thus 
particles, was of interest. Particle numbers in the stressed antibody samples were determined by light 
obscuration and flow imaging microscopy. The analysis of the stressed antibody samples revealed a 
strong increase in particle numbers upon heat and stir stress. It was noticeable, that the total particle 
count of heat stressed Bevacizumab was much higher when determined by flow imaging microscopy 
than by light obscuration. It is known from literature that particle numbers determined by flow imaging 
microscopy are higher than determined by light obscuration. Especially small, transparent particles 
cannot be detected easily by light obscuration28,29. Thus, light obscuration might underestimate the 
number of subvisible particles present in a protein formulation29. This could also be the reason for the 
higher particle count detected by flow imaging microscopy in heat stressed Bevacizumab samples. The 
section of pictures of some particles present in the sample show rather translucent, non-spherical 
particles which might not have been detected by light obscuration. However, the data confirm the 
general recommendation to use orthogonal methods to analyze and quantitate subvisible particles in 
protein formulations. After filtration of the stressed Bevacizumab samples, particle numbers 
decreased strongly and, according to the results of flow imaging microscopy, resulted in a particle 
burden comparable to the unstressed protein. This was expected, since it has already been shown that 
in-line filtration is a powerful tool to reduce particle numbers in biologics12. Besides analyzing 
subvisible particles, the samples were also analyzed for the presence of soluble aggregates, chemical 
modifications or conformational changes. It could be shown that the filtration process itself did not 
have an influence on the level of soluble aggregates and the extent of chemical modifications. Slight 
differences between the filtered and non-filtered samples were observed in the tertiary structure of 
the protein. However, the slight changes in intrinsic and extrinsic fluorescence intensity for stir and 
heat stressed Bevacizumab samples prior to filtration might be due to the presence of particles in the 
sample. After filtration, fluorescence intensity was almost on the level of unstressed Bevacizumab 
again, indicating no dramatic changes in conformation by the filtration process. The same was true for 
the secondary structure which was analyzed by FT-IR spectroscopy. A critical issue, regarding protein 
loss, is the hold-up volume of filters which can vary among different filter products and is dependent 
of the filter diameter. For the PharmAssure® filter with a diameter of 25 mm used in this study, the 
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hold-up volume was very high with almost 700 µl. When using the Acrodisc® filter which holds a 
diameter of 13 mm, the hold-up volume was approximately 130 µl. In both cases, the hold-up volume 
could be minimized by an air purge. However, when only small amounts of protein solution are 
available, the hold-up volume is often too high and a critical point that should be addressed by 
manufacturers. This was also shown in Benjamin Werner’s study12. To exclude random filter defects, 
the quality of the PharmAssure® filter was assessed by filtering a solution of a model monoclonal 
antibody at a similar concentration as in the Bevacizumab samples. Among ten different filter of the 
same kind, no outlier could be detected. Therefore, it can be assumed that the filter quality of the used 
PharmAssure® filter was adequate for the HuALN study. 
The effect of in-line filtration was also tested in a 2D in vitro dendritic cell assay. One advantage of 2D 
in vitro assays is the possibility to test many samples at the same time, since the assays are usually 
performed in a well-plate format. In addition to the exposure to heat and stir stress, Bevacizumab was 
also exposed to light and treated with 1% tert-butyl hydroperoxide (tBHP), for this study. Finally, the 
immunogenicity of all stressed samples prior to and after filtration was tested in the 2D dendritic cell 
assay. In contrast to Bevacizumab after stir and heat stress, whereby no or moderate chemical 
modifications could be observed by Protein A and ion exchange chromatography, exposure to light 
and incubation with 1% tBHP of Bevacizumab resulted in extensive chemical modifications. Light 
exposure as well as incubating the protein sample with tBHP are known methods to trigger oxidative 
reactions5,19,30,31. Due to a reduced binding affinity of Bevacizumab after light stress and incubation 
with tBHP to Protein A, it can be assumed that methionine residues in the Fc part of the antibody were 
oxidized by exposure to light and tBHP. Additionally, the samples were also investigated using ion 
exchange (IEX) chromatography to detect further chemical modifications. IEX chromatography is based 
on the interaction of charge variants of the protein with the column material and often used to detect 
chemical changes of proteins such as C-terminal processing of lysin residues, deamidation, glycation 
or amino acid sequence variations32,33. IEX chromatography of Bevacizumab after 24h light stress and 
incubation with 1% tBHP for 16h resulted in strong modifications of the charge variants of the 
monoclonal antibody, since the chromatogram clearly changed compared to unstressed Bevacizumab. 
In the case of Bevacizumab exposed to tBHP, protein still bound to the column, but no accurate peak 
separation could be achieved. For the light stressed samples, no peak was detectable anymore. To 
confirm that the correct method was used we analyzed Bevacizumab that was exposed to light for 
different time points and found that binding and separation affinity decreased with longer exposure 
times to light. This was already true for 2h light stress indicating that light had a significant influence 
on the charge level of Bevacizumab. Analysis of the samples by size exclusion chromatography revealed 
that light stress triggered the formation of soluble aggregates and fragments (as described in Chapter 
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4) whereas the level of soluble aggregates was only slightly elevated after incubation of Bevacizumab 
with 1% tBHP. As described for heat and stir stressed Bevacizumab, the filtration process did not have 
any influence on the level of soluble aggregates. Besides soluble aggregates and chemical alterations, 
light stress and tBHP also triggered the formation of particles. Particle numbers were decreased by the 
filtration process, even though the total particle count after filtration of the light stressed samples was 
only reduced by factor 3, approximately. However, particles larger 10 and 25 µm were removed 
efficiently by filtering the sample. 
Summarizing the analysis of the unstressed and stressed Bevacizumab samples, it can be stated, that 
filtration of the samples primarily led to a decrease in particle numbers, as expected. Heat stressed 
Bevacizumab contained soluble aggregates and chemical modifications were detected. However, 
filtration did not influence the level of soluble aggregates or chemical modifications. This was also true 
for the light stressed Bevacizumab and Bevacizumab after incubation with tBHP. These samples were 
significantly altered by exposure to light and tBHP. It was true for all stressed samples that aggregate 
levels did not represent aggregate levels of marketed products. However, it has been shown recently 
that only particles with extensive chemical modifications triggered immunogenicity5. 
The immunogenicity of Bevacizumab after heat and stir stress prior to and after filtration was tested 
in a 3D human artificial lymph node model. High donor to donor variability, a high response of donor 2 
to the formulation buffer and problems with the cell culture medium during the bioreactor run with 
donor 1 made it difficult to interpret the data of the 3D HuALN study. Cytokine analysis of cultures of 
donor 1 and 2 revealed slight tendencies towards a TH1 and pro-inflammatory answer for the heat 
stressed sample, but normalized values were not much higher than 1 and therefore, it cannot be 
spoken of a significant upregulation. Moreover, due to supply difficulties, a different cell culture 
medium had to be used for bioreactor runs with donor 1. This might have changed the DC marker 
expression pattern and negatively influenced the ability of dendritic cells to be activated. Cytokine 
analysis of culture supernatants of the bioreactor run with donor 2 resulted in a strong TH1 and 
proinflammatory immune response for formulation buffer which served as negative control or 
“placebo”. High immune response to formulation buffer has also been observed in literature34. The 
formulation buffer has been tested for the presence of endotoxins and the analysis revealed an 
endotoxin level of < 0.25 EU/mL fulfilling the limits of the European Pharmacopoeia for water for 
injection35. Thus, there is no plausible explanation for the immune response to formulation buffer. 
Besides cytokine analysis, the cell culture supernatants were screened for the presence of IgM 
antibodies. All three donors showed an unspecific IgM profile, independent of the applied stress 
conditions or prior to or after filtration. The plateau in the IgM profile of donor 3 between day two and 
five is due to a pump failure of the automated sampling system during a weekend. Therefore, the 
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sample on day 5 represents a pool out of the samples of day two to five and the mean is displayed for 
all days. However, no differences between the stressed antibody samples could be observed. Based 
on this data and the results of the first HuALN experiment (Chapter 5), it becomes obvious, that the 
number of donors plays a significant role. Using three donors for one experiment is not sufficient, 
especially when there is one outlier as it was the case for this study (donor 2). Increasing the number 
of donors implies a higher number of bioreactors which comes along with longer run times, costs and 
space issues. Therefore, it must be evaluated carefully if the HIRIS III model is the right model to test 
the immunogenicity of protein aggregates or if a miniature HuALN, which is currently under 
development36, is more appropriate for this purpose. 
In the 2D DC assay, the immunogenicity of Bevacizumab after heat, stir, light and chemical oxidation 
stress using tBHP was tested prior to and after filtration. Analysis of several DC marker and cytokines 
revealed no significant difference between filtered and non-filtered samples. The basic issue was that 
levels of the different DC marker or cytokines after stimulation with any of the stressed samples were 
barely increased compared to the negative controls including, media and buffer only and the 
unstressed protein solution. Therefore, it is also difficult to make a statement about the effect of in-
line filtration. The reason for the low responses might be a short incubation time of 22 hours of the 
stressed samples with dendritic cells. It is common for 2D assays to keep incubation times rather short 
with the aim to observe early events of an immune response7,37–39. Few studies prolonged incubation 
times to 72 hours40 or added a time point after 7 days7,39. However, compared to a run time of up to 
four weeks for the HuALN model, incubation times for 2D in vitro assays are short and the focus is on 
early immune responses. As for the experiments using the HuALN model, high donor to donor 
variability was observed. The levels regarding the cytokine concentrations differed substantially. This 
is a known problem and often faced in studies using in vitro assays with cells from human donors. 
Joubert et al. used PBMCs from 50 donors to include a high number and frequency of HLA-types39. Due 
to difficulties with the supply of blood samples, only two donors could be included in the 2D in vitro 
assay in this study. The possibility to include several donors in a 2D DC assay represents an advantage 
of the 2D assay, since it is easier to include more donors in a well plate format than to run several 
bioreactors at the same time. 
6.5 Conclusion 
In this study, the effect of in-line filtration on the immunogenicity of protein aggregates of 
Bevacizumab was investigated using a 3D human artificial lymph node model and a 2D dendritic cell 
assay. Whereas small trends towards a TH1 and pro-inflammatory immune answer could be observed 
in the HuALN model, only negligible differences in the cytokine secretion profile or the activation of 
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DC marker could be detected in the 2D dendritic cell assay. Thus, no remarkable differences in the 
immune responses of the formulation buffer, unstressed and stressed Bevacizumab samples could be 
detected. Besides, the study underlines the issue of donor to donor variability indicating that more 
than two to six donors are needed for in vitro assays to draw reasonable assumptions. Unfortunately, 
the effect of in-line filtration could not be evaluated. The results of this study lead to the assumption 
that stressed Bevacizumab samples either lead to no or only low immunogenicity or that the HuALN 
model in its current edition (HIRIS III) is not able to evaluate the effect of in-line filtration. However, 
further investigations are necessary to show a positive effect of in-line filtration on the immunogenicity 
of biologics. 
  
In-line filtration as a possibility to reduce the immunogenicity of protein aggregates 
- 159 - 
 
6.6 References 
1. 2.9.20 Partikelkontamination – Sichtbare Partikeln. European Pharmacopoeia 9.0, 458 (2017). 
2. 9.0/0520 Parenteralia. European Pharmacopoeia 1323–1327 (2017). 
3. 2.9.19 Partikelkontamination- Nicht sichtbare Partikeln. European Pharmacopoeia 438–441 
(2014). 
4. United States Pharmacopeia. <788> Particulate Matter in Injections. USP 34, 326–328 (2011). 
5. Boll, B. et al. Extensive chemical modifications in the primary protein structure of IgG1 
subvisible particles are necessary for breaking immune tolerance. Mol. Pharm. 14, 1292–1299 
(2017). 
6. Kijanka, G. et al. Submicron Size Particles of a Murine Monoclonal Antibody Are More 
Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous 
Administration in Mice. J. Pharm. Sci. 107, 2847–2859 (2018). 
7. Telikepalli, S. et al. Physical characterization and in vitro biological impact of highly aggregated 
antibodies separated into size-enriched populations by fluorescence-activated cell sorting. J. 
Pharm. Sci. 104, 1575–1591 (2015). 
8. Ratanji, K. D. et al. Subvisible aggregates of immunogenic proteins promote a Th1-type 
response. Toxicol. Sci. 153, 258–270 (2016). 
9. Chisholm, C. F. et al. Silicone Oil Microdroplets Can Induce Antibody Responses Against 
Recombinant Murine Growth Hormone in Mice. J. Pharm. Sci. 105, 1623–1632 (2016). 
10. Joubert, M. K. et al. Highly aggregated antibody therapeutics can enhance the in vitro innate 
and late-stage T-cell immune responses. J. Biol. Chem. 287, 25266–25279 (2012). 
11. Carpenter, J. F. et al. Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps 
That May Compromise Product Quality. J. Pharm. Sci. 98, 1201–1205 (2009). 
12. Werner, B. P. & Winter, G. Expanding bedside filtration – a powerful tool to protect patients 
from protein aggregates. J. Pharm. Sci. 107, 2775–2788 (2018). 
13. Werner, B. P. & Winter, G. Particle contamination of parenteralia and in-line filtration of 
proteinaceous drugs. Int. J. Pharm. 496, 250–267 (2015). 
14. Villa, G. et al. In-Line Filtration Reduces Postoperative Venous Peripheral Phlebitis Associated 
Chapter 6 
- 160 - 
 
With Cannulation: A Randomized Clinical Trial. Anesth. Analg. 127, 1367–1374 (2018). 
15. Perez, M. et al. Dynamic Image Analysis to Evaluate Subvisible Particles during Continuous Drug 
Infusion in a Neonatal Intensive Care Unit. Sci. Rep. 7, 1–8 (2017). 
16. Perez, M. et al. Effectiveness of in-Line Filters to Completely Remove Particulate Contamination 
during a Pediatric Multidrug Infusion Protocol. Sci. Rep. 8, 4–11 (2018). 
17. Perez, M., Maiguy-Foinard, A., Barthélémy, C., Décaudin, B. & Odou, P. Particulate Matter in 
Injectable Drugs: Evaluation of Risks to Patients. Pharm. Technol. Hosp. Pharm. 1, 91–103 
(2016). 
18. Pan, H. et al. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A 
and FcRn. Protein Sci. 18, 424–433 (2009). 
19. Loew, C. et al. Analytical protein a chromatography as a quantitative tool for the screening of 
methionine oxidation in monoclonal antibodies. J. Pharm. Sci. 101, 4248–4257 (2012). 
20. Khawli, L. A. et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties 
and pharmacokinetics in rats. MAbs 2, 613–624 (2010). 
21. Poole, R. A., Hawe, A. & Jiskoot, W. in Analysis of Aggregates and Particles (eds. Mahler, H.-C. 
& Jiskoot, W.) 201–226 (2012). 
22. Ladokhin, A. S. in Encyclopedia of Analytical Chemistry (ed. Meyers, R. A.) 5762–5779 (John 
Wiley&Sons Ltd, 2000). 
23. Hawe, A., Sutter, M. & Jiskoot, W. Extrinsic fluorescent dyes as tools for protein 
characterization. Pharm. Res. 25, 1487–1499 (2008). 
24. Kong, J. & Yu, S. Fourier transform infrared spectroscopic analysis of protein secondary 
structures. Acta Biochim. Biophys. Sin. (Shanghai). 39, 549–559 (2007). 
25. Loew, C. et al. Analytical protein a chromatography as a quantitative tool for the screening of 
methionine oxidation in monoclonal antibodies. J. Pharm. Sci. 101, 4248–4257 (2012). 
26. Banchereau, J. & Steinmann, R. M. Dendritic cells and the control of immunity. Nature 392, 
245–252 (1998). 
27. Nascimento, C. R. et al. The influence of Ouabain on human dendritic cells maturation. 
Mediators Inflamm. 2014, 1–15 (2014). 
In-line filtration as a possibility to reduce the immunogenicity of protein aggregates 
- 161 - 
 
28. Zölls, S. et al. Flow Imaging Microscopy for Protein Particle Analysis-A Comparative Evaluation 
of Four Different Analytical Instruments. AAPS J. 15, 1200–1211 (2013). 
29. Huang, C. T., Sharma, D., Oma, P. & Krishnamurthy, R. Quantitation of protein particles in 
parenteral solutions using micro-flow imaging. J. Pharm. Sci. 98, 3058–3071 (2009). 
30. Li, S., Schöneich, C. & Borchardt, R. T. Chemical Instability of Protein Pharmaceuticals : 
Mechanisms of Oxidation and Strategies for Stabilization. Biotechnol. Bioeng. 48, 490–500 
(1995). 
31. Gaza-Bulseco, G., Faldu, S., Hurkmans, K., Chumsae, C. & Liu, H. Effect of methionine oxidation 
of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J. 
Chromatogr. B Anal. Technol. Biomed. Life Sci. 870, 55–62 (2008). 
32. Farnan, D. & Moreno, G. T. Multiproduct high-resolution monoclonal antibody charge variant 
separations by pH gradient ion-exchange chromatography. Anal. Chem. 81, 8846–8857 (2009). 
33. Williams, A. & Frasca, V. Ion-Exchange Chromatography. Curr. Protoc. Protein Sci. 15, 8.2.1.-
8.2.30 (1999). 
34. Freitag, A. J. et al. Investigation of the immunogenicity of different types of aggregates of a 
murine monoclonal antibody in mice. Pharm. Res. 32, 430–444 (2015). 
35. 9.1/0169 Wasser für Injektionszwecke. European Pharmacopoeia 6111–6115 
36. Giese, C. et al. Immunological substance testing on human lymphatic micro-organoids in vitro. 
J. Biotechnol. 148, 38–45 (2010). 
37. Moussa, E. M., Kotarek, J., Blum, J. S., Marszal, E. & Topp, E. M. Physical Characterization and 
Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-
Based Model. Pharm. Res. 33, 1736–1751 (2016). 
38. Ahmadi, M. et al. Small amounts of sub-visible aggregates enhance the immunogenic potential 
of monoclonal antibody therapeutics. Pharm. Res. 32, 1383–1394 (2015). 
39. Joubert, M. K. et al. Use of in vitro assays to assess immunogenicity risk of antibody-based 
biotherapeutics. PLoS One 11, 1–22 (2016). 
40. Rombach-Riegraf, V. et al. Aggregation of human recombinant monoclonal antibodies 
influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS 
One 9, e86322 (2014). 
  
 
 
 
 
Chapter 7 
Particle numbers in biologics: Can in-line filtration 
reduce the particle burden? 
 Particle numbers in biologics: Can in-line filtration reduce the particle 
burden?  
Particle numbers in biologics: Can in-line filtration reduce the particle burden? 
- 163 - 
 
 Introduction 
Particulate matter in biopharmaceutical products has always been a challenge for pharmaceutical 
manufacturers and poses risks to patients1–4. Even though pharmaceutical manufacturers strive to 
develop and produce high quality products meeting the specifications of the Pharmacopoeias 
regarding particle numbers5, complications in clinical routine such as infusion or injection of particulate 
matter still occur6. A critical parameter is post-production handling of biopharmaceutical products by 
end-users such as nurses, doctors or patients.7,8. Transportation or incorrect handling of the product 
by clinic staff such as exposure to mechanical stresses, contact with interfaces, temperature 
fluctuations, freeze-thaw cycles, or exposure to light might trigger protein aggregation and particle 
formation7,8. Jiskoot et al. recently described post-production handling as “a weak link” in the supply 
chain of biological products8. In this study, the authors surveyed procedures in a hospital and observed 
several incidents such as agitation of a vial filled with a biological, turbid protein solutions or careless 
handling of infusion bags with protein pharmaceutics8. The infusion or injection of particulate matter 
to patients might trigger complications and side reactions such as phlebitis9. Therefore, it is 
recommended to remove any particulate material prior to infusion or injection to the patient. A very 
effective tool to reduce the particle burden in biologicals is in-line filtration. Werner et al. analyzed 
particle counts of liquid protein products prior to and after in-line filtration and showed that in-line 
filtration is a powerful tool to reduce particle numbers above 0.2 µm10,11. Besides the effect of in-line 
filtration, also critical parameters such as particle shedding, protein adsorption, protein denaturation 
or the hold-up volume of filters were assessed. The focus in the current study was especially on 
lyophilized biologicals. Particle numbers after reconstitution might be elevated due to incorrect 
reconstitution procedures of the product. Telikepalli et al. investigated a lyophilized monoclonal 
antibody IgG1 after performing a shaking stress study and found that the number of subvisible particles 
and the turbidity were increased after reconstitution12. Usually, biologicals are lyophilized to increase 
stability and shelf life time of a liquid protein formulation13. However, with regards to particle 
formation and mistreatment of biologicals, lyophilized products are critical products since a 
reconstitution step is necessary before use. 
The aim of this study was to analyze the particle burden in marketed products and to evaluate if in-
line filtration is a possibility to reduce the particle burden. The focus hereby was on lyophilized 
products. Three biologics varying in molecular size, indication and protein concentration were included 
in this study. While Gammagard® had a protein concentration of 50 mg/mL after reconstitution, 
Actilyse® had a concentration of 1 mg/mL after reconstitution. Flixabi® was at a moderate protein 
concentration of 10 mg/mL after reconstitution. Liquid products were also investigated to compare 
the particle burden between liquid and lyophilized products. A lyophilized model monoclonal antibody 
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IgG1, three lyophilized and three liquid marketed protein drugs were selected and purchased. The 
turbidity was measured and the number of subvisible and submicron particles was determined by light 
obscuration, flow imaging and tunable resistive pulse sensing (TRPS) prior to and after in-line filtration. 
This study was carried out in collaboration with Andreas Stelzl who performed all TRPS measurements. 
 Results 
 Turbidity 
 Monoclonal antibody IgG1 
After lyophilization of the monoclonal antibody IgG1 and subsequent reconstitution, the turbidity of 
the protein solution was analyzed prior to and after applying an in-line filtration step using an 
Acrodisc® syringe filter with a pore size of 0.2 µm. The results are displayed in Figure 7-1A. The turbidity 
of the reconstituted protein solution was at 0.92 FNU and could be decreased to 0.83 FNU after 
filtration. The lyophilized product was stored for six months at 2-8°C, reconstituted, and analyzed 
again. Results (Figure 7-1B) showed that the turbidity of the reconstituted protein solution was at 
0.82 FNU prior to and at 0.86 FNU after filtration. Thus, a storage period over six months did not 
influence the turbidity of the reconstituted monoclonal antibody substantially. 
A 
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Figure 7-1: Turbidity measurements of IgG1 directly after lyophilization and reconstitution (A) and after storage of the 
lyophilized protein for six months at 2-8°C and reconstitution (B). Turbidity was measured prior to and after in-line filtration 
using an Acrodisc® filter with a pore size of 0.2 µm. 
 Marketed lyophilized products 
The lyophilized products Actilyse® (Alteplase), Gammagard® (human immune globulin) and Flixabi® 
(Infliximab) were reconstituted according to the technical information (see also Chapter 3), and the 
turbidity of the reconstituted protein solutions was measured prior to and after filtration using an 
Acrodisc® syringe filter with a pore size of 0.2 µm. The results are displayed in Figure 7-2A-C. It was 
true for all products that filtration led to a decrease in turbidity. However, turbidity values prior to 
filtration differed. The turbidity of Actilyse® after reconstitution was at 0.81 FNU and could be 
decreased to 0.58 FNU after filtration (Figure 7-2A). In contrast, Gammagard® showed a relatively high 
turbidity of 9.02 FNU prior to filtration which could be reduced to 7.70 FNU by filtration of the 
reconstituted protein solution (Figure 7-2B). The turbidity of reconstituted Flixabi® prior to filtration 
was at 2.94 FNU and could slightly be reduced by filtration to a value of 2.73 FNU (Figure 7-2C). Even 
though the levels of turbidity prior to filtration were different for each of the products, a decrease in 
turbidity after filtration was achieved for all products. 
 Marketed liquid products 
Besides lyophilized products, the turbidity of liquid biological products was analyzed. Three products 
were chosen: Pulmozyme® (Dornase alfa) at a concentration of 1 mg/mL, Beriglobin® (human immune 
globulin) at a concentration of 160 mg/mL and Truxima® (Rituximab) at a concentration of 10 mg/mL. 
The results of turbidity measurements prior to and after filtration are displayed in Figure 7-3A-C. The 
turbidity of Pulmozyme® was at 0.49 FNU prior to filtration and did not change upon filtration (Figure 
7-3A). Turbidity measurements of Truxima® (Figure 7-3B) revealed similar results: Turbidity was at 
2.67 FNU prior to filtration and could only be reduced by only 0.06 FNU to 2.61 FNU after filtration. In 
contrast, the turbidity of Beriglobin® (Figure 7-3C), containing human immune globulin, was at 
24.3 FNU prior to filtration. After filtration, turbidity of Beriglobin® was at 18.24 FNU. Thus, a decrease 
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of approximately 6 FNU could be achieved by filtration of the protein solution. In contrast to the 
lyophilized products, which showed a trend of decreasing turbidity after applying a filtration step, a 
notable decrease in turbidity after filtration could only be detected for Beriglobin® for the group of 
liquid products. 
A 
 
B 
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Figure 7-2: Turbidity measurements of the lyophilized products Actilyse® (A), Gammagard® (B) and Flixabi® (C). Turbidity 
was measured prior to and after in-line filtration using an Acrodisc® filter with a pore size of 0.2 µm. 
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Figure 7-3: Turbidity measurements of Pulmozyme® (A), Beriglobin® (B) and Truxima® (C). Turbidity was measured prior to 
and after in-line filtration using an Acrodisc® filter with a pore size of 0.2 µm. 
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 Analysis of subvisible particles by light obscuration and flow imaging 
 Monoclonal antibody IgG1 
The number of subvisible particles ≥ 1 µm of the lyophilized monoclonal antibody IgG1 was determined 
by light obscuration and flow imaging. The measurements were performed directly after lyophilization 
and reconstitution of the monoclonal antibody and after six months storage at 2-8°C and 
reconstitution prior to and after filtration of the reconstituted protein solution. The results of light 
obscuration and flow imaging measurements are displayed in Figure 7-4 and Figure 7-5, respectively. 
The total particle count for particles ≥ 1 µm directly after lyophilization and reconstitution was 695 ± 
383 particles/ mL determined by light obscuration (Figure 7-4A) and 1599 ± 209 particles/mL 
determined by flow imaging (Figure 7-5A). After filtration of the reconstituted solution, the total 
particle count could be reduced to less than 200 particles/mL (Figure 7-4A and Figure 7-5A). After six 
months of storage at 2-8°C, particle numbers increased to 2418 ± 1292 particles/mL and 3132 ± 234 
particles/mL determined by light obscuration (Figure 7-4B) and flow imaging (Figure 7-5B), 
respectively. Filtration of the stored and reconstituted protein solution resulted again in a decrease of 
particle burden to approximately 200 particles/mL or less (Figure 7-4B and Figure 7-5B). In summary, 
particle counts of the lyophilized monoclonal antibody were rather low. However, an increase in 
particle numbers during storage for six months at 2-8°C could be detected. Particle numbers after 
filtration could be reduced to approximately 200 particles/mL. 
 Marketed lyophilized products 
The results of particle measurements for particles ≥ 1 µm of the marketed lyophilized products 
Actilyse®, Gammagard® and Flixabi® after reconstitution prior to and after filtration are displayed in 
Figure 7-6 and Figure 7-7. Common for all proteins was that filtration resulted in a decrease of particles, 
as expected. The total particle count of all filtered reconstituted protein solutions could be reduced to 
less than 1000 particles/mL. However, the total particle counts directly after reconstitution and prior 
to filtration differed between the proteins. The highest particle number was detected for 
Gammagard®. The reconstituted, non-filtered protein solution had a particle burden of 13120 ± 2196 
particles/mL measured by light obscuration (Figure 7-6B) and 49530 ± 1222 particles/mL determined 
by flow imaging (Figure 7-7B). Light obscuration measurements of reconstituted Actilyse® (Figure 7-6A) 
and Flixabi® (Figure 7-6C) resulted in 5707 ± 223 and 4772 ± 366 particles/mL, respectively. Flow 
imaging measurements revealed higher particle numbers of 16498 ± 1607 particles /mL for Actilyse® 
(Figure 7-7A) and 13092 ± 269 particles/mL for Flixabi® (Figure 7-7C). 
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Figure 7-4: Total particle counts per mL determined by light obscuration of the monoclonal antibody IgG1 directly after 
lyophilization (A) and after six months of storage at 2-8°C of the lyophilized protein (B). Particle numbers were measured 
directly after reconstitution and after an additional filtration step using an Acrodisc® syringe filter with a pore size of 
0.2 µm. 
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Figure 7-5: Total particle counts per mL determined by flow imaging of the monoclonal antibody IgG1 directly after 
lyophilization (A) and after six months of storage at 2-8°C of the lyophilized protein (B). Particle numbers were measured 
directly after reconstitution and after an additional filtration step using an Acrodisc® syringe filter with a pore size of 
0.2 µm. 
 Marketed liquid products 
As for the lyophilized products, the particle burden of particles ≥ 1 µm was also determined prior to 
and after filtration of three selected liquid products. Pulmozyme® (Dornase alfa), Beriglobin® (human 
immune globulin) and Truxima® (Rituximab) were chosen as liquid formulations to compare particle 
counts in liquid and lyophilized protein formulations. The number of subvisible particles was analyzed 
by light obscuration and flow imaging and results are displayed in Figure 7-8A-C and Figure 7-9A-C. 
Again, common for all products was that filtration resulted in a decrease of particles ≥ 1 µm. However, 
particle numbers prior to filtration were at different levels. Pulmozyme® had a rather low particle 
burden of 832 ± 85 particles/mL and 2319 ± 170 particles/mL prior to filtration measured by light 
obscuration (Figure 7-8A) and flow imaging (Figure 7-9A), respectively. After filtration, particle 
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numbers were even lower resulting in a total particle count of 283 ± 25 and 516 ± 40 particles/ mL 
determined by light obscuration and flow imaging, respectively. In contrast, the particle burden of 
Beriglobin®, containing human immune globulin, was at 77905 ± 2625 particles/mL (determined by 
light obscuration, Figure 7-8B) and 354593 ± 33201 particles/mL (determined by flow imaging, Figure 
7-9B). Filtration of the human immune globulin solution resulted in a decrease of particles to 13530 ± 
8935 (determined by light obscuration) and 28487 ± 1509 particles/mL ≥ 1 µm (determined by flow 
imaging). However, the particle burden after filtration remained higher than for Pulmozyme®, 
Truxima® or the lyophilized products. The particle burden of Truxima®, containing the monoclonal 
antibody Rituximab, was at approximately 6000 particles/ml prior to filtration and 300 particles/mL 
after filtration (Figure 7-8C and Figure 7-9C). The difference in particle numbers measured by light 
obscuration or flow imaging was negligible for this protein. In summary, it was also true for liquid 
products that filtration resulted in a decrease of the total particle count for particles ≥ 1 µm. 
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Figure 7-6: Total particle counts per mL determined by light obscuration of Actilyse® (A), Gammagard®(B) and Flixabi®(C). 
Particle numbers were measured directly after reconstitution and after an additional filtration step using an Acrodisc® 
syringe filter with a pore size of 0.2 µm. 
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Figure 7-7: Total particle counts per mL determined by flow imaging of Actilyse® (A), Gammagard®(B) and Flixabi®(C). 
Particle numbers were measured directly after reconstitution and after an additional filtration step using an Acrodisc® 
syringe filter with a pore size of 0.2 µm. 
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Figure 7-8: Total particle counts per mL determined by light obscuration of Pulmozyme®(A), Beriglobin®(B) and Truxima®(C) 
prior to and after (in-line-) filtration using an Acrodisc® syringe filter with a pore size of 0.2 µm. 
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Figure 7-9: Total particle counts per mL determined by flow imaging of Pulmozyme®(A), Beriglobin®(B) and Truxima®(C) 
prior to and after (in-line-) filtration using an Acrodisc® syringe filter with a pore size of 0.2 µm. 
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 Analysis of submicron particles by tunable resistive pulse sensing (TRPS) 
Tunable resistive pulse sensing (TRPS) is a relatively new technique to measure the number of 
submicron particles in protein solutions. TRPS has been successfully used to analyze submicron particle 
levels in blood plasma14, to analyze bacterial cell concentration and cell volume15 or for quantifying 
virus particles16,17. Until now, no literature is available on using TRPS to monitor the levels of submicron 
particles in biologicals. The technique is based on the coulter counter principle with the difference that 
TRPS uses a tunable pore18. The operating principle of TRPS and details of sample preparation have 
been described in Chapter 5 (Section 5.3.2) and Chapter 3 (Section 3.7.2.1), respectively. All TRPS 
measurements in this study were performed by Andreas Stelzl. 
 Monoclonal antibody IgG1 and marketed lyophilized products 
Figure 7-10 displays the results of TRPS measurements of the marketed lyophilized products 
Gammagard®, Actilyse®, Flixabi® and a monoclonal antibody IgG1 after reconstitution prior to or after 
filtration using an Acrodisc® syringe filter with a pore size of 0.2 µm. The graphs show the number of 
particle counts which were acquired within 10 minutes (Figure 7-10A) and the particle concentration 
(particles /mL) (Figure 7-10B), which was calculated based on calibration beads measurements. For 
TRPS measurements, only the stored (6 months, 2-8°C) monoclonal antibody IgG1 was used. The 
calculation of particle concentration revealed that Gammagard®, human immune globulin at a 
concentration of 50 mg/mL, showed the highest particle concentration of particles of approximately 
4*107 particles/mL, followed by Actilyse® with a particle concentration of approximately 1.5*107 
particles/mL in the size range of 200 - 2000 nm. Flixabi®, containing the monoclonal antibody 
Infliximab, had a particle concentration of approximately 2.5*106 particles /mL and the monoclonal 
antibody IgG1 showed the lowest particle concentration of particles sized between 200 and 2000 nm 
of less than 106 particles/mL. After filtration of the reconstituted protein solutions, the particle 
concentrations in the range of 200 - 2000 nm were reduced. In the case of the model monoclonal 
antibody IgG1 and Flixabi®, the particle concentration could even be reduced to the particle 
concentration of the electrolyte which was used as blank. The evaluation of particle counts during a 
measurement time of 10 minutes (Figure 7-10A) showed the same trends with the exception that less 
particle counts for Gammagard® than for Actilyse® were detected, even though the particle 
concentration for Gammagard® was higher (Figure 7-10B). This can be explained by different sample 
preparation procedures. Due to the protein concentration of 50 mg/mL and therefore increased 
viscosity of the solution, Gammagard® had to be diluted 1/10 prior to TRPS measurements. Due to the 
dilution, less particles were counted in the Gammagard® sample than in the Actilyse® sample. 
However, the final calculated particle concentration was higher for Gammagard® than for Actilyse®. In 
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summary, TRPS revealed that a conventional sterile syringe filter with a pore size of 0.2 µm can be 
used to reduce the particle burden of submicron particles in the tested lyophilized biologics. 
A 
 
B 
 
Figure 7-10: Number of particles counts/ 10 minutes as intermediate result (A) and the final particle concentration 
(particles/mL) (B) of the lyophilized products detected by TRPS using a NP 300 nanopore. 
Figure 7-11 displays the concentrations of submicron (determined by TRPS) and micron particles 
(determined by light obscuration) of Gammagard®, Actilyse®, Flixabi® and the monoclonal antibody 
IgG1. The graph illustrates that products with high levels of micron particles also contained a substantial 
amount of submicron particles as shown for Gammagard®, for example. Products containing less 
particles in the micron range such as Flixabi® or the monoclonal antibody IgG1 also contained less 
submicron particles. 
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Figure 7-11: Graphical illustration of the particle concentration of submicron particles (black dots) determined by TRPS and 
of micron particles (red dots) determined by light obscuration of Gammagard®, Actilyse®, Flixabi® and the lyophilized 
monoclonal antibody IgG1. 
 Marketed liquid products 
The results of TRPS measurements of the marketed liquid products Beriglobin®, Pulmozyme® and 
Truxima® are displayed in Figure 7-12. As displayed for the lyophilized products, Figure 7-12 displays 
the number of particle counts which were acquired within 10 minutes (Figure 7-12A) and the particle 
concentration (particles /mL) (Figure 7-12B) which was calculated based on calibration beads 
measurements. The measurements were performed with the liquid protein formulation prior to and 
after a filtration step using an Acrodisc® syringe filter with a pore size of 0.2 µm. Again, the product 
containing human immune globulin, Beriglobin®, contained the highest number of particles in the 
range of 200 – 2000 nm. TRPS measurements revealed the highest particle count of approximately 450 
particles within 10 minutes measurement time and approximately 108 particles/mL in the range of 200 
– 2000 nm for Beriglobin®. In contrast, Pulmozyme® had a very low submicron particle burden of less 
than 20 particle counts within 10 minutes and a particle concentration of approximately 105 
particles/mL. The particle concentration of the monoclonal antibody Rituximab (Truxima®) was at 
approximately 3*106 particles/mL. It was true for all liquid protein products that filtration by a syringe 
filter with a pore size of 0.2 µm resulted in a decrease of particle counts and particle concentration as 
indicated by the dark grey bars in Figure 7-12A and B. 
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Figure 7-12: Number of particles counts/ 10 minutes as intermediate result (A) and the final particle concentration 
(particles/mL) (B) of the liquid products detected by TRPS using a NP 300 nanopore. Graph C displays an enlargement of 
graph B. 
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As already described for the lyophilized products, a relation between the level of micron and 
submicron particles could also be shown for the liquid products. Figure 7-13 displays the 
concentrations of submicron and micron particles of Beriglobin®, Pulmozyme® and Truxima®. It was 
also true for the liquid biologicals that high numbers of micron particles correlated to high numbers of 
submicron particles as shown for Beriglobin®. Accordingly, lower numbers of micron particles were 
related to lower numbers of submicron particles as shown for Pulmozyme® and Truxima®. 
 
Figure 7-13: Graphical illustration of the particle concentration of submicron particles (black dots) determined by TRPS and 
of micron particles (red dots) determined by light obscuration of Beriglobin®, Pulmozyme®, Truxima®. 
 Discussion 
The aim of this study was to investigate the particle burden in marketed lyophilized products and 
evaluate if in-line filtration might be a possibility to reduce not only the number of subvisible but also 
of submicron particles and thus, possibly reduce side effects associated with the infusion or injection 
of biologics. Four different lyophilized proteins were selected as test products: A lyophilized 
monoclonal antibody IgG1, highly concentrated human immune globulin (Gammagard®), recombinant 
tissue plasminogen activator (rt-PA, Actilyse®) and a monoclonal antibody (Infliximab, Flixabi®). For 
comparison, particle numbers were also tested in three marketed liquid products. 
Even though it is challenging to quantify protein aggregation by measuring turbidity, an increased or 
decreased turbidity might indicate the initiation or reduction of protein aggregation19. In this study, 
the turbidity of most of the tested products was decreased after filtration. Differences in turbidity prior 
to and after filtration were dependent on the protein concentrations of the tested products. The 
turbidity of Pulmozyme® containing Dornase alfa at a concentration of 1 mg/mL was at 0.49 FNU prior 
to filtration and could not be decreased remarkably by filtration. Contrarily, the turbidity of products 
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with a high protein concentration such as Gammagard® and Beriglobin® was higher prior to filtration 
and a clear decrease in turbidity was detectable after filtration. In summary, the overall trend, 
especially for the lyophilized products, was a decrease in turbidity after filtration indicating a reduced 
particle burden after filtration. 
Particles ≥ 1 µm were analyzed by light obscuration and flow imaging. In-line filtration of the products 
resulted in a reduction of particles in all cases. However, particle numbers prior to filtration differed 
between the different products. While particle numbers of Gammagard® and Beriglobin®, both 
containing human immune globulin at relatively high concentrations of 50 mg/mL and 160 mg/mL, 
respectively, were higher, the particle burden of the monoclonal antibody products Flixabi® and 
Truxima®, both at a concentration of 10 mg/mL, was lower. Pulmozyme®, containing Dornase alfa at a 
concentration of 1 mg/mL, showed low particle counts. Differences in particle numbers determined by 
light obscuration and flow imaging can be explained by the different underlying techniques. Flow 
imaging microscopy is superior in detecting small transparent particles and therefore particle numbers 
are often higher than detected by light obscuration20. One should keep in my mind, that all marketed 
products fulfilled the limitations of the European Pharmacopoiea limiting the number of particles ≥ 
10 µm and ≥ 25 µm. Accordingly, for containers with a volume of less than 100 mL, particles ≥ 10 µm 
are limited to 6000 particles/container and particles ≥ 25 µm to 600 particles/container5. However, the 
number of particles smaller than 10 µm is not limited by the European Pharmacopoeia or the USP. The 
gap in monitoring subvisible particles between 0.1 – 10 µm may lead to a compromised product quality 
as discussed in a commentary article by Carpenter and co-authors21. The particle measurements in the 
current study showed that the products contained a considerable number of particles between 1 and 
10 µm of partially more than 5000 particles/mL with some exceptions to higher particle numbers such 
as Gammagard® or Beriglobin® and others to lower particles numbers such as Pulmozyme®. The 
comparison of the particle burden of a lyophilized monoclonal antibody IgG1 after reconstitution 
directly after production and after storage for six months resulted in elevated particle numbers for the 
stored product. This indicates that storage of a lyophilized product may influence the particle burden.  
For evaluating the effect of in-line filtration, depletion factors for particles ≥ 1, 2 and 10 µm were 
calculated by dividing the particle counts prior to filtration by the particle counts after filtration. 
Depending on the particle numbers prior to filtration, the effect of in-line filtration was larger or 
smaller. Depletion factors for particles ≥ 1 µm (Figure 7-14) varied strongly between factors of 10 to 
120. However, the depletion factors for most of the products was between 10 – 20. This was also true 
for the depletion factors for particles ≥ 2 µm (Figure 7-15). The number of particles ≥ 10 µm could be 
reduced 5-10-fold, on average (Figure 7-16). In some cases, depletion factors which were calculated 
based on the results of flow imaging microscopy were much higher than those calculated based on 
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light obscuration results. This can be explained by the higher particle counts detected by flow imaging 
prior to filtration as described above. Recently, the analysis of submicron particles attracted great 
interest. Not only because submicron particles are not limited by the Pharmacopoeia, but also because 
of the suspicion to trigger immunogenicity. Kijanka and co-authors recently published a study showing 
that submicron particles of a murine monoclonal antibody were more immunogenic than micron size 
or soluble aggregates after subcutaneous administration to mice22. Even though several analysis 
methods such as particle tracking analysis (PTA), differential centrifugal sedimentation (DCS), dynamic 
light scattering (DLS), transmission electron microscopy (TEM), resonant mass measurements (RMM) 
or flow cytometry are available to measure submicron particles1,18,23–25, the analysis of submicron 
particles remains complex and challenging. In this study, tunable resistive pulse sensing (TRPS) was 
used to analyze submicron particles prior to and after filtration of the purchased biopharmaceutical 
products. The measurements showed that the tested products also contained particles in the 
submicron range. Depletion factors for submicron particles (Figure 7-17) revealed that the submicron 
particle burden after filtration could be reduced 10-fold, on average. Thus, it could be shown that also 
the number of particles in the range of 200 - 2000 nm could be reduced by using a standard sterile 
syringe filter with a pore size of 0.2 µm. 
 
Figure 7-14: Depletion factor for particles ≥ 1 µm of IgG1 prior to and after storage, Gammagard®, Actilyse®, Flixabi®, 
Beriglobin®, Pulmozyme® and Truxima®. The depletion factors were calculated by dividing the particle burden prior to 
filtration by the particle burden after filtration. 
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Figure 7-15: Depletion factor for particles ≥ 2 µm of IgG1 prior to and after storage, Gammagard®, Actilyse®, Flixabi®, 
Beriglobin®, Pulmozyme® and Truxima®. The depletion factors were calculated by dividing the particle burden prior to 
filtration by the particle burden after filtration. The value for the depletion factor of Truxima® (light obscuration) is 441. 
 
Figure 7-16: Depletion factor for particles ≥ 10 µm of IgG1 prior to and after storage, Gammagard®, Actilyse®, Flixabi®, 
Beriglobin®, Pulmozyme® and Truxima®. The depletion factors were calculated by dividing the particle burden prior to 
filtration by the particle burden after filtration. 
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Figure 7-17: Depletion factor for submicron particles of IgG1 after storage, Gammagard®, Actilyse®, Flixabi®, Beriglobin®, 
Pulmozyme® and Truxima®. The depletion factors were calculated by dividing the particle burden prior to filtration by the 
particle burden after filtration. 
In summary, it could be shown that some of the tested products contained a considerable number of 
particles smaller than 10 µm. Moreover, the results of this study showed a relation between the level 
of submicron and micron particles in biologics. Products with a high number of particles in the micron 
range also showed high levels of submicron particles. However, further studies are needed to show a 
mathematical correlation between the levels of submicron and micron particles. In addition, this study 
revealed that in-line filtration using a standard sterile syringe filter with a pore size of 0.2 µm 
represents an effective tool to reduce not only the number of micron size but also the number of 
submicron particles in biopharmaceutical lyophilized or liquid products. Based on the results of this 
study, total particle counts were slightly higher in lyophilized products than in liquid products. To 
investigate if the particle burden in lyophilized products is constantly higher than in liquid 
formulations, a larger scale study would be necessary. Moreover, it should be mentioned that the 
particle burden in protein solutions is not only dependent on the formulation (lyophilized or liquid) but 
also on further parameters such as protein concentration or formulation excipients such as the 
addition of sugars or detergents26–29. However, regarding the post production handling by end-users 
such as doctors and clinic staff, lyophilized products pose a greater risk to be treated incorrectly, since 
a reconstitution step is necessary prior to application. It has been shown before that the reconstitution 
step including reconstitution time and medium may be critical parameters regarding the formation of 
protein aggregates30,31. 
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 Summary 
The overall aim of this thesis was to evaluate the immunogenicity of protein aggregates in a 3D matrix 
assisted human artificial lymph node model which was developed by Giese and co-workers1. The 
HuALN has been used successfully to test the immunogenicity of vaccines before2 but has not been 
utilized for testing unwanted immunogenicity. 
Within the scope of this thesis, the HuALN was used for the first time to test and evaluate the 
immunogenicity of protein aggregates of two monoclonal antibodies. The focus of this thesis laid 
especially on investigating the capability of the 3D HuALN model to represent a new test model for 
evaluating the immunogenicity of protein aggregates. Besides, differently produced protein 
aggregates were investigated to gain insight which types of protein aggregates are most immunogenic. 
In order to test the immunogenicity of protein aggregates in the HuALN model, several studies were 
necessary to determine suitable concentrations of the monoclonal antibodies and stress conditions, 
and to generate protein aggregates in a reproducible way. Moreover, the stability of the generated 
protein aggregates had to be ensured over the reactor run time of the HuALN model. 
Further, the 3D human artificial lymph node model was used to investigate the biological effect of in-
line filtration. In addition, the effect of in-line filtration was investigated using a 2D in vitro dendritic 
cell assay which was established within the scope of this thesis. Finally, it was investigated if in-line 
filtration would be a possibility to reduce particle numbers in marketed lyophilized and liquid products. 
Chapter 1 provides a general introduction of the topic immunogenicity of protein aggregates. In 
Chapter 2, the scope of this thesis is described, and Chapter 3 includes all materials and methods used 
for this thesis. 
In Chapter 4, aggregation studies on the monoclonal antibodies Adalimumab and Bevacizumab were 
described. Adalimumab and Bevacizumab were exposed to stir, light and heat (only Bevacizumab) 
stress for different periods of time and analyzed by various protein analysis methods such as light 
obscuration, size exclusion chromatography, dynamic light scattering, FT-IR and fluorescence 
spectroscopy. Exposing the monoclonal antibodies to different stress conditions for distinct periods of 
time resulted in different aggregation levels. While stir stress primarily led to insoluble aggregates, 
light stress strongly triggered the formation of soluble aggregates. Heat stress of Bevacizumab resulted 
in the formation of soluble and insoluble aggregates at the same time. Based on the results of this 
study, time points for all stress conditions for Adalimumab and Bevacizumab were selected: 24 hours 
stir stress with a rotation speed of 240 rpm for Adalimumab and Bevacizumab, 24 hours (Bevacizumab) 
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or 48 hours (Adalimumab) exposure to light at 55 ± 5 W/m² and four days exposure to 50°C of 
Bevacizumab. The selected conditions were used for further studies. 
To ensure a consistent composition of the stressed samples during the 3D HuALN reactor run time of 
four weeks, the stability of the stressed Adalimumab and Bevacizumab samples was investigated after 
storage at 2-8°C for a period of six weeks directly after production and after being stored at -80°C. The 
study revealed that the composition of stressed samples of Adalimumab and Bevacizumab did not 
change dramatically when stored at 2-8°C for six weeks. When the stressed samples were stored at 
- 80°C for six months, thawed and subsequently stored at 2-8°C for further six weeks, light stressed 
Adalimumab trended towards the formation of larger aggregates, whereas no changes in the 
composition of Bevacizumab samples were detected. Thus, it was possible to store all stressed samples 
at 2-8°C for a period of six weeks and therefore, the quality of the stressed samples was ensured during 
the 3D HuALN reactor time of four weeks. 
The evaluation of immunogenicity of the differently produced protein aggregates of Adalimumab and 
Bevacizumab in a 3D human artificial lymph node model is described in Chapter 5. Prior to the 
stimulation of the 3D HuALN model, a 2D DC-/T-cell assay was performed to determine an appropriate 
concentration of the stressed samples for the HuALN study. Results revealed that stressed samples of 
Adalimumab were used at concentrations of 1 mg/mL and stressed Bevacizumab samples at 
concentrations of 0.5 mg/mL for further cell or HuALN studies. 
3D HuALN bioreactors were stimulated with the differently stressed samples of Adalimumab and 
Bevacizumab, and with dendritic cells that have already been stimulated with the stressed samples 
prior to the reactor start. The reactor run time was 28 days including repeated stimulations on day 0, 
7, 14 and 21. The analysis of cytokines revealed that Bevacizumab after heat stress resulted in a pro-
inflammatory and TH1 immune response. No trends in immune response could be shown for any of 
the stressed samples of Adalimumab. Besides the analysis of cytokines, cell culture supernatants were 
also analyzed for the presence of IgM antibodies and anti- drug antibodies (ADAs). The analysis 
revealed unspecific IgM profiles for all stressed samples and no ADAs could be found in any of the 
samples. 
Irrespective of the pro-inflammatory and TH1 immune response upon stimulation with heat stressed 
Bevacizumab, no trends of immune response could be detected. The rather low immune response and 
the fact that no anti-drug antibodies could be found led to the investigation of the diffusion behavior 
of polystyrene particles as a surrogate for particles formed by aggregated antibodies through a dextran 
gel which was used as matrix in the 3D HuALN bioreactors for stromal and immune cells. In this study, 
a Franz cell model was used to mimic the HuALN model and polystyrene particles at sizes of 26 nm and 
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2 µm served as model particles to investigate the diffusion behavior of particles through the dextran 
matrix. Whereas 26 nm sized particles were equally distributed throughout the gel, 2 µm sized particles 
accumulated primarily at the top of the gel, indicating a potential self-selecting effect for larger 
aggregates. 
The focus of Chapter 6 and 7 was on in-line filtration of biologicals. In Chapter 6, the effect of in-line 
filtration on immunogenicity was investigated using the 3D HuALN model. Stir and heat stressed 
samples of Bevacizumab were prepared and the HuALN system was stimulated with the stressed 
samples prior to and after filtration. Sampling was performed daily, and cell culture supernatants were 
analyzed for the presence of cytokines and IgM antibodies. A high donor to donor variability between 
the three tested donors impeded a proper evaluation of the results, thus it was almost impossible to 
evaluate the difference in immune response between the filtered and non-filtered samples. 
Besides, the effect of in-line filtration was also investigated using a 2D dendritic cell assay. In addition 
to stir and heat stress, Bevacizumab was also exposed to light and incubated with tert-butyl 
hydroperoxide (tBHP). All stressed samples were analyzed thoroughly, and dendritic cells were 
stimulated with the stressed samples prior to and after filtration. Results of cytokine and DC marker 
analysis revealed no difference between filtered and non-filtered samples. However, the low immune 
response of dendritic cells and the variability between the immune response of the used donors 
impeded again a sound evaluation of the biological effect of in-line filtration. 
In Chapter 7, a study investigating particle numbers in marketed lyophilized products and the effect of 
in-line filtration of reconstituted lyophilized biopharmaceuticals was described. Three marketed 
lyophilized biologicals were reconstituted according to the manufacturer’s description and numbers 
of particles ≥ 1 µm and ≤ 1 µm were analyzed prior to and after applying an in-line filtration step using 
a standard syringe filter with a pore size of 0.2 µm. For comparison, the particle numbers were also 
determined in liquid biopharmaceutical products prior to and after filtration. The results showed that 
some of the tested products contained a considerable number of particles ≤ 10 µm which are not 
limited by the European Pharmacopoeia or the USP. Lyophilized products slightly tended to higher 
particle numbers than liquid products. However, filtration of the protein solutions resulted in a strong 
decrease of particle numbers in all products. It was remarkable that even the number of particles in 
the submicron range could be reduced by filtration with a standard sterile syringe filter with a pore 
size of 0.2 µm. 
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 Conclusion and Outlook 
Within the scope of this thesis a 3D human artificial lymph node model could be evaluated as a new 
test model for the evaluation of immunogenicity of protein aggregates. The HuALN study revealed a 
pro-inflammatory and TH1 response for heat stressed Bevacizumab compared to unstressed 
Bevacizumab or stressed samples of Adalimumab. Thus, the system could differentiate between the 
immunogenicity of different proteins (Adalimumab and Bevacizumab) and differently produced 
protein aggregates of the same protein. This thesis also revealed that the capability of the HuALN 
system to investigate the long-term immune answer is useful, especially regarding a long-term therapy 
with biologicals. In addition, the cellular structure of a human lymph node with germinal centers and 
follicles is simulated by implementing stromal cells3 and also the set-up of the experiment is close to 
the processes of the human immune response. Therefore, the human artificial lymph node model 
represents a promising model to improve the predictability of immunogenicity of protein aggregates 
in humans. 
Despite of all advantages of the human artificial lymph node model (see Chapter 1 and 5), there are 
also limitations which became apparent during the experiments performed as part of this thesis. First, 
a high donor to donor variability made assessment of the results not straight forward and it was almost 
impossible to draw profound assumptions. To determine the number of donors for immunological cell 
assays is one of the major challenges. On the one hand, a large number of donors is valuable to 
represent a broad HLA diversity4. On the other hand, costs, time and practicability of the experiment 
must be taken into consideration. Additionally, the number of donors is also dependent on the assay. 
Cell assays in a well-plate format allow to include a higher number of donors than in vivo animal studies 
or in vitro bioreactor studies. For the HuALN experiments described in this thesis, three donors were 
used, respectively. However, due to high donor to donor variability, it is recommended to use at least 
6-10 donors for future studies using the 3D HuALN as test model for immunogenicity. Since each 
bioreactor is connected to a fluidic system and tempered in a cabinet dryer, only a limited number of 
bioreactors can be run at the same time. To implement a higher number of bioreactors running at the 
same time, it is necessary to further develop the 3D HuALN, e.g. by increasing its throughput volume. 
ProBioGen is currently developing a miniaturized human artificial lymph node model. The so-called IG-
device™ combines 12 culture units on a base plate2 and may represent a meaningful step to include a 
higher number of donors and samples into immunogenicity studies. 
The study in this thesis indicated that particles in the micron range might not be able to diffuse through 
the dextran matrix and thus, cannot get in contact with embedded immune cells. If this hypothesis will 
be confirmed by studies using the human artificial lymph node instead of a Franz Cell model, the 3D 
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human artificial lymph node model could not be used for testing the immunogenicity of protein 
aggregates in the micron size range. 
The low immune responses of most of the stressed samples of Adalimumab and Bevacizumab might 
also counter the on-going debate about protein aggregates as a trigger for immunogenicity and lead 
to the question how critical protein aggregates regarding immunogenicity really are. To date, the 
immunogenicity of protein aggregates has been primarily tested in 2D dendritic cell assays and mice 
as described in Chapter 1 and published as review article5. The studies were often contradictive and 
2D in vitro assays and in vivo mouse models have limitations, primarily the questionable predictiveness 
of immunogenicity in humans. Testing the immunogenicity of protein aggregates in a 3D human 
artificial lymph node system mimicking the human immune system best compared to a 2D cell assay 
or a mouse model, even high levels of protein aggregates of Adalimumab and Bevacizumab did not 
lead to strong immunogenic responses. 
Concerning the types of protein aggregates posing the greatest risk to be immunogenic, at present, 
protein aggregates with chemical modifications and submicron particles are strongly discussed6,7. This 
could partly also be shown in this thesis, since oxidative changes and submicron particles could be 
detected in the heat stressed sample of Bevacizumab. On the other hand, strongly oxidized 
Bevacizumab (by light or tBHP) did not lead to the secretion of cytokines or activation of dendritic cells 
in a 2D cell assay. This might indicate that protein aggregates, even with strong chemical modifications, 
might not be as critical as suspected in regard to immunogenicity. However, the focus of this thesis 
was on the evaluation of the HuALN as a new test model. By carefully selecting stress conditions 
samples containing primarily insoluble or soluble aggregates could be generated. However, protein 
aggregates were not further fractionated, thus the stressed samples contained a variety of protein 
aggregates. The relatively high amount of protein aggregates in the samples was intended and we were 
aware that aggregate levels in the samples did not correspond to those present in marketed biologics. 
To investigate the immunological risk of certain types of protein aggregates a fractionation by 
asymmetrical flow field flow fractionation as shown by Angelika Freitag8, for example, would be 
necessary. 
In-line filtration showed to be an effective tool to reduce particles in the submicron and micron range 
and might be helpful to reduce increased particle levels in biologicals, especially particles generated 
by incorrect post-production handling, transportation or storage. However, it remains unclear if in-line 
filtration is also an effective tool to reduce immunogenicity. Further studies are needed to show the 
biological effect of in-line filtration. 
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In summary, a 3D human artificial lymph model has been evaluated as new model for testing the 
immunogenicity of protein aggregates. Even if further studies are needed to investigate the diffusion 
behavior of particles through the dextran gel matrix or to improve the economic efficiency, the 3D 
human artificial lymph node is a promising step into the future regarding test models for 
immunogenicity of biologicals and might bridge the gap between animal studies and clinical studies. 
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 List of abbreviations 
ADA Anti-drug antibody 
AF4 Asymmetrical flow field flow fractionation 
ANS 8-Anilino-1-naphthalenesulfonic acid 
APC Antigen presenting cell 
ATSVF Adipose tissue stromal vascular fraction 
AUC Area under the curve 
BCR B-cell receptor 
Bis-ANS 4,4′-Dianilino-1,1′-binaphthyl-5,5′-disulfonic 
acid 
BSA Bovine serum albumine 
CD  Cluster of differentiation 
ConA Concanavalin A 
CSFE Carboxyfluorescein succinimidyl ester 
DC Dendritic cell 
DLS Dynamic light scattering 
DPBS Dulbecco’s phosphate buffered saline 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence activated cell sorting 
FNU Formazine nephelometric unit 
FRC Fibroblastic reticular cells 
FT-IR Fourier transform infra-red spectroscopy 
GM-CSF Granulocyte macrophage colony stimulating 
factor 
hGH Human growth hormone 
HLA  Human leukocyte antigen 
HMW High molecular weight 
HuALN Human artificial lymph node model 
IEX Ion exchange chromatography 
INF-y Interferon gamma 
LMW Low molecular weight 
LPS Lipopolysaccharide 
mAb Monoclonal antibody 
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MHC Major histocompatibility complex 
MoDC Monocyte-derived dendritic cells  
NTA Nanoparticle tracking analysis 
OVA Ovalbumin 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PDI Poly dispersity index 
PGE2 Prostaglandin E2 
PK Pharmacokinetics 
PTFE Polytetrafluorethylene  
RMM Resonant mass measurement 
tBHP tert-butyl hydroperoxide 
TCR T-cell receptor 
TD T-cell dependent 
TH1/Th1 T-helper cells 1 
TH2/Th2 T-helper cells 2 
TI T-cell independent 
TNF-α Tumor necrosis factor alpha 
TRPS Tunable resistive pulse sensing 
scFV Humanized single chain variable antibody 
fragments 
SEC  Size exclusion chromatography 
USP United States Pharmacopoeia 
WCX Weak cation exchange 
Zave Z-average 
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